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Introduction 
Childhood is the period of growth and development. This is also true for the immune 
system, which contains all elements at birth but requires further development and 
education to reach full potential. Initially, defense against invading microorganisms relies 
mostly on innate immunity and protection by transplacentally acquired maternal 
immunoglobulins; the child’s own adaptive immunity develops gradually to a fully 
expanded and matured immune system towards adulthood. Defects anywhere in this 
process can lead to immunodeficiency causing difficulties in the handling of infections. 
The immunodeficiency is called primary when these defects are determined by factors 
in the host. The immunodeficiency is called secondary when external influences like 
human immunodeficiency virus or side effects of medication are the cause. This thesis 
focuses on primary immunodeficiency. A wide variety of primary immunodeficiencies 
(PIDs) have been described, with predominantly antibody deficiencies (PADs) being the 
most common [1].
This introduction discusses the general principles of immunity, focusing on the adaptive 
immune system including the normal development of B- and T-lymphocytes, followed 
by the characteristics of PADs with a special emphasis on the hypogammaglobulinemias 
including the current classification schemes and use of patient registries. Finally, the aims 
of this thesis are outlined.
General principles of immunity
The immune system, which protects us against infections, consists of two major 
elements: innate and adaptive immunity. The innate immune system is a highly conserved 
response that provides immediate host defense. Next to physical and chemical barriers, 
the innate immune system comprises circulating effector proteins and cells with innate 
phagocytic activity: neutrophils, macrophages and natural killer (NK) cells. These immune 
cells respond quickly, but sometimes damage normal tissues due to lack of specificity. 
The adaptive immune system can generate an antigen specific reaction of B- and 
T-lymphocytes and can lead to the generation of immunological memory [2].
The adaptive immune system
The adaptive immune system is a tightly regulated network of B-lymphocytes (‘humoral’ 
immunity) and T-lymphocytes (‘cellular’ immunity); it connects with the innate immune 
system through antigen presenting cells (APCs; originating from the innate as well as 
adaptive systems). After developing and selection in the primary lymphoid organs (thymus 
and bone marrow), lymphocytes travel to the secondary lymphoid organs (lymph nodes 
and spleen) where they become activated by their encounter with antigens. During early 
development, each lymphocyte creates a unique antigen receptor resulting in a large 
and diverse repertoire of antigen specific receptors with the goal to be able to recognize 
all potential pathogens. When a lymphocyte recognizes an antigen for the first time, this 
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leads to (1) clonal proliferation with production of large numbers of effector cells and 
(2) production of long-lived memory cells which can be quickly activated in the future 
when the same antigen is encountered again [3].
Normal B cell development
B cells develop from hematopoietic stem cells in the bone marrow, where they pass 
through several developmental stages without encountering antigen. Here, they create 
their antigen specificity embedded in their unique B cell receptor (BCR). The BCR 
possesses an antigen binding moiety which is composed of a membrane-bound antibody 
that has a unique and randomly determined antigen-binding site. Initially the BCR 
membrane-bound immunoglobulin molecule is of the IgM isotype. Furthermore, the 
BCR contains a signal transduction moiety: a heterodimer called CD79, consisting of 
Ig-α and Ig-β. Both Ig-α/Ig-β span the plasma membrane and have a cytoplasmic tail 
bearing an immunoreceptor tyrosine-based activation motif (ITAM) which can induce 
intra-cellular signal transduction after binding of tyrosine kinases. The uniqueness of 
each B cell receptor is created by so-called V(D)J recombination in the immunoglobulin 
genes. The immunoglobulin genes are made up of three different types of segments: V 
(variable), D (diversity) and J (joining). During the rearrangement process, one V, one D 
and one J segment are randomly joined together to form a heavy chain (IgH). Later, one 
V and one J segment are randomly combined to form a light chain. During this VJ 
rearrangement of the light chain, fragments of DNA are separated from the BCR; these 
DNA strains remain in a stable episomal form in the nucleus, known as kappa-deleting 
recombination excision circles (KRECs) [4]. Every BCR eventually consists of two identical 
heavy chains and either two Igκ or Igλ light chains . These light chains consist of a 
constant (C
l
 ) and a variable (V
l
) domain. The kappa and lambda light chains have no 
apparent functional differences. The heavy chains determine the different immunoglobulin 
isotypes: α - IgA 1, 2, δ – IgD, γ - IgG 1, 2, 3, 4, ε - IgE, μ - IgM [3, 5]. Also the heavy chains 
consist of a constant (C
h
) and a variable (V
h
) region. The common hypervariable region 
of both chains is called the complementary determining region (CDRs). The variable 
(Fab) region of the immunoglobulin can bind to antigens, whereas the constant (Fc) 
domain receptor is a ligand for Fc receptors on innate immunity phagocytes. Different 
immunoglobulin isotypes differ in Fc fragment and therefore differ in Fc receptor affinity 
and specificity. If the process of creating a unique BCR finally leads to a functional BCR 
and the cell is not autoreactive, the cell migrates out of the bone marrow to the periphery 
as a transitional B cell. Transitional B cells are characterized by expression of bone marrow 
B cell markers like CD10, CD24, CD38 and CD44 [6].
Once these transitional B cells enter the peripheral blood they develop into naive (mature) 
B cells [7]. These naive B cells circulate through the lymphatic system and lymph nodes 
where they can encounter antigens. When the BCR of a naive B cell recognizes an 
antigen, another stimulus is necessary to activate the B cell into proliferation and 
differentiation. Most antigens (protein antigens) require participation of T cells 
(T-dependent antigens). Then, CD40 on the B cell and CD40L on the follicular helper 
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Figure 1. B cell development
A. antigen independent B cell development in the bone marrow.
BCR: B cell receptor, HSC: hematopoietic stem cell, imm B: immature B cell, trans B: transitional B cell
B. antigen and T cell dependent B cell development
1: differentiation of transitional B cell into short-lived plasma cell secreting low affinity antibodies without somatic 
hypermutation
2: proliferation and differentiation in germinal centers of lymph nodes leading to class-switched memory B cells 
or antibody secreting plasma cells
CD: cluster of differentiation, CSR: class switch recombination, mat naive B: mature naive B cell, mem B: memory 
B cell, MHCII: major histocompatibility complex type II, PC: plasma cell, SHM: somatic hypermutation, TCR: T 
cell receptor, Th cell: T helper cell, trans B: transitional B cell
CD19: B-lymphocyte antigen CD19, CD27: tumor necrosis factor receptor superfamily 7 (TNFRSF7), CD38: cyclic 
adenosine diphosphate (ADP) ribose hydrolase, CD40: tumor necrosis factor receptor superfamily 5 (TNFRSF5), 
CD40L: CD40 ligand, =CD154
C. antigen dependent and T cell independent B cell development occurring in the marginal zone of the spleen 
or lamina propria in the gut
Marg zone B: marginal zone B cell, mat naive B: mature naive B cell, PC: plasma cell, SHM: somatic hypermutation, 
trans B: transitional B cell
Adapted from Bonilla 2010, Le Bien 2008, Thesis Driessen 2013.
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T cell interact at the margin between primary follicles and T cell areas in secondary 
lymphoid tissues. This, in combination with co-stimulatory signals from receptors such 
as ICOS (inducible T cell costimulator), CTLA-4 (cytotoxic T-lymphocyte-associated 4), 
CD28 and PD-1 (programmed cell death 1) as well as soluble factors such as interleukin 
(IL)-4 and IL-21, serves as the needed secondary stimulus [8]. After this, activated B cells 
will secrete immunoglobulins with the same specificity as their BCR. Activated B cells 
can enter one of two pathways. Either the B cell immediately becomes a short-lived 
plasma cell secreting low-affinity antibody without somatic hypermutation, or it enters 
a follicle to form a germinal center. In the germinal center the B cell can increase its 
affinity for antigens by induction of somatic hypermutations (SHM) in the variable regions 
of its Ig genes [9]. Furthermore, the B cell can switch from the production of IgM and 
IgD to one of the other isotypes, IgG, IgA, or IgE. This process is called class-switch 
recombination (CSR) [10]. Both processes, SHM and also CSR, are triggered by activation-
induced cytidine deaminase (AID) [11]. The ‘upgraded’ B cell with high affinity BCR can 
differentiate into a memory B cell, which persists after antigen challenge and can rapidly 
expand during secondary responses, or into an antibody secreting plasma cell [12]. The 
Ig-isotypes differ in size, structure and function (Table 1).
T cell independent (TI) antigens (e.g. polysaccharide antigens) can activate B cells without 
the help of T cells. They can either activate via the BCR and other receptors such as 
toll-like receptors (TI-1) or via extensive cross-linking of the BCR because of the repetitive 
nature of the antigen, like pneumococcal polysaccharides (TI-2). This activation occurs 
in the marginal zone of the spleen or in the lamina propria in the gut [13, 14] and leads 
Table 1. Properties of immunoglobulin isotypes/subclasses.
Serum (%) Structure Function
IgG 75 Monomer All (except IgG-4):
Secondary immune response
(proteins: IgG1++, IgG2+, IgG3++)
(polysaccharides: IgG1+, IgG2+++, IgG3+/-)
Complement fixation +
Opsonisation +++
Neutralisation of toxins and viruses
IgG-1 67 of IgG Monomer
IgG-2 22 of IgG Monomer
IgG-3 7 of IgG Monomer
IgG-4 4 of IgG Monomer
IgM 10 Pentamer Primary immune response
Complement fixation +++
Opsonisation +
IgA 15 Monomer, dimer Mucosal response
IgA-1 Monomer, dimer
IgA-2 Monomer, dimer
IgD <0.5 Monomer Unclear
IgE <0.01 Monomer Allergy
Immunity against helminths
Ig = immunoglobulin. Edited from Schroeder 2010 [18].
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to a memory B cell type with a high affinity BCR through SHM but without CSR [15]. 
Additional activation through the transmembrane activator and calcium-modulator and 
cyclophilin ligand interactor (TACI) can lead to class switch recombination and subsequent 
isotype switching in a pathway independent of CD40 [16]. However, the magnitude of 
isotype switching is substantially smaller than that induced by CD40 ligation [17]. 
The T cell independent B cell is called the marginal zone B cell or natural effector B cell. 
A summary of the surface markers of these peripheral B cell subpopulations is shown in 
Table 2.
Normal T cell development
T cells develop from common lymphoid progenitors originating from the bone marrow 
or – in the fetus – liver [19]. Under the influence of IL-7, these cells develop into T cell 
progenitors in the thymus. Further differentiation of the progenitor cells is characterized 
by coordinated series of genomic rearrangements creating functional genes encoding 
the α and β or γ and δ chains of the T cell antigen receptor (TCR). Then VDJ rearrangement 
similar to the process described in B cell development occurs, creating a wide diversity 
of different TCRs. In this process of VDJ rearrangement fragments of DNA are excised 
from the TCR; these DNA strains remain in a stable episomal form in the nucleus, known 
as T cell receptor excision circles (TRECs) [3].
Surface expression of an αβ or γδ TCR marks the transition from a pre-T cell to a double 
positive thymocyte (expressing CD4 as well as CD8 on their surface), situated in the outer 
cortex of the thymus. Further differentiation into single positive thymocytes is found in 
the medulla of the thymus. This is regulated by a process of positive and negative 
selection involving major histocompatibility complex (MHC) molecules. Thymocytes that 
interact with epithelial MHC class I molecules will retain their CD8, whereas those 
selected on MHC class II retain their CD4, both becoming single-positive T-lymphocytes. 
However, negative selection is exerted on T cells of which the TCR binds with very high 
avidity to self-MHC molecules, ensuring that auto-reactive T cell precursors are not 
permitted to mature. These fully differentiated but antigen-naive cells leave the thymus 
by entering the circulation [3].
Table 2. Surface markers of peripheral B cell subpopulations.
Cell type Surface markers
Transitional B cell CD19+CD38++IgM++
Naive B cell CD19+CD27-IgM+IgD+
Class switched plasmablast CD19+CD38+++IgM-
Natural effector B cell CD19+CD27+IgM+IgD+
Switched memory B cell CD19+CD27+IgM-IgD-
CD=cluster of differentiation. Ig=immunoglobulin. Adapted from Bonilla 2010 [3].
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In the periphery, T cells are activated by interaction of their TCR with antigenic peptide 
- MHC complexes on APCs [20]. This activation can lead to several different effector cell 
types.
The largest subgroup of T cells in the blood is the CD4+ TCRαβ+ population. These cells 
coordinate the cells and interactions in the network and are therefore called T helper 
(Th) cells. They originate from the antigen-naive CD4+ cells (Th0). Different Th cell 
subtypes have been recognized; Th1 and Th2 cells are the major players as effector T 
cells [3]. 
• Th1 cells: these cells differentiate from naive Th0 cells under the influence of IL-12 
and produce cytokines (interferon [IFN]-γ and IL-2) that stimulate cell-mediated 
responses activating mononuclear phagocytes, NK cells, and cytolytic T cells into 
killing of intracellular microbes and virally infected targets [3].
• Th2 cells: stimulated by IL-4 Th0 cells differentiate into the second form of helper 
cells producing different cytokines (IL-4, IL-5, IL-10 and IL-13) enhancing antigen 
production and also hypersensitivity, and parasite induced immune responses.
• Th17 cells: they are named after their secretion of IL-17, a potent pro-inflammatory 
cytokine. Different types of IL-17 are capable of driving granulocyte recruitment and 
tissue damage; they have a role in auto-inflammatory and chronic allergic responses 
[21].
• Treg cells: these CD25+ regulatory T cells also express CD4 and can dampen the 
immune activation [22].
• Tfh cells: this special subgroup of Th cells in lymph nodes and spleen is called follicular 
Th cells. These CD4+ memory T cells express the chemokine receptor CXCR5, 
triggering B cells and leading to GC formation [3].
Cytotoxic T cells expressing the CD8 molecule can destroy cells by binding to their MHC 
class I molecules, which present peptides from intracellular pathogens or transformed 
proteins. This leads to production of granzymes and perforin activating apoptosis of the 
infected cell. Simultaneous binding of Fas ligand on Fas (CD95) of the target cells further 
triggers this apoptotic process. The CD8+
 
cells represent a major fraction of the circulating 
T cells [3].
Only a small subset of T cells express γδ TCR. Most of these T cells are double negative 
(no CD4 or CD8). Possibly, they have a role in the response to mycobacterial antigens.
Helper T cells as well as cytotoxic T cells can differentiate into memory cells. This 
differentiation is influenced by the duration and intensity of antigenic stimulation [23]. 
A summary of the surface markers of these peripheral T cell subpopulations is shown in 
Table 3.
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Figure 2. T cell development
A. antigen independent T cell development in the thymus. D+T: double positive T cell, HSC: hematopoietic stem 
cell, S+T: single positive T cell, TCR: T cell receptor. 4: CD4, 8: CD8.
B. antigen dependent development of T helper cell in the peripheral blood and lymph node/spleen into different 
effector cells. APC: antigen presenting cell, CXCR5: chemokine receptor 5, MHC: major histocompatibility 
complex, Tc: cytotoxic cell
C. antigen dependent development of cytotoxic T cell. MHC: major histocompatibility complex, Tc: cytotoxic T cell
Adapted from Bonilla 2010
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The developing immune system in children
Prenatally, the immune system is in favor of immune suppression and even in the first 
weeks after birth the immune responses are still mostly suppressive. The innate immune 
system relies on very ancient responses such as the production of superoxides. Further 
innate immune maturation takes place in the next years, but full capacity is not reached 
until teenage [25].
In the adaptive immune system, there is a massive increase in lymphocytes in the first 
weeks after birth. This is largely independent of gestational age at birth [26]. This 
expansion applies for B cells as well as T cells. They further increase during the first years 
of life, and then normalize to adult levels in school children [27]. Numbers of memory B 
cells are low at birth, this is explained by the lack of antigenic stimulation during prenatal 
life [26].
Transplacental transport of IgG during the third trimester protects infants during the first 
six months of life. In newborns IgM is the most commonly produced immunoglobulin. 
During the first years of life more class switching occurs and at one year of age IgG levels 
have reached 70% of adult levels but IgA levels are still only 30% of adult levels [25].
Young children have an impaired antibody response to polysaccharide antigens. This T 
cell independent response to encapsulated bacteria occurs mainly in the marginal zone 
of the spleen, which is not fully developed until two years of age [25].
Predominantly antibody deficiencies
Predominantly antibody deficiencies (PADs) result from developmental defects in the B 
cell population. The hallmark is a marked reduction or absence of immunoglobulins, 
with an increased susceptibility to mostly bacterial infections that typically involve the 
upper and lower respiratory tract. No exact incidence of PAD is known. An epidemiological 
study in a single state in the USA showed an incidence of 98:100.000 persons [28]. Several 
genetic defects underlying PADs have been described [29]. Because of the limited 
genotype-phenotype correlation additional genetic and/or environmental factors 
probably play a role [30].
Defects in the early stages of B cell development (mostly defects in the pre-BCR molecule 
or pre-BCR signaling pathway) can lead to the absence of circulating mature B cells and 
Table 3. Surface markers of peripheral T cell subpopulations.
Cell type Surface markers
Naive T cell CD45RA+CD27+CD28+CCR7+
Terminally differentiated T cell CD45RA+CD27-CD28-CCR7-
Effector memory T cell CD45RA-CD27-CD28-CCR7-
Central memory T cell CD45RA-CD27+CD28+CCR7+
Adapted from Saule 2006 [24].
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all immunoglobulin isotypes. The most common cause of an early B cell defect is X-linked 
agammaglobulinemia caused by a mutation in the gene for Bruton’s kinase (BTK) [31]. 
Other defects in the pre-BCR can lead to rare, autosomal-recessive forms of 
agammaglobulinaemia: defects in the μ-heavy chain (IGHM) [32] or the λ5 chain [33], 
the pre-BCR and BCR co-receptors Igα and Igβ (CD79α and CD79β) [34, 35] and 
components of the pre-BCR and BCR signaling pathways, including the p85α subunit of 
phosphoinositide 3-kinase (PI3K) [36] and the scaffold protein B cell linker (BLNK) [37]. 
Defects in CSR also lead to very low levels of IgG, IgA and IgE, but accompanied by 
normal to increased IgM levels. Depending on the molecular defect, SHM can be affected 
as well [30].
B cell defects in later phases of the developmental pathway can lead to various forms 
of hypogammaglobulinemia. This group of PADs is by far the most common entity of 
PIDs, comprising nearly half of all diagnoses in the European Society for 
Immunodeficiencies (ESID) online database [1]; the molecular basis of these diseases is 
as yet largely unknown.
The clinical picture of hypogammaglobulinemia 
Patients with hypogammaglobulinemia suffer from recurrent ear-nose-throat (ENT) and 
airway infections. Hypogammaglobulinemias comprise a heterogeneous group of 
diseases in which at least one of the immunoglobulin isotypes, subtypes, or functional 
antibody types is decreased. 
Common variable immunodeficiency disorders (CVID) is the most severe form with an 
estimated prevalence of 1:25,000. Most patients are detected in (young) adulthood, but 
symptoms often start during childhood, and more than one third of CVID diagnoses are 
made in children <14 years of age [38]. CVID is defined by a marked decrease of IgG and 
marked decrease of IgA with or without low IgM (at least 2 SD below the mean for age), 
with impaired response to immunization and/or low switched memory B cells (<70% of 
age-related normal value). The diagnosis should not be made before 4 years of age. 
Other defined causes of hypogammaglobulinemia as well as profound T cell deficiency 
have to be excluded before a diagnosis of CVID can be made (www.esid.org; probable 
CVID; accessed on April 25, 2016). Furthermore, CVID is associated with an increased 
susceptibility to autoimmune disorders and malignancies [39, 40]. Patients with idiopathic 
primary hypogammaglobulinemia who do not fulfill the CVID criteria show similar 
infectious episodes, but lack the autoimmune complications [41]. Several gene defects 
have been described in CVID in the past decade: inducible costimulatory (ICOS) [42], 
TACI [43], B cell activation factor receptor (BAFF-R) [44], lipopolysaccharide responsive 
beige-like anchor protein (LRBA) [45], phospholipase Cγ2 (PLCG2) [46], protein C kinase 
δ (PRKCD) [47], CD19 [48], CD20 [49], CD21 [50],CD81 [51] and NF-κB1 Subunit p50 [52]. 
However, these gene defects are responsible for only 5-10% of the CVID patients; the 
genetic background in the majority of patients is still unknown. Several CVID classification 
schemes based on immunophenotyping of B cells have been published. Low numbers 
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of switched memory B cells are associated with splenomegaly, granulomas [53, 54] and 
lymphoproliferation [53], whereas high numbers of transitional B cells in patients with 
low switched memory B cells can increase the risk of lymphadenopathy [54]. High 
numbers of immature CD21-/low B cells are associated with increased incidence of 
splenomegaly [54, 55] and autoimmune cytopenia [55]. Division of CVID patients into 
clinical phenotypes showed that only the group with polyclonal lymphocytic infiltration 
had a 5-fold increased risk of lymphoid malignancy. Predictive markers for this polyclonal 
lymphocytic infiltration were higher levels of IgM and lower circulating CD8 cells [56].
Other forms of hypogammaglobulinemia can exist as isolated phenomenon or appear 
in combination. Especially the combination of more than one partial antibody deficiency 
will lead to clinically significant disease with recurrent respiratory tract infections [57]. 
Nothing is as yet known about the genetic background of these forms of 
hypogammaglobulinemia, with the exception of increased susceptibility to IgA-deficiency 
in case of a TACI mutation [58]. Patients with IgA-deficiency can suffer from autoimmunity 
and allergy in addition to the recurrent infectious episodes. On the other hand, 85-90% 
of IgA-deficient people are asymptomatic [59].
IgG-subclass deficiency is defined as a deficiency in one or more IgG-subclasses (>2 SD 
below age-matched reference values) with normal or near normal IgG concentration. 
Specific polysaccharide antibody deficiency (SPAD) is diagnosed when there is profound 
alteration of the antibody response to polysaccharide antigens, either after documented 
invasive infection with e.g. S. pneumoniae or after test immunization with an unconjugated 
pneumococcal (or other) polysaccharide vaccine. In both diseases, T cell and more 
severe B cell defects should be excluded (www.esid.org; accessed on April 25, 2016). 
Patients with IgG-subclass deficiency or SPAD can be asymptomatic, but if not typically 
present with increased susceptibility to bacterial ENT and respiratory tract infections. Of 
the IgG-subclass deficiencies especially IgG2 deficiency seems to be relevant, the more 
so when combined with SPAD [60]. 
Hypogammaglobulinemia in children
Hypogammaglobulinemia is the most common form of immunodeficiency in children, 
but the exact prevalence is not known [61]. It is important to note that every child starts 
with a ‘physiological hypogammaglobulinemia’ during the first six months of life, the 
immunoglobulin levels increase during normal immune maturation. In some cases this 
hypogammaglobulinemia persists longer, leading to so-called transient hypogamma-
globulinemia of infancy (THI). THI generally resolves before the age of 2 years [62], but 
may last much longer [63]. The diagnosis can only be made with certainty in retrospect. 
If the hypogammaglobulinemia does not resolve with age, nor fits the diagnostic criteria 
of CVID, it is named ‘unclassified’. Children with ‘unclassified’ hypogammaglobulinemia 
suffer from a higher frequency of infectious episodes and autoimmune disease compared 
to children with THI [64]. At the moment it is not possible to predict which child will develop 
a more or less severe immunodeficiency in the future, and which child will recover. 
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Impaired response to polysaccharide antigens is a physiological phenomenon in children 
below the age of 2 years, reflecting the ongoing B cell development during the first years 
of life. However, the majority of infants show an adequate response to certain 
pneumococcal serotypes [65]. From 2 to 3 years of age onwards, children can mount 
an adequate response to polysaccharide antibodies; in some cases this physiological 
non-responsiveness can last until around 6 years of age. Because most polysaccharide 




 subclass deficiency is often associated 
with SPAD [61].
Hypogammaglobulinemia and chromosomal disorders
Several PID syndromes have been identified and increasingly their genetic background 
has been unraveled [66]. Syndromes with chromosomal abnormalities of number or 
structure are considered as a distinct group of PID syndromes [67]. Well-known examples 
are Down syndrome (trisomy 21) which is associated with T and B cell abnormalities [68] 
and DiGeorge syndrome (22q11 deletion) which is associated with mild to very severe T 
cell dysfunction [69]. Also, Turner syndrome [70] and Wolf-Hirschhorn syndrome [71] are 
known to be associated with immunodeficiency, mostly antibody disorders. It is as yet 
unknown how many other chromosomal aberrations are associated with immunological 
abnormalities. 
Diagnostic challenge of PAD in children
Identifying children with PAD, especially the milder forms like IgG-subclass deficiency 
and/or SPAD, among the many children seen in everyday practice can be challenging. 
In healthy children aged 0-2 years up to 11 respiratory infections per year, up to 8 
infections per year for children 3-5 years and up to 4 infections per year for children 
6-12 years is considered normal [72]. At least 6% of the children presents to a physician 
with recurrent respiratory infections [73, 74]. Most of these are self-limiting, viral upper 
respiratory tract infections. The infections are typically seasonal, with a higher incidence 
in autumn and winter when children are exposed to a large number of viruses at home 
and in day-care centres or nursery schools. These infections are generally mild and do 
not lead to hospitalization. In general between infectious episodes children are well and 
show normal growth [75].
So, frequent upper respiratory tract infections in the first years of life are not exceptional, 
and this makes it difficult to decide which children with recurrent infections are at the 
end of the normal spectrum and which children need further immunological work-up. 
Studies show that the incidence of underlying PID in children with recurrent lower 
respiratory infections varies between 9.7%-16.1% [76-80]. The Jeffrey Model Foundation 
developed 10 warning signs for PID based on expert opinion to help physicians identifying 
patients at risk for PID [21]. Of these warning signs only a positive family history, parental 
consanguinity and the need for intravenous antibiotics are truly predictive for PAD in 
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retrospective studies among patients referred to tertiary centres [81, 82]. A limitation of 
these warning signs is that they focus mainly on the infections. Therefore, patients 
primarily presenting with other signs such as severe allergy, autoimmunity or malignancy 
may be missed [83].
Another challenge is formed by a group of children who spontaneously recover during 
follow-up, since hypogammaglobulinemia in young children can be a physiological 
phenomenon due to the developing immune system. Therefore, several diagnoses should 
not be made until a certain age. According to the ESID criteria, CVID and IgA-deficiency 
can only be diagnosed in children >4 years of age (www.esid.org). No age limits for the 
diagnosis of IgG-subclass deficiency and SPAD have been defined by ESID so far, but it 
is better not to use this diagnosis before the age of 3-4 years either.
Use of age-matched reference values for lymphocyte subpopulations
Immunophenotyping of lymphocyte subpopulations is an important tool in the 
diagnosis of immunological and hematological diseases. When absolute numbers of 
lymphocyte subpopulations fall outside predetermined reference ranges, this indicates 
possible disease. When this thesis was started, the available reference values comprised 
only a small selection of lymphocyte subpopulations, determined in relatively small 
groups; also, methods were used which are not used in daily (diagnostic) practice [27, 
84-90]. Lymphocyte subpopulations were also increasingly used to classify patients 
with CVID into subgroups with different clinical prognosis according to the composition 
of their B-lymphocyte compartment [53-55]. These classifications were mainly 
developed with data obtained in adults, which does not mean these cutoffs are 
applicable in children. 
The use of registries and surveys to study rare diseases
Because PIDs are relatively rare disorders, international collaboration is necessary to 
study the clinical characteristics of these diseases. Registries and surveys can be very 
useful tools in this process. Since 2004, the ESID has been running an online database 
for primary immunodeficiencies: the ESID Online Database. This database registers 
demographical, clinical and laboratory characteristics of patients with PID [91]. The aim 
of the ESID Online Database is to build a common data pool and estimate the disease 
burden of PID in Europe and to provide an internet-based database for clinical and 
research data on patients with PID. In 2014 the database contained 8002 patients 
<20 years of age (47% of total) (www.esid.org). In the Netherlands, the national 
surveillance institute for pediatric diseases (“Nederlands Signalerings Centrum voor 
Kindergeneeskunde” [NSCK]) collects data on specific diagnoses among all practicing 
pediatricians; from March 1, 2009, to November 1, 2011 data on children diagnosed with 
hypogammaglobulinemia were collected. Within ESID, researchers also collect data by 
sending around surveys among its members around a specific diagnosis or clinical 
research question.
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Aim and outline of this thesis
The aims of the studies described in this thesis are:
1) to get more insight into the pitfalls the developing immune system creates for 
doctors confronted by children with potential primary immunodeficiency by:
 a.  developing reliable age matched reference values for newly described lymphocyte 
subpopulations in children used in current PID diagnosis
 b.  testing existing disease classification schemes for applicability in children
 c. studying the effect of age on somatic hypermutation levels in children
2) to study in detail the clinical picture and characteristics of children with antibody 
deficiencies focusing on hypogammaglobulinemia using data from (inter)national 
registries and surveys.
In Part 1 the age-related reference values of different players of the immune system in 
healthy children are shown. Chapter 1 presents the reference values of B cell 
subpopulations in children in comparison with adult values, and discusses the impact of 
the obtained results on the use of current adult classification schemes for CVID in 
children. Chapter 2 focuses on the peripheral T cell compartment of healthy children. 
In chapter 3 the levels of somatic hypermutations in B cell receptors in healthy children 
using the IgK-restriction enzyme hot-spot mutation assay (IgK-REHMA) are shown.
Part 2 shows the clinical characteristics of pediatric hypogammaglobulinemia in different 
study populations. In chapter 4 a large European cohort of children with 
hypogammaglobulinemia is described using data of the ESID Online Database. Chapter 
5 discusses the challenge of IgG-subclass deficiency and specific polysaccharide antibody 
deficiency in a Dutch pediatric cohort obtained through the system of the Dutch Pediatric 
Surveillance Unit. A cohort of patients with chromosomal aberrations and primary 
immunodeficiency, consisting mainly of antibody deficiency, collected through an 
international ESID survey is presented in chapter 6.
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PART ONE
Peripheral Lymphocyte Development during Childhood
Determination of Reliable Age Matched Reference Values 
for Newly Described Lymphocyte Subpopulations in Children
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CHAPTER 1
Age-matched Reference Values for B-Lymphocyte 
Subpopulations and CVID Classifications in Children
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Abstract
Age-matched reference values are generally presented with 5th and 95th percentiles as 
‘normal’ reference range. However, they are mostly determined in relatively small groups, 
which renders this presentation inaccurate. We determined reference values for 
B-lymphocyte subpopulations in healthy children with the statistical method of tolerance 
intervals that deals far better with the relatively small numbers tested, and compared 
these to the cut-off values used in the currently used EUROclass classification for 
common variable immunodeficiency disorders (CVID) in children. CVID is a heterogeneous 
group of primary immunodeficiency diseases characterized by low serum immunoglobulin 
levels and inadequate response to vaccination. Disease-modifying heterozygous amino 
acid substitutions in TACI are found in around ±10% of CVID patients. Interestingly, we 
found that age is the primary determinant of TACI-expression on B-lymphocytes, 
independent of switched memory B-lymphocyte numbers. Immunophenotyping of 
B-lymphocyte subpopulations is increasingly used to classify patients with CVID into 
subgroups with different clinical prognosis according to the composition of their 
B-lymphocyte compartment. These classifications were mainly developed with data 
obtained in adults. Because of the maturing paediatric immune system, they may not be 
equally applicable in children: our and other age-matched reference values show great 
changes in the composition of the B-lymphocyte compartment during development. 
Although the greatest changes in B-lymphocyte subpopulations occur below the age 
of 2 years, when the diagnosis of CVID cannot yet be made, it is likely that a classification 
developed in adults cannot be used to classify the prognosis of children.





Common variable immunodeficiency disorders (CVID) is a heterogeneous group of 
primary immunodeficiency diseases characterized by late-onset hypogamma-
globulinaemia [1]. The diagnosis is based on low serum immunoglobulin levels, an 
inadequate response to vaccination, and exclusion of other causes of 
hypogammaglobulinaemia [1]. The diagnosis should not be made before the age of 2–4 
years [2]. It is more difficult to make an accurate diagnosis of CVID in children than in 
adults, because other primary immunodeficiency diseases like X-linked agammaglo-
bulinaemia may not have been detected yet in young children. Also, CVID develops 
gradually: IgA deficiency, IgG-subclass deficiencies, IgM deficiency, anti-polysaccharide 
and⁄or anti-protein antibody deficiencies accumulate until full-blown hypogamma-
globulinaemia is present [3]. With an estimated prevalence of 1:10,000 ranging to 
1:50,000, CVID is the most common symptomatic primary antibody deficiency, not only 
in adults, but in children as well [1, 4]. The prevalence of CVID increases with age [5]. 
It can also be difficult to distinguish developing CVID from delayed maturation of the 
immune system in so-called transient hypogammaglobulinaemia, which is relatively 
common especially in younger children [6]. The majority of CVID patients present with 
recurrent bacterial infections of the respiratory tract. In some patients with CVID, 
ultimately T-lymphocyte function deteriorates as well [7]. Gastrointestinal disease, 
lymphoproliferative disorders, autoimmune phenomena, and granulomatous 
inflammation are seen in subgroups of patients; in some patients these precede the 
recurrent infections [8]. Up to 73% of CVID patients develop chronic structural pulmonary 
complications. Although the incidence is lower, these pulmonary abnormalities are 
already present in children with CVID [9, 10]. Patients are treated with life-long 
replacement of immunoglobulins, but even with adequate immunoglobulin substitution 
chronic lung disease will develop in the majority of patients [11]. The exact aetiology of 
CVID is unknown, but causative gene mutations have been reported in a few families, 
including CD19 [12], CD20, B cell activating factor receptor (BAFF-R), the inducible 
costimulator (ICOS), and CD80 genes [13] and around 10% of CVID patients show 
disease-modifying heterozygous amino acid substitutions in the transmembrane and 
calcium-modulating cyclophilin ligand (CAML) interactor (TACI) [13, 14].
Immunophenotyping of lymphocyte subpopulations is an important tool in the diagnosis 
of immunological and haematological diseases. When absolute numbers of lymphocyte 
subpopulations fall outside predetermined reference ranges, this indicates possible 
disease. Lymphocyte subpopulations are also increasingly used to classify patients with 
CVID into subgroups with different clinical prognosis according to the composition of 
their B-lymphocyte compartment [15–17]. These classifications were mainly developed 
with data obtained in adults, however. Because of their maturing immune system, these 
classifications may not be equally applicable in children: age-matched reference values 
that have been determined for B-lymphocyte subpopulations in children show great 
changes in the composition of the B-lymphocyte compartment during development 
[18–26]. Not only do the absolute number of CD19+ B-lymphocytes show a massive 
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expansion shortly after birth, the relative distribution between naive (CD19+CD27-IgD+), 
natural effector (CD19+CD27+IgD+), switched memory (CD19+ CD27+IgD-) [18, 20, 23, 24, 
26], and CD21low (CD19+CD21lowCD38low) B-lymphocytes [24], as well as class-switched 
plasmablasts (CD19+CD38+++IgM-) and transitional B cells (CD19+CD38++IgM++) [18] also 
change significantly with increasing age. The most important shifts in B-lymphocyte 
subpopulations take place in the first weeks to months after birth, but development 
continues until adulthood.
Up to now, age-matched reference values are generally presented with 5th and 95th 
percentiles as ‘normal’ reference range. However, these studies were performed in relatively 
small groups, especially in the group(s) of youngest children, which renders this presentation 
inaccurate. For instance, in a group of 20 patients, the 5th percentile is determined only 
by the value obtained in the patient with rank order 2, and the 95th percentile only by the 
value obtained in the patient with rank order 19, implying that the distribution of the other 
sampled values does not play any role in inferring the percentile limits. 
We therefore determined reference values for B-lymphocyte subpopulations in healthy 
children using the statistical method of tolerance intervals that deals far better with the 
relatively small numbers tested, and used them to evaluate the applicability of the 
currently used EUROclass classification for CVID to children.
Material and methods
Subjects and samples
Leftover ethylenediaminetetraaceticacid (EDTA) blood from healthy children, who 
underwent venipuncture or blood sampling by heel prick or finger prick for other reasons, 
was used for the study. We also asked parents of otherwise healthy infants visiting the 
paediatric outpatient clinic permission to perform a venipuncture, heel prick, or finger prick 
for study purposes only; after informed consent 1–2 ml of EDTA blood was taken. Neonatal 
cord blood was obtained by venipuncture immediately after clamping of the cord. Patients 
with an active infection, diseases of the immune system, or on immunosuppressive therapy 
were excluded. Below 2 years of age, patients with perinatal problems such as prematurity 
(gestational age <35 weeks), birth weight <p10 or >p90, congenital or perinatal infection, 
artificial delivery, congenital deformities and suspected metabolic or neurological disease 
were also excluded. The study population was divided into ten age groups according to 
Comans-Bitter et al. [22]: neonatal cord blood (group 1), 1 week to 2 months (group 2), 
2–5 months (group 3), 5–9 months (group 4), 9–15 months (group 5), 15–24 months 
(group 6), 2–5 years (group 7), 5–10 years (group 8), 10–16 years (group 9), and 16 years 
and older (group 10). Blood samples were obtained between April 2008 and January 2011. 
This study was approved by the local Medical Ethics Committee. 
Flowcytometric analysis
Four-color flowcytometric immunophenotyping with directly labelled monoclonal 
antibodies (MAb) was used to determine the following lymphocyte sub populations: 




T-lymphocytes (CD3+), B-lymphocytes (CD19+), natural killer (NK) cells (CD3+CD16+and⁄or 
CD56+), naive B-lymphocytes (CD19+CD27-IgM+IgD+), natural effector B-lymphocytes 
(CD19+CD27+IgM+IgD+), IgM only memory B-lymphocytes (CD19+CD27+IgM+IgD-), 
switched memory B-lymphocytes (CD19+CD27+IgM-IgD-), transitional B cells 
(CD19+CD38++IgM++), CD21low B cells (CD19+CD21lowCD38low), and class-switched 
plasmablasts (CD19+CD38+++IgM-). We also analyzed the expression of CD5, CD10, CD20, 
CD24, CD38, Igκ and Igλ, and TACI and BAFF-R on CD19+ B-lymphocytes. 
Aliquots were incubated for 15 min in the dark at room temperature with a mixture of 
optimally titrated MAbs within 24 h after sampling. The antibodies we used are CD3 
fluoresceïne-isothiocyanate (FITC), CD5 FITC, CD38 FITC, CD4 phycoerythrin (PE), 
CD16 PE, CD20 PE, CD24 PE, CD56 PE, BAFF-R PE, CD8 peridinin chlorophyll protein–
cyanin (PerCP-Cy-5.5), CD19 PerCP-Cy5.5, CD45 PerCP-Cy5.5, CD10 allophycocyanin 
(APC), CD14 APC, CD21 APC, CD27 APC [all Becton Dickinson (BD), San Jose, California 
USA], SmIgκ FITC, SmIgD FITC, SmIgλ PE, SmIgM PE (Dakopatts, Glostrup, Denmark), 
CD235a FITC, CD71 PE (Sanquin, Amsterdam, The Netherlands) and TACI Biotin 
(Peprotech, Rocky Hill, USA)⁄streptavidine APC (BD). Before surface staining, erythrocytes 
were lysed with ammonium chloride (NH
4
Cl). Remaining cells were washed twice with 
phosphate buffered saline⁄bovine serum albumin 0.5%, and analysed with a FACSCalibur 
flowcytometer (BD) using CellQuestPro software. Calibration of the flowcytometer 
took place with CaliBRITE beads according to the manufacturer’s instructions (BD) en 
daily quality control with Cyto-Cal (microgenics Duke Scientific, Fremont CA, USA) 
following the guidelines of Kraan et al. [27]. The lymphogate was checked with a 
CD3⁄CD14 labelling and considered correct if less than 1% monocyte contamination 
was present. T-lymphocytes and NK-cells were used to check the ‘lymphosum’ 
(B+T+NK = 100 ± 5%).
Leukocyte count and differential were determined with a routine haematology analyzer 
(XE 2100, Sysmex, Kobe, Japan). In neonatal cord blood, the lymphogate was corrected 
for contamination with erythroid cells (normoblasts and unlysed erythrocytes) using the 
following formula: corrected % of lymphocyte subpopulation = % of lymphocyte 
subpopulation within the lymphogate x 100⁄[100 - (%CD71+ normoblasts + %CD235+CD71- 
unlysed erythrocytes within the lymphogate)]. The absolute size of each lymphocyte 
subpopulation was calculated by multiplying the relative size of the lymphocyte 
subpopulation and the absolute lymphocyte count. 
Statistics
The number of subjects in the different age groups varied between 10 and 21 per tested 
subpopulation; numbers that are too low to determine robust percentile points at 5 and 
95%. Confidence intervals may seem to offer an alternative, but deal with estimating the 
range of the population mean, and do not cover the distribution of the population values. 
The proper statistical procedure is to calculate the tolerance interval which enclosures 
a specific proportion of the population, estimated on the basis of the values sampled. 
The tolerance interval takes into account the sample size, the noise in the estimates of 
the mean and standard deviation, and the confidence about the tolerance interval [28]. 
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We set the proportion to be included at 0.90 (two-sided, comparable to the percentile 
points p5 and p95), with a confidence level of 0.95.
Tolerance intervals assume normally distributed populations. Most of our data were 
positively skewed. In 75% of the cases the means were larger than the median (339 out 
of 450 subsets of measurements = 45 sets of measurements in 10 age groups). 
Logarithmic transformation reduced the number of cases to 42% (187), which is much 
closer to the expected percentage (50%). Two tests of normality were applied to each 
subset of the 450 measurements, the Kolmogorov–Smirnov test and the Shapiro–Wilks 
test. The original values returned 94 (21%) and 118 (26%) significant violations (α = 0.05) 
of the normality assumption. The log-transformed values returned 33 (7%) and 42 (9%) 
violations, which is fairly close to the expected percentage (5%). The logarithmic 
transformation has the additional advantage that the estimated tolerance intervals do 
not include non-existing negative values. All values given in the tables are the re-
transformed logarithmic values. To evaluate the age effect in the 45 sets of measurements 
a one-way ANOVA test (α = 0.05) was applied. 
The correlations of TACI and BAFF-R values with B cell subpopulations and age were 
assessed with the Pearson product-moment correlations and partial correlations. The 
logarithmic transformation was applied both to age in months (because of the large age 
range in the older groups; a value of 1 was added) and the measured values (because of 




Absolute B-lymphocyte numbers double during the first months of life and then gradually 
decrease almost fivefold from the second half of the first year of life to adult values; this 
is almost entirely caused by expansion of the naive B-lymphocyte pool, and to a small 
extent by expansion of transitional cells (Figure 1), which are higher in the youngest age 
groups.
Age-matched reference values
The absolute and relative sizes of the measured B-lymphocyte subpopulations are shown 
in Tables 1 and 2, respectively. The data were not normally distributed, given the means 
of the different subpopulations being larger than the median in 75% of the subsets of the 
measurements in the different age groups. We therefore used logarithmic values to 
calculate the value intervals (see ‘Material and methods’). With the provided reference 
values in Tables 1 and 2, we give a 95% chance that 90% of healthy children will show 
absolute numbers within this range. All sets of measurements showed a statistically 
significant age effect (α = 0.05), except for absolute and relative values of CD19+CD20- 
B cells; this subpopulation was very small in number in all age-groups.




TACI and BAFF-R expression
We determined TACI and BAFF-R expression in a randomly selected subgroup (total 
group n = 36; cord blood n = 6, 1 week to 2 months n = 2, 2–5 months n = 2, 5–9 months 
n = 3, 9–15 months n = 3, 15–24m n = 2, 2–5 years n = 2, 5–10 years n = 4, 10–16 years 
n = 4, adults n = 8). All children showed >95% BAFF-R positivity on CD19+ cells, with a 
mean fluorescence intensity of 226 (on a scale of 1024 channels). The mean fluorescence 
intensity of TACI-expression was 11 (on a scale of 1024 channels) on TACI- CD19+ cells 
(background staining) and 104 (on a scale of 1024 channels) on TACI+ CD19+ cells. 
A median of 2.6% (range 1.0–12.6%) of B-lymphocytes were TACI-positive. 
No correlation was found between switched memory B-lymphocyte numbers and the 
percentage of TACI+ B-lymphocytes (r = 0.213, P = 0.213); a negative correlation was 
found between naive B-lymphocyte numbers and the percentage of TACI+ B-lymphocytes 
(r = -0.738, P = 0.000), and a positive correlation between the percentage of TACI+ 
B-lymphocytes and age (r = 0.538, P = 0.001). A partial correlation was computed 
controlling for age to investigate whether the negative correlation between the 
percentage of TACI+ B-lymphocytes and naive B-lymphocyte numbers was based on 
the developmental role of age only. After correction for age, the negative correlation 
between the percentage of TACI+ B-lymphocytes and naive B-lymphocyte numbers 
disappeared (r = -0.318, P = 0.063), showing that age is the primary determinant of 
TACI-expression on B-lymphocytes.
Figure 1 
Composition of the B-lymphocyte compartment during childhood (median per age group). Diagonal striped bars 
transitional B cell (CD19+CD38++IgM++). Grey bars naive B cell (CD19+CD27-IgM+IgD+). White bars natural effector 
B cell (CD19+CD27+IgM+IgD+). Asterisk IgM only memory B cell (CD19+CD27+IgM+IgD-). Black bars switched 
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Table 1 Absolute numbers of B-lymphocytes in peripheral blood. 
Population N = Cord blood N = 1 w – 2 m N = 2 – 5 m N = 5 – 9 m N = 9 – 15 m N = Population 15 – 24 m N = 2 -5 y N = 5 – 10 y N = 10- 16 y N = > 16 y N =








































































































































































































































































































































































































Mean and 90% range x 10e9/l. W = week, m = month, y = year.
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Mean and 90% range x 10e9/l. W = week, m = month, y = year.
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Table 2 Relative numbers of B-lymphocytes in peripheral blood.

























































































































































































































































































































































Mean and 90% range. W = week, m = month, y = year. a % of total lymphocytes. b % of B-lymphocytes.




Table 2 Relative numbers of B-lymphocytes in peripheral blood.

























































































































































































































































































































































Mean and 90% range. W = week, m = month, y = year. a % of total lymphocytes. b % of B-lymphocytes.
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Evaluation of EUROclass classification
The B-lymphocyte subpopulations used in the EUROclass CVID classification clearly 
show an age-related development during childhood. When our group of healthy children 
would be assessed according to the EUROclass classification, 40 out of 97 children would 
be classified in one of the subgroups due to the fact that they show lower relative 
numbers of switched memory B-lymphocytes (Figure 2). Within this group 27 children 
showed high relative numbers of transitional B cells. However, 38 of these 40 children 
were younger than two years of age, when the diagnosis of CVID cannot yet be made.
Discussion
B cell immunophenotyping characteristics correlate with clinical complications in adults 
with CVID and are therefore used for classification of patients; currently, the EUROclass 
classification is most commonly used [17]. We and others [18-26] demonstrate that the 
B-lymphocyte compartments of normal adults and children of various ages differ 
considerably, implicating that data obtained in adults should not be extrapolated to children. 
These differences seem logical when looking at normal B cell development: after initial 
maturation in the bone marrow, the first cells to emigrate into the peripheral blood are 
transitional (CD19+CD38++IgM++) B cells and naive B-lymphocytes (CD19+CD27-IgM+IgD+) 
[29, 30]. The next step leads to short-lived antibody-secreting plasma cells, switched 
Figure 2 
The age-related development of B-lymphocyte subpopulations used in the EUROclass CVID classification (median 
per age group). (A) Switched memory B-lymphocytes (CD19+CD27+IgM-IgD-) with cut-off used in the EUROclass 
CVID classification (grey line) at 2%. (B) Transitional B cells (CD19+CD38++IgM++) with cut-off used in the EUROclass 
CVID classification (grey line) at 9%. (C) CD21low⁄CD38low B cells (CD19+CD38lowCD21low) with cut-off used in the 
EUROclass CVID classification (grey line) at 10%. All measured as percentage of CD19+ B-lymphocytes in peripheral 
blood.




memory B-lymphocytes, or natural effector cells, depending on the environment during 
activation, and the presence or absence of help from T-lymphocytes [31–34]. These last 
steps are antigen dependent; they are also the steps that are disturbed in CVID. CD21low B 
cells (CD19+CD21lowCD38low) are rare in the blood of healthy individuals but can be found 
in patients with autoimmune disease [35]. Forty out of our 97 normal healthy children could 
be ‘classified’ in the CVID-subgroup with the highest risk of complications according to the 
EUROclass system, but 38 of them were younger than 2 years of age, when the diagnosis 
of CVID cannot yet be made. A similar pattern is seen in other recently published data of 
B-lymphocyte subpopulations in healthy children [18]. Two papers have been published 
examining the EUROclass classification in children with CVID. Van de Ven et al. showed 
that two of nine children with CVID and heterozygous TACI mutations belonged to the 
EUROclass high-risk group based on immunophenotyping results (smB-Trhigh) [36]. Yong et 
al. showed the correlation in a small group of children with CVID: children with few or 
absent switched memory B-lymphocytes (<5⁄ml; n = 24) exhibited a more severe clinical 
phenotype and more autoimmune cytopenia (21% vs. 0%) than those with higher numbers 
of switched memory B-lymphocytes (n = 21) [37]; but this cohort is too small to extrapolate 
the data to the entire paediatric population. However, the great changes of these populations 
during development emphasize that a classification developed in adults cannot simply be 
extrapolated to classify the prognosis of children. A large, multicenter study is needed to 
evaluate the immunophenotyping characteristics of children with CVID and to correlate 
these with their clinical phenotype to create a reliable paediatric CVID classification. 
Nearly 10% of CVID patients show a disease-modifying mutation in the gene encoding for 
TACI (TNFRSF13B), a tumour necrosis factor receptor expressed mainly by activated 
B-lymphocytes (like marginal zone and memory B-lymphocytes), activated T-lymphocytes, 
monocytes, and dendritic cells. It mediates isotype switching, promotes plasma cell 
differentiation, and is essential for thymus-independent antibody responses, but also has 
an inhibitory role in B cell homeostasis [14]. Lack of TACI-expression can be used as a 
screening method before performing genetic analysis for the gene. There is little 
information about normal TACI-expression in healthy adults [38], and none in children, 
however. Plasma levels of BAFF and APRIL (both ligands of TACI) are significantly higher 
in patients with CVID, and correlate inversely with age in healthy subjects [39], suggesting 
a positive age effect for TACI. Preterm neonatal naive B-lymphocytes show lower BAFF-R 
fluorescence intensity compared to adult naive B-lymphocytes, but in the same study no 
significant difference between TACI-expression on naive B-lymphocytes was found 
between cord blood and adults [38]. However, a lower gene expression of TACI determined 
by RT-PCR was seen in preterm cord blood compared to adult blood [38]. We found lower 
percentages of TACI+ B-lymphocytes in younger children compared to older children and 
adults. We did not find any effect of age on the BAFF-R expression on B-lymphocytes. This 
means that a low number of TACI-positive B-lymphocytes in young children is not 
indicative of a potential TACI-mutation.
In conclusion, we established statistically reliable reference ranges of B-lymphocyte 
subpopulations for children of different ages for all B cell subpopulations relevant in CVID 
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patients. Although the greatest changes in B-lymphocyte subpopulations occur below the 
age of 2 years when the diagnosis of CVID cannot yet be made, the development of the 
peripheral B-lymphocyte population during childhood emphasizes the potential dangers 
of using a classification developed in adults to classify the prognosis of children and 
demonstrates the need for a separate paediatric CVID classification.
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CHAPTER 2
Paediatric Reference Values for 
the Peripheral T Cell Compartment
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Abstract
Immunophenotyping of blood lymphocyte subpopulations is an important tool in the 
diagnosis of immunological and haematological diseases. Paediatric age-matched 
reference values have been determined for the major lymphocyte populations, but 
reliable reference values for the more recently described T-lymphocyte subpopulations, 
like different types of memory T-lymphocytes, recent thymic emigrants, regulatory T 
cells and CXCR5+ helper T-lymphocytes, are not sufficiently available yet. We determined 
reference values for the absolute and relative sizes of T-lymphocyte subpopulations in 
healthy children using the lysed whole blood method, which is most often used in 
diagnostic procedures. When the absolute numbers of some or all T-lymphocyte 
subpopulations fall outside these reference ranges, this may indicate disease. The 
reference values show the course of T-lymphocyte development in healthy children. 
Absolute T-lymphocyte numbers increase 1.4-fold during the first months of life, and 
after 9–15 months, they decrease threefold to adult values; this is mainly caused by the 
expansion of recent thymic emigrants and naive cells. Helper and cytotoxic T-lymphocytes 
show the same pattern. Regulatory T cells increase in the first 5 months of life and then 
gradually decrease to adult values, although the absolute numbers remain small. The 
relative number of CXCR5+ cells within the CD4+CD45RO+ T-lymphocytes increases 
during the first 6 months of life and then remains more or less stable around 20%.





Immunophenotyping of blood lymphocyte subpopulations is an important tool in the 
diagnosis of immunological and haematological diseases, also in children. Paediatric 
age-matched reference values have been determined for the major lymphocyte 
populations (B-, T-, helper T- and cytotoxic T-lymphocytes, and NK cells) [1–4]. These 
studies reported an increase in the absolute number of CD3+ T-lymphocytes immediately 
after birth and a gradual decrease from 2 years of age to adulthood. CD3+CD4+ helper 
T-lymphocytes showed the same pattern, but CD3+CD8+ cytotoxic T-lymphocytes were 
reported to remain stable up to 2 years of age and then to show a gradual decrease 
towards adult levels. Absolute numbers of NK cells decrease rapidly during the first 2 
months of life and continue to gradually decrease thereafter. 
In the past decade, new insights in the composition of the peripheral T cell compartment 
have revealed several ‘new’ subpopulations, like different types of memory T-lymphocytes 
[5–7], recent thymic emigrants [8, 9], regulatory T cells [10] and CXCR5+ helper 
T-lymphocytes [11]. In the maturing immune system of children, these subsets are of 
special interest; they support the diagnostic process and in some cases, the evaluation 
of treatment strategies of immunological diseases in children [12]. Van Gent et al. [13] 
recently used thawed, cryopreserved, isolated peripheral blood mononuclear cells to 
determine different T-lymphocyte subpopulations in children, but this technique can 
affect the composition and phenotype of (subpopulations of) the peripheral lymphocyte 
compartment [14, 15]. Hence, these data are not suitable as reference values for lysed 
whole blood testing results, the technique most commonly used in routine diagnosis. 
Therefore, we determined reference values for T-lymphocyte subpopulations in healthy 
children using the lysed whole blood method.
Methods
Subjects and samples
Leftover ethylenediaminetetraaceticacid (EDTA) blood from healthy children, who 
underwent venipuncture or blood sampling by heel prick or finger prick for other reasons, 
was used for the study. We also asked parents of otherwise healthy infants visiting the 
paediatric outpatient clinic permission to perform a venipuncture, heel prick or finger 
prick for study purposes only; after informed consent, 1–2 ml of EDTA blood was taken. 
Neonatal cord blood was obtained by venipuncture immediately after clamping of the 
cord. Patients with an active infection, diseases of the immune system or on 
immunosuppressive therapy were excluded. Below 2 years of age, patients with perinatal 
problems such as prematurity (gestational age <35 weeks), birthweight <p10 or >p90, 
congenital or perinatal infection, artificial delivery, congenital deformities and suspected 
metabolic or neurological disease were also excluded. The study population was divided 
into ten age groups according to Comans-Bitter et al.[2]: neonatal cord blood (group 1), 
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1 week–2 months (group 2), 2–5 months (group 3), 5–9 months (group 4), 9–15 months 
(group 5), 15–24 months (group 6), 2–5 years (group 7), 5–10 years (group 8), 10–16 
years (group 9) and 16 years and older (group 10). Blood samples were obtained between 
April 2008 and January 2011. This study was approved by the local Medical Ethics 
Committee. 
Flow cytometric analysis
Four-colour flow cytometric immunophenotyping with directly labelled monoclonal 
antibodies (MAb) was used to determine the following lymphocyte subpopulations: 
T-lymphocytes (CD3+), B-lymphocytes (CD19+), natural killer (NK) cells (CD3-CD16+ and⁄or 
CD56+), helper T-lymphocytes (CD3+CD4+), cytotoxic T-lymphocytes (CD3+CD8+), NK-T 
cells (CD3+CD16+and⁄orCD56+), naive helper T-lymphocytes (CD3+CD4+CD45RA+CD27+), 
terminally differentiated helper T-lymphocytes (CD3+CD4+CD45 RA+CD27-), central 
memory helper T-lymphocytes (CD3+CD4+CD45RA-CD27+), effector memory helper 
T-lymphocytes (CD3+CD4+CD45RA-CD27-), naive cytotoxic T-lymphocytes 
(CD8+CD45RA+CD197+CD27+), terminally differentiated cytotoxic T-lymphocytes 
(CD8+CD45RA+CD197-CD27-), central memory cytotoxic T-lymphocytes (CD8+CD45RA-
CD197+CD27+), effector memory cytotoxic T-lymphocytes (CD8+CD45RA-CD197-CD27-) 
[16], recent thymic emigrants (CD3+CD4+CD45RA+CD31+) and regulatory T cells 
(CD3+CD4+CD25++CD127-). We also analysed the expression of T cell receptor (TCR)-αβ 
and TCR-γδ on the CD4+ and on the CD8+ T-lymphocytes, as well as the expression of 
CD185 (=CXCR5) on CD3+CD4+CD45RO+ T-lymphocytes. 
Aliquots were incubated for 15 min in the dark at room temperature with a mixture of 
optimally titrated MAbs within 24 h after sampling. The antibodies used were CD3 
fluoresceïne-isothiocyanate (FITC), CD45RA FITC, TCR- αβ FITC, CD4 phycoerythrin (PE), 
CD16 PE, CD31 PE, CD56 PE, CD127 PE, CD197 PE (=CCR7), TCR- γδ PE, CD3 peridinin 
chlorophyll protein-cyanin (PerCP-Cy-5.5), CD4 PerCP-Cy-5.5, CD8 PerCP-Cy-5.5, CD19 
PerCP-Cy-5.5, CD45 PerCP-Cy-5.5, CD4 allophycocyanin (APC), CD14 APC, CD25 APC, 
CD27 APC, CD45RO APC, CD185 Alexa Fluor®488 (all Becton Dickinson, San Jose, CA, 
USA), CD235a FITC and CD71 PE (Sanquin, Amsterdam, the Netherlands). 
Before surface staining, erythrocytes were lysed with ammonium chloride (NH
4
Cl). 
Remaining cells were washed twice with phosphate-buffered saline⁄bovine serum 
albumin 0.5% and analysed with a FACSCalibur flow cytometer (Becton Dickinson) using 
CELLQUESTPRO software (Becton Dickinson). Calibration of the flow cytometer took 
place with CaliBRITE beads according to the manufacturer’s instructions (Becton 
Dickinson) and daily quality control with Cyto-Cal (microgenics Duke Scientific, Fremont 
CA, USA) following the guidelines of Kraan et al. [17]. 
The lymphogate was checked with a CD3⁄CD14 labelling and considered correct if <1% 
monocyte contamination was present. B-lymphocytes and NK cells were used to check 
the ‘lymphosum’ (B + T + NK = 100 ± 5%). Leucocyte count and differential were 
determined with a routine hematology analyzer (XE 2100; Sysmex, Kobe, Japan). 
In neonatal cord blood, the lymphogate was corrected % of lymphocyte subpopulation 




= % of lymphocyte subpopulation within the lymphogate x 100⁄(100 - [%CD71+ 
normoblasts + %CD235+CD71- unlysed erythrocytes within the lymphogate]). The 
absolute size of each lymphocyte subpopulation was calculated by multiplying the 
relative size of the lymphocyte subpopulation and the absolute lymphocyte count. 
Statistics
The number of subjects in the different age groups varied between 8 and 21 per tested 
subpopulation, numbers that are too low to determine robust percentile points at 5% 
and 95%. Confidence intervals may seem to offer an alternative, but deal with estimating 
the range of the population mean, and do not cover the distribution of the population 
values. The proper statistical procedure is to calculate the tolerance interval, which 
enclosures a specific proportion of the population, estimated on the basis of the values 
sampled. The tolerance interval takes into account the sample size, the noise in the 
estimates of the mean and standard deviation, and the confidence about the tolerance 
interval [18]. We set the proportion to be included at 0.90 (two-sided, comparable to the 
percentile points p5 and p95), with a confidence level of 0.95. 
Tolerance intervals assume normally distributed populations. Most of our data were 
positively skewed. In 75% of the cases, the means were larger than the median (426 of 
570 subsets of measurements = 57 sets of measurements in 10 age groups). Logarithmic 
transformation reduced the number of cases to 43% (244), which is much closer to the 
expected percentage (50%). Two tests of normality were applied to each subset of the 
57 measurements: the Kolmogorov–Smirnov test and the Shapiro– Wilks test. The 
original values returned 135 (24%) and 180 (32%) significant violations (α = 0.05) of the 
normality assumption. The log-transformed values returned 64 (11%) and 73 (13%) 
violations, which is far more close to the expected percentage (5%). The logarithmic 
transformation has the additional advantage that the estimated tolerance intervals do 
not include non-existing negative values. However, after logarithmic transformation, the 
tolerance intervals sometimes seemed to be rather broad, in particular in the case of the 
relative numbers. This is explained by the large standard deviations in these groups with 
very low concentration levels, which easily lead to measurement errors and extreme 
differences between the low and high values in the measurements. In 30 cases, the ratio 
of the highest and lowest values of the logarithmic standard deviations was >1.100. In 
these cases, the right limit of the tolerance interval was based on the original values, as 
indicated by an asterisk in the tables. All other values given in the tables are the 
retransformed logarithmic values. To evaluate the age effect in the 57 sets of 
measurements, a one-way ANOVA test (α = 0.05) was applied. All calculations and tests 
were performed with SPSS 16.0 for Windows (IBM, Armonk, NY, USA).
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Results
The absolute and relative sizes of the measured T-lymphocyte subpopulations are shown 
in Tables 1 and 2. All sets of measurements showed a statistically significant age effect 
(α = 0.05), except for absolute and relative values of terminally differentiated helper 
T-lymphocytes, possibly due to the small numbers of this subpopulation, and for the 
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Composition of the T-lymphocyte compartment during childhood (median per age group). (A) naive helper T 
cells (CD3+CD4+CD27+CD45RA+) (grey bars), recent thymic emigrants (CD3+CD4+CD45RA+CD31+) (black bars), 
terminally differentiated helper T cells (CD3+CD4+CD27-CD45RA+) (bars with *), effector memory helper T cells 
(CD3+CD4+CD27-CD45RA-) (bars with **) and central memory helper T cells (CD3+CD4+CD27+CD45RA-) (white 
bars). (B) naive cytotoxic T cells (CD3+CD8+CD45RA+CD197+) (grey bars), terminally differentiated cytotoxic T cells 
(CD3+CD8+CD45RA+CD197-) (diagonal striped bars), effector memory cytotoxic T cells (CD3+CD8+CD45RA-CD197-) 
(horizontal striped bars) and central memory cytotoxic T cells (CD3+CD8+CD45RA-CD197+) (white bars).




Absolute T-lymphocyte numbers increase 1.4-fold during the first months of life, and 
after 9–15 months, they decrease threefold to adult values. NK cells show more than 
50% decrease of absolute numbers immediately after birth, with a more gradual decrease 
until 2– 5 years of age and a small increase in later childhood. Helper T-lymphocytes as 
well as cytotoxic T-lymphocytes show the same pattern as total T-lymphocytes with an 
increase in the first months of life and a decline after 9– 15 months of age. The expansion 
of total T-lymphocytes is caused mainly by naive helper T-lymphocytes, although naive 
cytotoxic T-lymphocytes also almost double during the first 15 months of life, but their 
numbers are smaller (Figure 1). Central memory helper T-lymphocytes are already present 
at birth and remain relatively stable, whereas effector memory helper T-lymphocytes are 
almost absent at birth and gradually increase in later years. Absolute counts of terminally 
differentiated helper T-lymphocytes remain extremely low. Memory cytotoxic 
T-lymphocytes are already present at birth; central memory cytotoxic T-lymphocytes 
follow the pattern of expansion and then gradual decrease, whereas effector memory 
T-lymphocytes show expansion until adulthood. Terminally differentiated cytotoxic 
T-lymphocytes form a substantial part of the total peripheral cytotoxic T-lymphocyte 
population and follow the pattern of expansion and then gradual decrease. Recent thymic 
emigrants increase 1.6-fold in the first 5 months of life and then gradually decrease 
almost 8-fold to adult values, not unexpectedly following the pattern of naive helper 
T-lymphocytes (Figure 1). 
Absolute numbers of regulatory T cells show a comparable pattern to naive helper 
T-lymphocytes, but their absolute numbers remain small. Their relative number within 
the total peripheral CD4+ T-lymphocyte population remains stable during life (Figure 2). 
The relative number of CXCR5+ cells within the CD4+CD45RO+ T-lymphocyte subset 
increases during the first 6 months of life and then remains more or less stable around 
20%. The absolute numbers of CD3+CD4+CD45RO+CXCR5+ cells increase during 
childhood until adult values are reached (Figure 3).
Discussion
In this study, we confirm – in accordance with previous publications [1–4, 13] – that the 
T-lymphocyte compartments of normal adults and children of various ages differ 
considerably. When studying the composition of the T-lymphocyte compartment in children 
for research purposes as well as in a diagnostic setting, it is important to realize this. 
Our results concerning the age distribution of absolute numbers of cytotoxic 
T-lymphocytes differ from previous studies, which report stable numbers during the first 
months of life, however; we found a clear increase of cytotoxic T-lymphocyte numbers 
until 9–15 months of age and a decrease thereafter, similar to the pattern found for helper 
T-lymphocytes. Helper T-lymphocyte and cytotoxic T-lymphocyte both show a massive 
increase of the naive population in early years, but there is a clear difference between the 
subset differentiation of helper and cytotoxic T-lymphocytes with increasing age. 
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The central memory pool of helper T-lymphocytes remains relatively stable over the 
years, and the effector memory and terminally differentiated subsets remain very small 
in number, but central memory and terminally differentiated cytotoxic T-lymphocyte 
double during the first months of life and then gradually decrease, whereas the effector 
memory subset shows increasing numbers with age. Our age-related reference values 
for these subpopulations can be used to help discern normal from abnormal 
T-lymphocyte development in children. 
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Regulatory T cells during childhood (median per age group). (A) absolute numbers of regulatory T cells (CD3+CD4+ 
CD25++CD127-). (B) relative numbers of regulatory T cells (CD3+CD4+CD25++CD127-) within CD4+ T-lymphocytes.




The neonatal CD4+ compartment contains more recent thymic emigrants than the adult 
CD4+ compartment [8, 9]. Not unexpectedly, our data show that recent thymic emigrants 
follow the pattern of naive helper T-lymphocytes after the neonatal period (Figure 1). 
Recent thymic emigrants are not only interesting when exploring the maturing immune 
system, abnormal numbers are also associated with several diseases: decreased numbers 
of recent thymic emigrants are seen in children with rheumatoid factor–negative 
polyarticular juvenile idiopathic arthritis and in adults with SLE and psoriasis [19–21], 
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CXCR5+ memory helper T-lymphocytes during childhood (median per age group). (A) absolute numbers of CXCR5+ 
memory helper T-lymphocytes (CD3+CD4+CD45RO+CXCR5+). (B) relative numbers of CXCR5+ cells within 
CD4+CD45RO+ memory T-lymphocytes.
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whereas type I diabetes is associated with increased recent thymic emigrants in children 
and adolescents [22]. 
Dysfunction of regulatory T cells is associated with autoimmune disease, immuno-
pathology and allergy [23]. Several primary immunodeficiency diseases are associated 
with abnormalities of regulatory T cells; one example is ‘immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked’ [24]. Also, subgroups of common variable 
immunodeficiency (CVID) patients show decreased numbers of regulatory T cells, 
associated with specific clinical phenotypes [25]. Especially when exploring the latter 
in children, it is important to evaluate the results using age-related reference values 
(Figure 2). 
The CXC chemokine receptor 5 (CXCR5) is widely expressed on B-lymphocytes and is 
required for the development of follicles in secondary lymphoid tissue [26]. CXCR5 is 
also expressed on a subset of circulating memory helper T-lymphocytes in the germinal 
centres of secondary lymphoid organs where they efficiently support the production of 
immunoglobulins IgA and IgG [11, 27, 28]. Interestingly, CXCR5+ memory T-lymphocytes 
are virtually absent at birth and increase in numbers during the first year of life, paralleling 
the start of infantile IgA and IgG production (Figure 3). 
In conclusion, we determined age-related reference values for the peripheral 
T-lymphocyte compartment, including several more recently described subpopulations, 
using the lysed whole blood method and the statistical method of tolerance intervals to 
obtain reliable data that efficiently use all the information available. When absolute 
numbers of some or all T-lymphocyte subpopulations fall outside these reference ranges, 
this may indicate disease. Our data enable evaluation of these T-lymphocyte 
subpopulations in primary immunodeficiencies and auto-immune diseases in childhood.
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Table 1 Absolute numbers of T-lymphocytes.
Population N = Cord blood N = 1 w – 2 m N = 2 – 5 m N = 5 – 9 m N = 9 – 15 m N = Population 15 – 24 m N = 2 -5 y N = 5 – 10 y N = 10- 16 y N = > 16 y** N =
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Mean and 90% range x 10e9/l. W = week, m = month, y = year. * The right limit of this tolerance interval was based on the original values (see 
Method). ** Age range: 16 – 76 years. Median age: 33 years.
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Mean and 90% range x 10e9/l. W = week, m = month, y = year. * The right limit of this tolerance interval was based on the original values (see 
Method). ** Age range: 16 – 76 years. Median age: 33 years.
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Table 2  Relative numbers of T-lymphocytes.











































































































































































































































































































































































































































































































































































































































w = week, m = month, y = year. a %of total peripheral lymphocyte population, b % of CD4+ T-lymphocytes, c % of CD8+ T-lymphocytes, d % of CD4+CD45RO+ 
T-lymphocytes, e % of TCR alpha/beta+ T-lymphocytes, f % of TCR gamma/delta+ T-lymphocytes. * The right limit of this tolerance interval was based on 
the original values (see Method). ** Age range: 16 – 76 years. Median age: 33 years.
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w = week, m = month, y = year. a %of total peripheral lymphocyte population, b % of CD4+ T-lymphocytes, c % of CD8+ T-lymphocytes, d % of CD4+CD45RO+ 
T-lymphocytes, e % of TCR alpha/beta+ T-lymphocytes, f % of TCR gamma/delta+ T-lymphocytes. * The right limit of this tolerance interval was based on 
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Abstract
Somatic hypermutation (SHM) is an important step in the antigen-driven B cell 
development creating B-lymphocytes expressing high-affinity antibody receptors. It is 
known that the peripheral B-lymphocyte compartments of healthy children and adults 
differ considerably. However, the development of SHM with age has not been studied 
in detail before. Therefore, we used the IgK-restriction enzyme hot-spot mutation assay 
(IgK-REHMA) to get an estimation of SHM levels in different age groups in order to relate 
this to the size of the memory B-lymphocyte subpopulations. We show that the level of 
SHM increases rapidly during the first two years of life. This reflects the changes of the 
memory B cell subpopulations, but also changes in the SHM within memory B cell 
subsets, probably reflecting an increase of secondary memory B cell responses. 





Somatic hypermutations (SHM) are introduced in a programmed process in the variable 
regions of immunoglobulin genes to generate higher-affinity B cell receptors (BCR) in 
memory B cells. In bone marrow, pro- and pre-B cells develop from hematopoietic stem 
cells, and a unique BCR is generated by V(D)J recombination of the immunoglobulin (Ig) 
heavy chain and light chain loci. Antigen exposure in the periphery induces activation 
and further differentiation into so-called switched memory B-lymphocytes (smB) in 
germinal center (GC) reactions in secondary lymphoid tissues by two separate processes: 
class-switch recombination (CSR), which leads to loss of surface IgM, and gain of surface 
IgG, IgA or IgE, and SHM, which leads to enhanced antibody affinity [1]. Non-switched 
memory B-lymphocytes (nsmB) mutate their immunoglobulin receptor at least partly 
outside of a germinal center, without CSR [2].
The peripheral B-lymphocyte compartments of healthy adults and children of various 
ages differ considerably [3]. It has not been studied in detail how SHM develops with 
increasing age, nor how it is related to the development of populations of smB and nsmB 
cells. We used the IgK-restriction enzyme hot-spot mutation assay (IgK-REHMA) [4] to 
get an estimation of SHM levels in healthy children of different age groups and in adults 
in order to relate this to the size of the B cell subsets. We compared these values to those 
obtained in a group of common variable immunodeficiency disorders (CVID) patients 
that we published before [5].
Material and methods
After approval by the medical ethics committees of the Jeroen Bosch Hospital and 
Erasmus MC, and after informed consent was obtained from the parents and patients 
>12 years, peripheral blood samples were collected from 7 neonates (cord blood), 49 
healthy children (mean age 5.3 years, range 1 week – 15.6 years), 8 healthy adults (> 16 
years) [3], and 23 CVID patients [5]. The blood was collected from healthy children and 
adults, who underwent venipuncture or blood sampling by heel prick or finger prick for 
other reasons (e.g. minor surgery). Patients with an active infection, suspected or proven 
diseases of the immune system, or on immunosuppressive therapy were excluded.
To estimate the frequency of SHM, the IgK-REHMA assay was used. In brief, a RT-PCR 
reaction was performed using a HEX-coupled Vk3-20U forward primer and a FAM-
coupled Vk3-20L reverse primer. The PCR products were digested with DdeI and Fnu4HI 
and run on an ABI3130XL capillary sequencer (Applied Biosystems). Unmutated gene 
products could be visualized as 106- or 109-bp FAM-coupled fragments and mutated 
gene products as 244-bp FAM-coupled fragments [4]. This analysis estimates the amount 
of SHM in expressed Vk3/20 gene segments in a specific sequence motif (hotspot), 
displayed as percentage of mutated segments within the total peripheral blood cell 
population. Because only B-lymphocytes express these gene segments, this percentage 
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is a reflection of the percentage of mutated cells within the peripheral population of 
B-lymphocytes. However, the amount of SHM within a specific B cell subpopulation 
cannot be estimated.
Flowcytometric immunophenotyping with directly labeled monoclonal antibodies was 
used to determine the following lymphocyte subpopulations: B-lymphocytes (CD19+), 
transitional B cells (CD19+CD38++IgM++), naive B-lymphocytes (CD19+CD27-IgM+IgD+), 
nsmB comprising natural effector cells (CD19+CD27+IgM+IgD+) and IgM-only 
B-lymphocytes (CD19+CD27+IgM+IgD-), and smB (CD19+CD27+IgM-IgD-) [3, 5]. 
Statistical calculations were performed with SPSS 20 for Windows. We calculated the 
Pearson product-moment correlation between the estimated percentage of SHM and 
age (alpha = 0.05, two-tailed) with the logarithmic value of age in days, with cord blood 
designated as day 1, to cope with the non-linear, downward bending relationship 
between the estimated SHM percentage and age.
Results
We found that the percentage of mutated hot spots in rearranged Vk3-20 gene segments 
in peripheral blood using the IgkREHMA assay, which gives an estimate of the level of 
SHM, shows an increase during the first two years of life in healthy children (Figure 1a), 
and then remains at a relatively stable level throughout childhood (mean 68%, range 38-
89%, n=40). The Pearson product-moment correlation between the estimated percentage 
of SHM and age was significant and high (r(64) = 0.848, p=0.000). This pattern is clearly 
different from the development of the relative as well as the absolute numbers of smB 
and nsmB with increasing age (Figure 2; described before in reference 3) [3]. 
Figure 1
Percentage of somatic hypermutation (SHM) using the Igk-REHMA assay distributed for age. Every dot represents 
a healthy subject [A] or a CVID patient [B]. The dotted lines show the age groups used in the statistical analyses.





Percentages of non-switched memory B-lymphocytes (nsmB) [A], switched memory B-lymphocytes (smB) [C] 
and nsmB + smB  [E] within the total peripheral B cell population (CD19+) distributed for age. Absolute numbers 
of non-switched memory B-lymphocytes (nsmB) [B], switched memory B-lymphocytes (smB) [D] and nsmB + 
smB [F] distributed for age. Every dot represents a healthy subject. The dotted lines show the age groups used in 
the statistical analyses.
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There were also significant correlations between the percentage of SHM and the absolute 
numbers (r(64) = 0.354, p=0.004) and percentages of smB (r(64) = 0.624, p=0.001), as 
well as the percentages (r(62) = 0.395, p=0.002) but not the absolute numbers of nsmB 
(r(62) = -0.019, p=0.881) (Figure 3). The strong correlation between age and the 
percentage of SHM is still evident after correction for the absolute numbers of smB 
(partial correlation estimated percentage of SHM and age = 0.804, p=0.000) and the 
percentages of smB (partial correlation = 0.713, p=0.000). The same applies to the 
Figure 3
Percentage of somatic hypermutation (SHM) using the Igk-REHMA assay distributed for percentages [A] and 
absolute numbers [B] of non-switched memory B-lymphocytes (nsmB), and for percentages [C] and absolute 
numbers [D] of switched memory B-lymphocytes (smB). Every dot represents a healthy subject.




absolute numbers of nsmB (partial correlation estimated percentage of SHM and age = 
0.810, p=0.000) and the percentages of nsmB (partial correlation = 0.767, p=0.000). So, 
SHM increases more than expected based on the memory B cell subset size alone, 
suggesting an increase in SHM frequency in single B cells. 
As described before, CVID patients show variable, lower estimated percentages of SHM 
(mean percentage SHM 31%, range 6-77%, n=23; Figure 1b) compared to the healthy 
subjects (t[85]=4.917, p=0.000) [5].
Discussion
SHM is an important step in the antigen-driven B cell development creating 
B-lymphocytes expressing high-affinity antibody receptors. We show that the estimated 
level of SHM, using the IgK-REHMA assay, steeply increases during the first two years of 
life. This increase was associated with changes in size of the two B-lymphocyte 
subpopulations that contain SHM (smB and nsmB), but this could not explain the total 
observed increased SHM frequency. We hypothesize that the increase of SHM in 
childhood reflects an increase of the proportion of memory B cells originating from 
secondary GC-dependent B cell responses as well as an increase of the SHM frequency 
within the memory B cell compartment [6], reflecting immune maturation. A study in 
sorted (memory) B cells could confirm this hypothesis. However, this would need a lot 
more blood, which poses an ethical problem in young, otherwise healthy children.
Previous studies have shown that SHM levels are decreased in certain subgroups of CVID, 
but this was accompanied by diminished isotype switching, decreased B cell proliferation 
or decreased switched memory B cell subpopulations [4, 5, 7, 8]. So far, the clinical 
consequences of low levels of SHM by itself are unknown. A delayed maturation of SHM 
levels in the presence of normal memory B cell subset counts might therefore reflect 
the presence of persistent primary B cell responses and hence impaired immune 
maturation. We propose that if such a phenomenon exists, it may be associated with 
recurrent infections, which has to be explored in further studies. 
In conclusion, this study shows the increase of estimated percentages of SHM as 
measured by the IgK-REHMA assay in the first two years of life. This reflects changes of 
the memory B cell subpopulations in young children, but also in the SHM frequency 
within memory B cell subsets, probably reflecting an increase of secondary memory B 
cell responses. Sequencing of large numbers of immunoglobulin genes at the B cell 
subset level in young children, e.g. by using next generation sequencing, should be 
performed in future studies to confirm this hypothesis.
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CHAPTER 4
The PedPAD Study: 
Boys predominate in the Hypogammaglobulinemia 
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Abstract
Hypogammaglobulinemias are the most common primary immunodeficiency diseases. 
This group of diseases is very heterogeneous, and little is known about these diseases 
in children. In the Pediatric Predominantly Antibody Deficiencies (PedPAD) study, we 
analysed data from the ESID Online Database to get more insight into the characteristics 
of children with hypogammaglobulinemia; 46 centers in 18 different countries agreed 
to participate. Data from 2076 out of the 3191 children who were registered at the time 
of data extraction with a diagnosis of hypogammaglobulinemia (this excludes 
agammaglobulinemia and defects in class switch recombination) were available for 
analysis. The data set showed several limitations. Because of country related differences 
in diagnostic criteria used for classification of different types of primary 
hypogammaglobulinemia, further analysis of the data was performed in the combined 
data set. The most striking observation is the strong majority of male patients in the group 
of children with primary hypogammaglobulinemia (n=1292, 63%). This male 
predominance was observed in each of the 18 countries involved. The boys were younger 
at diagnosis (mean age males 5.3 years; mean age females 5.8 years). Moreover, one or 
more complications were more frequently reported in boys (12%) as compared to girls 
(5%). The male predominance suggests that patients with an undetected or unknown 
X-linked genetic cause are included in this group of children registered as primary 
hypogammaglobulinemia. 





Primary immunodeficiencies (PID) are inherited defects of the immune system, with 
predominantly antibody deficiencies (PAD) being the largest subgroup. The hallmark of 
PAD is a marked reduction or absence of immunoglobulins, with an increased 
susceptibility to mostly bacterial infections that typically involve the upper and lower 
respiratory tract. PADs can be divided into agammaglobulinemias, defects of class switch 
recombination and hypogammaglobulinemias. ‘Hypogammaglobulinemia’ is by far the 
most common entity, comprising nearly half of all PID diagnoses [1]. For most diseases 
in the first two subgroups, the genetic defects have been described, and their effects on 
B cell differentiation studied [2]. The hypogammaglobulinemia subgroup, however, is 
very heterogeneous, and much less is known about these diseases. Among the 
hypogammaglobulinemias, common variable immunodeficiency disorders (CVID) is the 
most commonly reported diagnosis in registries, followed by immunoglobulin (Ig) G 
subclass deficiency [1].
Because PIDs are relatively rare disorders, international collaboration is necessary to 
study the overall clinical characteristics of these diseases. Since 2004, the European 
Society for Immunodeficiencies (ESID) has been running an online database for primary 
immunodeficiencies: the ESID Online Database. This database registers demographical, 
clinical and laboratory characteristics of patients with PID [3]. At present, more than 
18,000 cases from 119 centers in Europe are registered [4]. Biennial reports from the 
ESID Online Database have been published, but none of these reports has focussed 
specifically on children [1, 5, 6]. Also, in other available literature most published data on 
hypogammaglobulinemia refer to adult patients. 
Children with hypogammaglobulinemia constitute a special group due to their maturing 
immune system. Some antibody deficiencies disappear over time and seem to be a 
physiological variation, whereas other antibody deficiencies remain and manifestations 
of more severe immunodeficiency will develop. Currently, it is impossible to predict 
which child will get better and which one will suffer from more or less severe disease in 
the future. Moreover, data from adults cannot be simply extrapolated to children. Separate 
studies have to be performed. We used the data from the ESID Online Database to get 
more insight in the characteristics of children with hypogammaglobulinemia.
Materials and Methods
The objective of this study was to describe numbers, geographical distribution, underlying 
diseases, age and laboratory values at presentation and diagnosis, the diagnostic delay 
and follow-up data in children with hypogammaglobulinemia (this excludes 
agammaglobulinemia and defects in class switch recombination) registered in the ESID 
Online Database.
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The system and structure of the ESID Online Database has been described before [3, 5]. 
The data of the ESID Online Database are stored on secure servers of the IT Centre of 
the University Hospital in Freiburg, Germany. The categorization is based on the 
classification defined by the International Union of Immunological Societies (IUIS) [7]. 
There is a set of identical fields for all patients, which comprises diagnosis, gender, age 
of patient at diagnosis, information whether it is a sporadic or familial case, current 
medication, adverse effects of treatment, basic laboratory values, and genetic mutation 
data. These fields form the ‘core data set’. Patients give informed consent before their 
data are entered into the database. The aim of the database is long-term documentation 
of a patient; documentation is requested at least once a year for each patient. The date 
of a patient’s attendance at the clinic is recorded and data associated with this patient 
visit, such as a change in the treatment regimen can be documented. Some centres and 
national networks are maintaining local databases for their PID patients. Their data are 
transferred electronically to the ESID database at regular intervals. The database has an 
inbuilt automatic quality assurance system including field type, range and plausibility 
checks. In addition, data sets are checked regularly for plausibility and completeness by 
the database administration.
For this study, all centers that registered children with hypogammaglobulinemia (age 
<19 years) were approached; 46 centers from 18 countries agreed to participate. Only 
data from patients reported by these collaborating centers were included in our study. 
Standard statistical analyses were applied to investigate associations between categorical 
variables (Chi square analysis and the Fisher exact test [Monte Carlo; 10,000 samples] 
when expected cell values were lower than 5) and differences between groups (the t-test 
[comparing two groups] and analysis of variance [comparing more than two groups]). 
That means that the data can be summarized as frequencies in cross-tabulations, e.g. 
by cross-tabulating country by gender, consanguinity cases (yes/no) or familial cases 
(yes/no). When age variables were involved (age of onset, presentation or diagnosis, all 
continuous variables) differences between groups were tested by using the t-test 
(comparing two groups) and analysis of variance (comparing more than two groups). 
The statistical software package used was IBM SPSS statistics 20.
Results
Data of 2076 out of 3191 children registered within the ‘Hypogammaglobulinemias’ 
registry at the time of data extraction were available for analysis. These data were 
collected in 46 centers in 18 different countries; some countries only reported one or a 
few diagnoses (Supplementary table 1). Estonia (20), Turkey (14), the Netherlands (8), 
Spain (4) and Greece (4) reported most affected children per one million inhabitants 
(Figure 1). In absolute numbers, Turkey reported most children (n=968), followed by 
Germany (n=257) and Spain (n=182). 




Unfortunately, the data set showed several limitations, making interpretation of the data 
challenging. Obvious mistakes were excluded from further analysis (e.g. date of diagnosis 
or laboratory value before date of birth or clinical presentation), as well as laboratory 
data without dates or units. Many entries were incomplete (Table 1); children frequencies 
in the statistical analyses may vary because of differences in data available in subsets of 
data. IgG-substitution was not clearly documented in most cases, therefore no analysis 
of reported IgG-levels was performed (IgG-substitution was reported for 1152 episodes 
in 598 patients; 813 intravenously, 331 subcutaneously, 2 intramuscularly administered, 
and 6 by unknown route).
Furthermore, when comparing immunoglobulin levels and diagnoses, we noticed that 
different criteria for registering under a certain diagnosis were used in different countries. 
The current ESID diagnostic criteria (www.esid.org) were not always followed. Because 
reliable immunoglobulin levels at diagnosis were lacking in many patients, diagnosis 
could not be checked in every patient [4]. Therefore, further analysis of the data was 
performed within the total group of children with primary hypogammaglobulinemia 
which includes the subregistries common variable immunodeficiency (CVID), deficiency 
of specific IgG, IgA with IgG subclass deficiency, isolated IgG subclass deficiency, other 
hypogammaglobulinemias, other immunoglobulin gene deletions, selective IgA 
deficiency, selective IgM deficiency and transient hypogammaglobulinemia of infancy 
(THI) of the registry (Table 2; n=2052). 
Figure 1
Number of pediatric patients per 1 million inhabitants registered in the ESID Online Database per country 
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General characteristics
The mean age at onset (defined as first symptoms) was 2.6 years (SD 3.15, median 1.0 
years, range 0-18 years, n=1833). The mean age at diagnosis was 5.5 years (SD 3.98, 
median 5.0 years, range 0-19 years, n=1508), resulting in a mean diagnostic delay of 2.6 
years (SD 2.87, median 2.0 years, range 0-17 years, n=1508). No information about 
survival was available in 594 patients (30%), 1416 patients (69%) were reported as alive 
at the last update (October 9th 2012). Although there were statistically significant 
differences in age at onset and age at diagnosis between countries, these were rather 
small (effect sizes of less than 0.10). In the sample of 1508 patients for whom the relevant 
age data was present, six countries had a small sample of 10 patients or less. We therefore 
excluded the Czech Republic (n=1), Austria (n=3), Portugal (n=8), Serbia (n=5), Slovakia 
(n=2) and Sweden (n=9) from this analysis. An analysis of variance was applied, giving a 
significant effect for age at diagnosis (F[1,11] =  2.217, p=0.012, partial η2 = 0.016) and 
age at presentation (F[1,11] =  3.818, p=0.000, partial η2 = 0.028).  Switzerland (5.17, n=18) 
had a mean age at presentation later than 4 years. Russia (7.4, n=18) had a mean age at 
diagnosis later than 7 years. No relevant subgroups were detected in a post-hoc analysis. 
Consanguinity was present in 133 patients (6%), absent in 1590 patients (78%), and not 
reported in 329 (16%). The consanguinity differences between the countries were 
significant (Fisher exact test = 120.68, df=17, p=0.000). Egypt (17 out of 37 patients, 47%) 
and Serbia (6 out of 6, 100%) reported by far the largest percentage of consanguineous 
cases, but several other countries showed higher percentages too: Turkey (87 out of 938 
patients, 9%) Russia (3 out of 15 patients, 20%), Sweden (3 out of 14 patients, 21%) and 
Austria (1 out of 6 patients, 17%). Consanguinity was not associated with gender (χ2 
 [1, n=1723] = 1.236, p=0.266), age at onset (t[1409] = -1.056, p=0.291)  or age at diagnosis 
(t[1409] = -1.079, p=0.281). 
Table 1. Available information in the ‘Hypogammaglobulinemias’ registry of the ESID Online Database.  
Data Number of patients with 
available data
Percentage of total group
Data on infections 414 20%
Data on auto-immunity 85 4%
Data on other concomitant diseases 276 13%
Data on therapy 1312 63%
Data on immunizations 16 0.8%
Data on blood count 1830 88%
Data on immunoglobulins 1872 90%
Data on IgG-subclasses 890 43%
Data on white blood cells 1333 64%
Data on T and B cells 827 40%
Data on additional lab values 319 15%
Total 2076 na
na = not applicable. 




Familial cases were present in 198 patients (10%), absent in 1500 patients (73%), and not 
reported in 354 patients (17%). The frequencies of familial cases between the countries 
differed significantly (Fisher exact test = 99.93, p=0.000). High numbers (more than 20%) 
were reported by the Netherlands (13 out of 34, 26%), Serbia (6 out of 6, 100%), and 
United Kingdom (6 out of 24, 25%). Familial cases were not associated with gender (χ2 
[1, n=1698] = 0.008, p=0.928), age at onset (t[1380] = -1.520, p=0.129) or age at diagnosis 
(t[1380] = 0.483, p=0.630). There were 58 family cases (28 families) reported with 
available information of the family member. If we look at the 19 families in which the 
child which was presented secondly was diagnosed after the firstly presented child, there 
was a significant decrease in diagnostic delay for the second child (one sample 
t test, test value 0: t(18) =-3.144, p=0.006).
A total of 297 patients reported consanguinity and/or familial cases. There was no 
association with gender (χ2 [1, N=1763] = 0.592, p=0.442), age at onset (t[1434] = 1.653, 
p=0.096) or age at diagnosis (t[1434] = 0.948, p = 0.344. Egypt (17 out of 36, 47%) and 
Serbia (6 out of 6, 100%) reported significantly higher numbers than other countries.
A gene mutation was reported in only 12 patients (n=7 Transmembrane activator and 
calcium modulator and cyclophilin ligand interactor [TACI], n=4 Cluster of differentiation 
[CD]19,  n=1 11q23 mutation).
Male patients are in the majority (63%; χ2 based on an equal distribution of males and 
females (χ2 [1, n=2052] = 137.93, p=0.000). This male predominance was present in each 
of the 18 countries. There was no specific association between country and gender 
Table 2. Different diagnoses reported in the 2076 children from the ‘Hypogammaglobulinemias’ registry. 








Common variable immunodeficiency (CVID) 469 23% 64%
Deficiency of specific IgG 39 2% 56%
IgA with IgG subclass deficiency 12 0.6% 67%
Isolated IgG subclass deficiency 301 15% 59%
Other hypogammaglobulinemias 188 9% 61%
Other immunoglobulin gene deletions 1 0.1% 100%
Secondary hypogammaglobulinemia 8 0.4% unknown*
Secondary selective IgA deficiency 15 0.7% unknown*
Selective IgA deficiency 513 25% 58%
Selective IgM deficiency 41 2% 89%
Thymoma with immunodeficiency 1 0.1% unknown*
Transient hypogammaglobulinemia of infancy 488 24% 69%
TOTAL HYPOGAMMAGLOBULINEMIA GROUP 2076 100% 63%
Only the diagnoses in italics were included in the group of “total primary hypogammaglobulinemia” that were 
used for further analysis. *Percentage cannot be calculated due to lack of data.
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(Fisher exact test, p=0.446). Furthermore, male patients tend to be younger at onset 
(mean age male patients 2.7 years; mean age female patients 3.1 years; t [1509] = 1.83, 
p=0.068) and differ significantly at diagnosis (mean age male patients 5.3 years; mean 
age female patients 5.8 years; t[1509] = 2.38, p=0.012).
Laboratory characteristics
IgA levels were available in 1469 patients; IgM levels were available in 1477 patients. 
We categorized them as low, normal or high for age [8]; 643 (44%), 796 (54%) and 30 
(2%) patients showed low, normal and high IgA levels at presentation, and 107 (7%), 1313 
(89%) and 57 (4%) patients showed low, normal and high IgM levels at presentation, 
respectively (Figure 2). IgA and IgM levels were not associated with gender (IgA: χ2 [2, 
n=1469] = 0.354, p=0.831; IgM: χ2 [2, n=1477] = 3.38, p=0.187) or consanguinity (IgA: χ2 
[2, n=1299] = 0.679, p=0.712; IgM: χ2 [2, n=1304] =0.498, p=0.780). Country was 
associated with IgA levels (Fisher exact test [n=1469] = 206.10, p=0.000) and with IgM 
levels (Fisher exact test [n=1477] = 138.08, p=0.000). Low IgA levels were reported 
frequently (more than 70%) in children from the Czech Republic (1 out of 1 patient, 100%), 
Egypt (26 out of 34 patients, 77%), Estonia (21 out of 27, patients 78%), Greece (25 out of 
35 patients, 72%), Poland (37 out of 50 patients, 74%), Russia (15 out of 21 patients, 71%), 
Slovakia (7 out of 7 patients, 100%), Spain (52 out of 57 patients, 91%) and Sweden (6 out 
of 8 patients, 75%). Low IgM levels were reported frequently (more than 15%) in the Czech 
Republic (1 out of 1 patient, 100%), Egypt (8 out of 34 patients, 24%), Germany (23 out 
of 27 patients, 18%), Russia (9 out of 22 patients, 41%), Slovakia (3 out of 7 patients, 43%) 
and the United Kingdom (8 out of 23 patients, 35%). The 57 patients with reported high 
IgM-levels were equally distributed among the countries. 
Figure 2
IgA and IgM levels at presentation of the children in the group of “total primary hypogamma globulinemia”. Patients 
are divided into different groups based on their levels of IgA and IgM at presentation: IgA low (left), IgA normal 
(middle), IgA high (right), IgM low (black), IgM normal (grey) and IgM high (white).
  




Blood counts (n=1247) showed 38 patients with severe neutropenia (<0.5 x10e9/L). 
Absolute numbers of B-lymphocytes (defined as CD19+ lymphocytes) were reported in 
780 patients, 23 without units. 52 of 757 patients (7%) show low absolute B cell numbers 
when compared to age matched reference values (range -0.004 to -0.18 x10e9/L below 
age matched reference value) [9]). For five patients absent B-lymphocytes were reported. 
Absolute T-lymphocyte numbers (defined as CD3+ lymphocytes) were reported in 792 
patients, 23 without units. 45 of 769 patients (6%) show low absolute T cell numbers 
when compared to age matched reference values (range -0.02 to -0.85 x10e9/L below 
age matched reference values) [9]. Absent T-lymphocytes were not reported.
Clinical phenotypes
We divided the hypogammaglobulinemia children with available data on complications 
(n=195 from 7 countries) in the different clinical phenotypes of CVID as described by 
Chapel in 2008 [10]: auto-immunity (n=80), polyclonal lymphocytic infiltration (n=31), 
enteropathy (n=7), and lymphoid malignancy (n=3). Additionally, the ESID Online 
Database contained two more relevant subgroups; ‘granulomatous infiltration’ (n=9) and 
‘pulmonary disease’ (n=107). It was not possible to define patients ‘without complications’, 
because of the incompleteness of the data. Some patients (n=42) fitted several clinical 
phenotypes.
No differences between countries in clinical phenotypes were observed (Fisher exact 
test [n=237] = 35.99, p=0.720), nor between males and females (χ2 [5, n=237] = 2.576, 
p=0.781). There was no association between clinical phenotype and gender (Fisher exact 
test [n=237] = 2.701, p=0.750). The clinical phenotypes were reported for 195 patients, 
41 females (5% of the 760 females) and 154 males (12% of the 1292 males). Males turn 
out to be overrepresented in the clinical phenotypes, over and above their 
overrepresentation in the total sample (χ2 [1, n=2052] = 23.688, p=0.000; odds ratio for 
gender = 2.373). This supports the hypothesis that male patients suffer more 
complications, and thus have more severe disease. However, there was no specific 
clinical phenotype that contained more boys.  
Follow-up
Not all centers reported follow-up data for (all of) their patients; 1546 infectious episodes 
were reported in 413 patients. Czech Republic, Italy, Portugal, Serbia and the United 
Kingdom reported no follow-up data on infectious episodes. Most infections were 
localized in the respiratory tract: upper respiratory tract infection (n=156), pharyngitis 
(n=283), bronchitis (n=183), otitis media (n=150) and pneumonia (n=283). In addition, 
1227 episodes of antimicrobial treatment were reported in 601 patients: antibiotics 
(n=1150), antifungals (n=28), antimalarials (n=1), antimycobacterials (n=12), antiparasitics 
(n=4) and antivirals (n=32). 
A total of 132 episodes of auto-immune disease were reported in 80 patients. Most 
frequently reported auto-immune diseases were: thyroiditis (n=16), coeliac disease 
(n=11), idiopathic thrombocytopenic purpura (n=20), insulin dependent diabetes mellitus 
20162306 proefschrift_Ellen Schatorje.indd   87 10-10-16   10:26
88
PART TWO | CHAPTER 4
(n=14) and hemolytic anemia (n=25). No differences between male and female patients 
were found in reported auto-immune disease (χ2 [1, n=2052 ] = 2. 264, p=0.132). 
However, country was associated with the frequency of auto-immune disease (Fisher 
exact test [n= 2052] = 14.945, p=0.000). Auto-immune diseases were reported frequently 
(more than 10%) in Austria (2 out of 14, 14%), Estonia (6 out of 27, 27%), Greece (13 out 
of 32, 31%), Poland (9 out of 76, 12%), and Sweden (4 out of 15, 27%). Age was only 
available for 39 patients with auto-immune disease. Mean age at onset in patients with 
reported auto-immune disease was 2.0 years and mean age at diagnosis was 5.5 years. 
The diagnostic delay was longer (2.6 years) in patients with auto-immune disease 
(t[1506]= -2.707, p=0.007 ).
Three cases of lymphoma were reported during follow-up, one each in Germany, Turkey 
and Spain; these were all male patients. One case of acute lymphoblastic leukemia was 
reported in a Dutch girl, and one case of a benign neoplasm of bone and articular 
cartilage was reported in a Spanish girl. Other concomitant diseases were reported in 
605 patients, ranging from possibly related issues such as hepatosplenomegaly and 
Down syndrome to unrelated issues like concussion and dizziness. Only ‘asthma’ was 
reported in more than 1% of the total group (n=76, 4%). It is not clear whether this is truly 
asthma, or a misdiagnosis of airway disease caused by the immunodeficiency. 
Discussion
Hypogammaglobulinemia in childhood is the laboratory manifestation of a very 
heterogeneous group of diseases; solid criteria for the diagnosis are difficult to define. 
The objective of this study was to obtain insight in the general, clinical and laboratory 
characteristics of children with hypogammaglobulinemia registered in the ESID Online 
Database and to see whether different clinical phenotypes could be defined. Analysis of 
the data was performed in the combined data set, because of country related differences 
in diagnostic criteria used for classification of different types of primary hypogamma-
globulinemia. Although this hampers comparison with separate diagnostic groups, the 
overall data are still very useful. No such large data set in children with 
hypogammaglobulinemia has been reported so far.
Strikingly, male patients are clearly in the majority (63%), whereas the diseases in the 
sub-registry ‘Hypogammaglobulinemias’ are not known to be inherited by the X-linked 
route. This male predominance was seen in every country. Furthermore, their younger 
age at onset and at diagnosis suggests more severe disease. This is supported by the 
occurrence of more complications in boys (12%) as compared to girls (5%). Although not 
discussed explicitly before, this predominance of males can be found in previously 
published papers [1, 10, 11]. In the study of Chapel et al. in which CVID patients are 
classified in different clinical phenotypes 58% of patients were males (mean age 49.4 
years) [10]. Also, in the latest update from the ESID Registry Working Party 60.8% of all 
registered patients were male, and 64.6% in the group of 15 years or younger [1]. A recent 




update from the German registry for PID also shows a higher percentage of boys: 57.2% 
male in the overall group and twice as many boys in children below 12 years of age [11]. 
They attributed this male predominance to known X-linked diseases such as X-linked 
agammaglobulinemia (XLA) and Wiskott-Aldrich Syndrome (WASP). This can be an 
explanation for the male predominance overall, but it cannot explain the higher 
percentage of boys in the group of children with primary hypogammaglobulinemia, and 
suggests that this group also contains patients with diseases inherited by the X-linked 
route. This can be due to either insufficient diagnostic procedures or atypical presentation 
(i.e. a known X-linked PID diagnosis has been missed in both cases), or to as yet unknown 
X-linked diseases that cause primary hypogammaglobulinemia. Little is known as yet 
about the genetic defects in primary hypogammaglobulinemias. Genetic defects in CVID 
patients have been discovered in the past years (e.g. Inducible costimulator [ICOS], TACI, 
BAFF-R, CD19-complex and CD20), but in more than 95% of CVID patients the genetic 
background is as yet unknown [2]. A search for known and unknown X-linked genetic 
defects in boys with primary hypogammaglobulinemia could be very interesting. Focusing 
on boys with early onset hypogammaglobulinemia and complications will probably give 
the highest yield. At least, they need to be evaluated for B-lymphocyte numbers and 
known X-linked disease like a mutation in the Bruton’s agammaglobulinemia tyrosine 
kinase gene.
A recent study from Driessen et al. showed that patients with idiopathic primary 
hypogammaglobulinemia (IPH), defined as patients with hypogammaglobulinemia who 
do not fulfill the diagnostic criteria for CVID, suffered from the same infectious 
complications as CVID patients (i.e. respiratory infections, bronchiectasis) but did not 
show the non-infectious complications (auto-immune cytopenia, polyclonal lymphocytic 
proliferation and persistent enteropathy) [12], which have been linked to increased 
mortality [10, 13]. In our study, auto-immune disease, polyclonal lymphocytic proliferation 
and enteropathy were reported in a minority of the total group of hypogammaglobulinemias 
(4%). Our data are compatible with the above interpretation, demonstrating a subgroup 
of patients with early onset of immune dysregulation. 
Unfortunately, the current ESID Online Database has several limitations making 
interpretation of the data challenging; many data had to be excluded, and the 
determination of different clinical or laboratory phenotypes was not possible. Currently, 
the ESID Registry Working Party is reorganizing the database. There will be three levels 
of documentation. Level 1 will consist of a baseline form at initial registration and a short 
yearly follow-up form; this level will offer good insight into the prevalence of PID. Level 
2 will consist of a diagnosis form and a current visit form, which is specific for each IUIS 
category; this level will give additional information on individual diseases. Temporary 
level 3 forms can be used for collecting in-depth information in dedicated studies. 
Because the quality of the data is dependent on the users who enter the data, more 
complex automated checks based on diagnostic criteria, training sessions with a uniform 
protocol containing clear definitions of diseases and the meaning of data fields and 
increased local as well as central monitoring are being considered. National registries 
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benefitted from employing data entry clerks, especially in the reporting rate [11, 14]. With 
the new database, more research on children with hypogammaglobulinemia will be 
possible in the future; particularly the level 3 option will be suited for this purpose. 
In conclusion, this study gives a first overview of the general characteristics of children 
with primary hypogammaglobulinemia as registered in the current ESID Online Database. 
Determining different clinical or laboratory phenotypes was not possible because of the 
limitations in the collected data. The male predominance in the group of children with 
hypogammaglobulinemias suggests X-linked diseases are ‘hidden’ in this group. This 
finding warrants further exploration.
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Abstract
Purpose
Immunoglobulin(Ig)G-subclass deficiency and specific polysaccharide antibody 
deficiency (SPAD) are among the most frequent causes of recurrent respiratory infections 
in children. Little is known about their prevalence, clinical presentation and prognosis. 
No study has been published in a Western-European nor in a mainly non-tertiary cohort 
until now. Therefore, we performed this observational cohort study in children recruited 
from secondary and tertiary pediatric practices all over the Netherlands.
Methods
Dutch pediatricians were monthly asked to report patients with IgG-subclass deficiency 
and/or SPAD. Demographic, clinical and laboratory characteristics were collected. 
Separate informed consent was asked from parents and children (≥12 years of age) for 
annual update of the medical status.
Results
49 children with confirmed IgG-subclass deficiency and/or SPAD were included. The 
majority of children (69%) was reported by four (out of 12) secondary hospitals with a 
pediatric immunologist in the staff. 45 children had ≥1 low IgG-subclass level and 11 had 
SPAD. IgG2 deficiency was the most prevalent IgG-subclass deficiency (37/49; 76%). 10% 
of these children already showed bronchiectasis. Two-thirds were male (33/49; 67%, 
p=0.015). From ten years of age, only boys were left and only boys showed progressive 
immunodeficiency during follow-up (11/24; 46%).
Conclusions
This is the first Western-European mainly non-tertiary cohort of children with IgG-
subclass deficiency and/or SPAD. The disease course is not always benign, especially in 
boys. Most children were reported and managed in secondary hospitals with a pediatric 
immunologist in the staff. To identify more patients, the awareness of these diseases 
among general pediatricians should increase.
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Introduction
Young children often suffer from respiratory infections, which are usually innocent and 
self-limiting. However, in some cases these infections are a sign of underlying primary 
immunodeficiency. It is difficult for pediatricians to decide in which children further 
investigations are warranted. Among primary immunodeficiencies, ‘predominantly 
antibody deficiency’ forms by far the largest subgroup [1]. Immunoglobulin (Ig) G-subclass 
deficiency and specific polysaccharide antibody deficiency (SPAD) are among the most 
common forms found in children who are analysed because of the clinical presentation 
of recurrent ear-nose-throat (ENT) and airway infections [2, 3].
IgG-subclass deficiency is defined as a deficiency in one or more IgG-subclasses (>2 SD 
below age-matched reference values) with normal or near normal IgG concentration. 
SPAD is diagnosed when there is profound alteration of the antibody response to 
polysaccharide antigens, either after documented invasive infection with e.g. S. 
pneumoniae or after test immunization with an unconjugated pneumococcal (or other) 
polysaccharide vaccine. For both diagnoses, T cell and more severe B cell defects should 
be excluded [4]. Children with IgG-subclass deficiency or SPAD can be asymptomatic, 
but if not typically present with increased susceptibility to bacterial ENT and respiratory 
tract infections, more often so when both IgG-subclass deficiency and SPAD are present 
in the same child [5]. Identifying children with IgG-subclass deficiency and/or SPAD 
among the many children seen in everyday practice can be challenging. Healthy young 
children can have up to 11 respiratory infections per year [6-8], so it is difficult to decide 
which children with recurrent infections are at the end of the normal spectrum and which 
children need further immunological work-up. Furthermore, it is not known which child 
with IgG-subclass deficiency and/or SPAD is just showing delayed maturation of the 
immune system with spontaneous resolve of the immunodeficiency within a few years, 
and in which child it is the first sign of a lasting primary antibody deficiency, or maybe 
even a development into a more severe one, like common variable immunodeficiency 
disorders (CVID).
Little is known about the prevalence, clinical presentation and prognosis of IgG-subclass 
deficiency and/or SPAD in children. An Australian study in a cohort from a tertiary center 
showed SPAD in 11/74 (15%) children with recurrent infections. SPAD was found in 10/91 
(11%) children with recurrent infections in a Finnish cohort from a tertiary center [9, 10]. 
Both studies excluded children with concomitant other immunodeficiencies. SPAD was 
associated with allergic rhinitis and chronic otorrhea in these children, independent of 
age. In a retrospective study among 59 Turkish children with IgG-subclass deficiency 
from a tertiary center, IgG3-deficiency was most commonly found; 30% of these children 
reached normal values around the age of six years. In contrast, children with an isolated 
IgG2-deficiency in this cohort (9%) all remained IgG2-deficient during follow-up [11]. In 
a group of Thai children with recurrent infections recruited in a tertiary care hospital, 
7/55 (13%) had an IgG-subclass deficiency. The most common presenting symptom was 
recurrent sinusitis (84%). Again, IgG3-deficiency was the most common IgG-subclass 
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deficiency found (56%) [12]. All of these studies were carried out in tertiary center cohorts 
and therefore in a highly selective population of children. No study has been published 
in a Western-European cohort until now, nor have children followed outside tertiary 
centers been included. Therefore, we performed this observational cohort study for 
IgG-subclass deficiency and/or SPAD in children recruited from secondary and tertiary 
pediatric practices all over the Netherlands, using the Netherlands Pediatric Surveillance 
Unit system to identify cases. More than one third of these children were only seen by 
a general pediatrician.
Methods
The objective of this study was to describe the number, geographical distribution, age, 
gender, clinical and laboratory characteristics of Dutch children diagnosed with IgG-
subclass deficiency and/or SPAD, reported to the Netherlands Pediatric Surveillance Unit 
(“Nederlands Signalerings Centrum voor Kindergeneeskunde” [NSCK]). The NSCK monthly 
asks all pediatricians in the Netherlands to report certain selected cases which they have 
seen during that past month in their hospital (in- as well as outpatient clinic). Between 
March 1, 2009, and November 1, 2011, all Dutch pediatricians were monthly asked to 
report all children they had seen with both newly and previously diagnosed IgG-subclass 
deficiency and/or SPAD (case definition in Table 1).
Demographic, clinical and laboratory characteristics were collected from all reported 
patients and stored in a database using Research Manager® software developed by 
Cloud9 Health Solutions. Patient data were encrypted and saved on a protected server; 
these data did not contain information that enabled identification of the identity of the 
Table 1. Case definition
1. Patient ≥2 and <18 years old, and
2. Serum IgG ≥4.0 g/l, and
3. a.  One or more IgG-subclasses (IgG1, IgG2, and/or IgG3) below age-related normal1 and/or
    b.  If patient is ≥3 years old: inadequate response to 23-valent unconjugated pneumococcal vaccine 
(Pneumo23® from Aventis Pasteur MSD) measured by antibody titers before and 3-4 weeks after 
vaccination.2 
N.B. all children born after the 1st of April 2008 received routine vaccination with 7-valent pneumococcal 
conjugate vaccine at the age of 2, 3, 4 and 11 months (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F). This means 
that the diagnosis of SPAD in them can only be based on the 16 other serotypes present in the 23-valent 
polysaccharide vaccine (1, 2, 3, 5, 7F, 8, 9N, 10A, 11A, 12F, 15B, 17F, 19A, 20, 22F, 33F).
1 de Vries E. Clin Exp Immunol 2012;167(1):108-19.
2 Vaccination response was considered inadequate if:
Antipneumococcal-IgG <20 U/ml and/or ≤4-fold increase of titer for type 3, and/or type 4 and 9
Or
≤4-fold increase of titer in at least 2 out of 4 of the evaluated serotypes (5, 7F, 8, 10A, 11A, 12F, 15B, 17F, 20, 
33F) and one titer <0,35 μg/ml.
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patients. Separate informed consent was asked from parents and children (≥12 years of 
age) for annual update of the medical status. The Medical Ethical Committee Brabant 
approved the study.
For the interpretation of the Ig levels, age-matched reference values were used [13]. 
Diagnosis of SPAD was made using the criteria displayed in Table 1. In the Netherlands, 
pneumococcal antibodies are only determined in certain laboratories, that use their own 
reference values. Until 2009, only three serotypes were determined using ELISA (conform 
an international standard protocol, referred to as the WHO protocol [14]), including the 
strongly-intermediate immunogenic serotypes 3, 4 and 9 [15, 16]. Since 2009, 
pneumococcal antibodies are determined using the Luminex system [17, 18] (initially 10 
serotypes; 7 serotypes since 2014). In our cohort, 10 patients were diagnosed using the 
old method (3 serotypes) and 11 using the new method (10 or 7 serotypes).
One-sample tests (Chi-Square, Kolmogorov-Smirnov) were carried out with SPSS, version 
21, to test age and gender distributions. 
Results
In total, 116 potential study participants were reported to the NSCK by pediatricians from 
36 different hospitals. After analysis of the data quality and completeness, 49 children 
with confirmed IgG-subclass deficiency and/or SPAD were included in the study (Figure 
1). In this group, 45 children had ≥1 low IgG-subclass level and 11 children had SPAD (7 
SPAD children had both IgG-subclass deficiency and SPAD, 1 child had SPAD and low-
normal total IgG, and 3 children had only SPAD). Fourteen children had more than one 
IgG-subclass deficiency; IgG2 deficiency was most prevalent (Figure 2). Five children 
also had IgA deficiency, 5 other children had slightly decreased IgG levels and 4 children 
had additional IgA deficiency as well as slightly decreased IgG levels. None of the children 
had additional IgM deficiency (Figure 3).
The median age of the 49 children was 5.6 years (mean age 7.1 years, range 2-18 years). 
Two-thirds of these children were male (33/49; 67%, One-Sample Chi-Square test, 
p=0.015). From ten years of age, only boys were left (Figure 4). The age distribution for 
girls between 2 and 9 years of age is not uniform (One-Sample Kolmogorov-Smirnov 
test, p=0.05). The same applies to boys (p=0.039). This seems to suggest an age effect 
with a decreasing number of children in the age range between 2 and 9 years of age, 
but more data are needed to corroborate such an effect.
The majority (n=34; 69%) of these 49 children was reported from a secondary hospital 
with a pediatric immunologist in the staff (Figure 1). The clinical problems the children 
encountered in the last year before entering the study are shown in Table 2. A striking 
ten percent of children (4 boys, 1 girl) already showed bronchiectasis. In 32 children 
(63%) chronic use of medication was reported, mostly asthma medication (n=20) or 
prophylactic antibiotics (n=19). Four children received immunoglobulin substitution.
Follow-up data of 24 children were available with a median follow-up period of 40 
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months (range 12-65 months): 19 patients with IgG-subclass deficiency and 5 patients 
with IgG-subclass deficiency and SPAD. Nineteen children (79%) were followed in a 
secondary hospital with a pediatric immunologist in the staff (Figure 1). Six children (25%) 
did not suffer from recurrent infections anymore, and in 3 of them the IgG-subclasses 
had reached normal values for age (the other 3 children were not re-tested). 
Figure 1. Study flowchart
116 potential study participants reported to NSCK
From 36 hospitals:
3 tertiary centers (9 children) 
4 secondary centers with a pediatric immunologist in the staff (52 children) 
29 secondary centers without a pediatric immunologist in the staff (55 children)
90 children 
From 26 hospitals:
3 tertiary centers (9 children) 
4 secondary centers with a pediatric immunologist in the staff (49 children) 
19 secondary centers without a pediatric immunologist in the staff (33 children)
49 children included in the study
From 13 hospitals:
1 tertiary center (1 child) 
4 secondary centers with a pediatric immunologist in the staff (34 children) 
8 secondary centers without a pediatric immunologist in the staff (14 children)
24 children available for follow-up
From 7 hospitals:
1 tertiary center (1 child) 
3 secondary centers with a pediatric immunologist in the staff (19 children) 
3 secondary centers without a pediatric immunologist in the staff (4 children)
26 children did not meet 
inclusion criteria or were
reported twice
Diagnosis could not be verified with the available 
data at time of report in 41 children:
- 6/90 IgG-subclasses within normal range for age
- 17/90 no IgG subclass or vaccine response; 
the available values within normal range for age 
- 18/90 no IgG subclass and vaccine response available 
No informed consent for follow-up or no 
follow-up data available in 25 children
Figure 1
Study flowchart
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Seven children (29%) showed a similar clinical picture as at baseline, their IgG-subclass 
deficiency and/or SPAD had persisted, but had not worsened either. Progression of the 
immunodeficiency was reported in 11 children (46%), these were all boys: 1 boy developed 
decreased IgA levels, 3 boys developed decreased IgG levels, 3 boys developed decreased 
IgA and IgG levels, and 4 boys developed full-blown CVID. Eight children (33%; all of 
them boys) received immunoglobulin substitution therapy at follow-up: 4 of them had 
initially presented with IgG-subclass deficiency combined with SPAD, 3 of them already 
had immunoglobulin substitution at the time of reporting.
IgG1 low IgG1 normal
IgG3 normal IgG3 normal



















Combination of IgG-subclass deficiencies
Table 2. Clinical problems in the past year at baseline
Yes No Unknown
≥4 ENT infections* 36 (73%) 10 (20%) 3 (7%)
>1 lower airway infection 28 (57%) 19 (39%) 2 (4%)
Bronchiectasis 5 (10%) 26 (53%) 18 (37%)
Hearing loss 1 (2%) 5 (10%) 43 (88%)
Severe infections** 9 (18%) 25 (51%) 15 (31%)
* ENT = ear, nose and throat
** Severe infections according to the reporting pediatrician. These included pyelonephritis (n=2), urinary tract 
infection (n=2), adenoiditis (n=2), enterovirus meningitis (n=1), sepsis (n=1), H. pylori infection (n=1), and 
mesenterial lymphadenitis (n=1).
20162306 proefschrift_Ellen Schatorje.indd   101 10-10-16   10:27
102












































0 12 24 36 48 60 74 84 96 108 120 132 144 156 168 180 192 204 216 228 240
Figure 3
Levels of Immunoglobulin isotypes. A: IgG in g/l; B: IgA in g/l; C: IgM in g/l. 
Every dot represents a patient. The bold black line is the lower limit of normal according to age-matched reference 
values (ref de Vries E. Clin Exp Immunol 2012;167(1):108-19).
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Discussion
The human IgG-subclasses were first described in the 1960’s by Terry and Fahey [19] and 
the first report of patients with IgG-subclasses deficiency was published in 1974 [20]. 
Since then, several cases and cohorts of patients with IgG-subclass deficiency have been 
described (for example [21]). It was found that co-occurrence of IgA and IgG-subclass 
deficiency leads to more and more severe recurrent infections [22-24]. Also, children 
with IgG2-subclass deficiency showed decreased responses to immunization with 
polysaccharide antibodies [25].
We describe a cohort of 49 children with IgG-subclass deficiency and/or SPAD collected 
from secondary and tertiary hospitals all over the Netherlands using the Netherlands 
Pediatric Surveillance Unit system. The majority of the children (69%) in our cohort were 
reported by four secondary hospitals with a pediatric immunologist in the staff. Our 
cohort contained only 1 child from a tertiary center. This means that most children with 
IgG-subclass deficiencies and/or SPAD are not referred to a tertiary center (at least in 
the Netherlands), probably because their disease is not considered to be very severe. It 
is unlikely that children with IgG-subclass deficiency and/or SPAD live in clusters around 
pediatric immunologists practising in secondary hospitals. Apparently, children with 
IgG-subclass deficiency and/or SPAD are often not recognized by general pediatricians. 
But is this important? Young children with ‘milder’ antibody deficiencies often recover. 
What they show is in fact a delayed maturation of the immune system, transient 
hypogammaglobulinemia of infancy, not an intrinsic immunodeficiency. This is seen in 
IgG-subclass deficiency and/or SPAD, but also in IgA deficiency, where 23% of the 
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Figure 4. 
Distribution of age and gender
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above 0.07 g/L during follow-up [26]. However, in some children the immunodeficiency 
persists or even develops into a more severe form, and recurrent pulmonary infections 
can lead to chronic pulmonary damage [27]. A study among 55 patients (27 children and 
28 adults) with specific antibody deficiency or CVID showed that immunoglobulin class 
concentrations do not predict bronchiectasis, but percentages and absolute numbers 
of CD19+CD27+IgD- memory switched B cells do [28]. This was not determined in most 
patients in our cohort, but 5 children (10%) in our cohort showed bronchiectasis at the 
time of inclusion. In three of them follow-up data were available; none had improved, 
and one had developed full-blown CVID. Also, significantly more boys (67%) than girls 
were reported. After the age of 9, only boys were reported, and only boys (11/33 boys 
at baseline) showed progressive immunodeficiency during follow-up. This confirms the 
predominance of boys as was described by us before in a European cohort of children 
with hypogammaglobulinemia from the ESID online Registry (63% male). Boys with 
hypogammaglobulinemia in the ESID online Registry were younger at diagnosis than 
girls and suffered more disease complications [2]. This is in contrast to the paper by Boyle 
et al. who did not find male sex to be a risk factor for developing SPAD [9]. Furthermore, 
van Winkle et al. showed that transient hypogammaglobulinemia resolved more quickly 
in male infants [29], but that cohort did not include older children. This gender difference 
is an important issue. Unidentified X-linked disease may play a role in boys with antibody 
deficiency; if so, this should influence treatment decisions, and it has consequences for 
potential recurrence in the family.
Twenty-five percent of the children with IgG-subclass deficiency and/or SPAD in our 
prospectively followed cohort recovered during follow-up. This is less than seen in other, 
retrospective studies of children with IgG-subclass deficiency (recovery 30-67%) or 
unclassified hypogammaglobulinemia (recovery 49%) [11, 30, 31]. However, follow-up 
data for our cohort were available in only half the children. This may have lead to an 
underrepresentation of recovered children during follow-up, because parents of children 
without persisting medical problems are probably less motivated to participate in a 
follow-up study.
The most prevalent IgG-subclass deficiency in our cohort was IgG2 deficiency: 24 
children had isolated IgG2 deficiency, 5 children had IgG1 and IgG2 deficiency, 5 children 
had IgG2 and IgG3 deficiency and 3 children had IgG1, IgG2 and IgG3 deficiency. This 
is in contrast with other published cohorts: IgG3 deficiency was most prevalent in cohorts 
of Thai and Turkish children with IgG-subclass deficiency [11, 12, 30]. In the Turkish studies 
78-90%, and in the Thai study 86% of the patients received prophylactic treatment to 
prevent infections, versus 47% in our cohort, suggesting a more severe phenotype in 
these tertiary populations. Additional data in a broad, much larger cohort are needed to 
assess whether IgG3 deficiency is indeed more severe than IgG2 deficiency; the ESID 
online Registry would be a good tool for this. 
Anti-polysaccharide antibodies were only examined in 21 children in our cohort (14 
children from a secondary hospital with a pediatric immunologist in the staff). This means 
that 28 children did not undergo a complete analysis. The clinical relevance of selected 
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IgG-subclass deficiency is controversial and determining the ability to produce specific 
antibodies is considered to be more important [32]. IgG-subclasses can however easily 
be determined in daily practice with a single venipuncture during the patient’s visit to 
the clinic. The production of specific antibodies requires two venipunctures and 
vaccination. Also, the interpretation of the vaccine response is difficult; it requires 
sufficient experience, since reference values are lacking.
Our study has several limitations. We collected our cohort by using the Netherlands 
Pediatric Surveillance Unit system. Therefore, we depended on the pediatricians in the 
different hospitals for the quality of the reported data. We could not confirm the diagnosis 
of IgG-subclass deficiency and/or SPAD in 41 out of 90 (46%) reported children. This 
was due to missing data in 35 children. In 6 children, all laboratory values were available 
but normal when using age-matched reference values. Possibly, their pediatricians had 
used different, non-age-specific, reference values. This is an important issue for 
educational improvement. 
Finally, IgG subclass deficiency can also be found in asymptomatic patients. Analysis of 
IgG subclasses among 8015 adult blood donors demonstrated that there were more 
individuals with low IgG2 concentrations than predicted by the log-normal distribution 
[33]. Also, 11 out of a cohort of 575 healthy children showed IgG2 concentrations >2SD 
below the mean for age. These asymptomatic children with subnormal IgG2 levels 
showed normal antibody responses to immunization with Haemophilus influenza type 
B polysaccharide antigens [34]. However, the children in our cohort were analyzed by 
their pediatrician because of their clinical presentation, and therefore were not 
asymptomatic.
Conclusion
This is the first description of a Western-European cohort of children with IgG-subclass 
deficiency and/or SPAD collected by pediatricians from secondary as well as tertiary 
hospitals; it was collected in the Netherlands. We show that IgG-subclass deficiency 
and/or SPAD are not always benign diseases: 10% of the children already showed 
bronchiectasis. There was an overrepresentation of boys and only boys showed 
immunological decline during follow-up. So, unidentified X-linked disease may play a 
role in boys with antibody deficiency. Most IgG-subclass deficiencies and/or SPAD were 
reported and managed in secondary hospitals with a pediatric immunologist in the staff, 
which raises the question if these patients are missed in general pediatric secondary 
hospitals. If we want to identify more patients, probably the awareness of these diseases 
among general pediatricians should increase.
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Abstract
Background 
Patients with syndromic features frequently suffer from recurrent respiratory infections, 
but  little is known about the spectrum of immunological abnormalities associated with 
their underlying chromosomal aberrations outside the well-known examples of Down 
and DiGeorge syndromes. Therefore, we performed this retrospective, observational 
survey study.
Methods
All members of the European Society for Immunodeficiencies (ESID) were invited to 
participate by reporting their patients with chromosomal aberration (excluding Down 
and DiGeorge syndromes) in combination with one or more identified immunological 
abnormalities potentially relating to primary immunodeficiency. An online questionnaire 
was used to collect the patient data.
Results
Forty-six patients were included from 16 centers (24 males, 22 females; median age 10.4 
years [range 1.0-69.2 years]; 36 pediatric, 10 adult patients). A variety of chromosomal 
aberrations associated with immunological abnormalities potentially relating to primary 
immune deficiency was reported. The most important clinical presentation prompting 
the immunological evaluation was ‘recurrent ear-nose-throat (ENT) and airway infections’. 
Immunoglobulin isotype and/or IgG-subclass deficiencies were the most prevalent 
immunological abnormalities reported.
Conclusions 
Our survey yielded a wide variety of chromosomal aberrations associated with 
immunological abnormalities potentially relating to primary immunodeficiency. Although 
respiratory tract infections can often also be ascribed to other causes (e.g. aspiration or 
structural abnormalities), we show that a significant proportion of patients also have an 
antibody deficiency requiring specific treatment (e.g. immunoglobulin replacement, 
antibiotic prophylaxis). Therefore, it is important to perform immunological investigations 
in patients with chromosomal aberrations and recurrent ENT or airway infections, to 
identify potential immunodeficiency that can be specifically treated.
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Background
‘Syndromic’ patients frequently suffer from recurrent respiratory infections; it is a major 
cause of morbidity and mortality in this patient group. However, in these patients 
immunological work-up is often not performed because an immunodeficiency is not 
suspected. The infections are often ascribed to food and saliva aspiration [1], structural 
abnormalities of the upper respiratory tract, neuromuscular problems, malnutrition or 
institutionalization. Besides, other problems are often more prominent than the recurrent 
infections. This may lead to underdiagnosis of ‘syndromic immunodeficiency’. However, 
identification of an underlying immune defect may be therapeutically actionable, which 
in turn may improve the quality of life in these patients: for instance hypogamma-
globulinemia can be treated with immunoglobulin replacement [2,3]. In addition, 
information regarding genes critical for the development and functioning of the immune 
system may be gained by analyzing the precise chromosomal defect and the concomitant 
immunological phenotype.
Several primary immunodeficiency (PID) disorders have been identified and increasingly 
their genetic backgrounds have been unraveled [4]. Syndromes with chromosomal 
abnormalities of number or structure are considered as a distinct group within PID [5]. 
Clear examples are Down syndrome (trisomy 21) [6] and DiGeorge syndrome (22q11 
deletion) [7]. Also, Turner syndrome [8] and Wolf-Hirschhorn syndrome [9] are known to 
be associated with immunodeficiency. In the past ten years, thirteen cases, three patient 
series and two families with other chromosomal aberrations and immunological 
abnormalities have been described in the literature [10-27]. There is one study that 
screened patients with dysmorphic disorders for immune defects. They showed a high 
incidence of immunodeficiency in this population (23 out of 29 patients had one or more 
defects); however, they also included 11 patients with Down syndrome [28]. We 
hypothesize that in patients with chromosomal aberrations, other than the well-known 
Down and DiGeorge syndromes, concomitant ‘syndromic’ immunodeficiency may be 
underdiagnosed. To unequivocally prove this, a large case-control study would be 
needed; this is not really feasible. To explore this further, we performed a retrospective, 
observational survey study.
Methods
An email message with the proposal to participate in a survey study was sent out to all 
members of the European Society for Immunodeficiencies (ESID) to identify as many 
patients known to ESID members as possible with a chromosomal aberration in 
combination with one or more identified immunological abnormalities relating to PID. 
Exclusion criteria were trisomy 21 (Down syndrome) and 22q11 deletion (DiGeorge 
syndrome), because the immunological abnormalities in these syndromes have been 
described in detail before [6, 7].  Those ESID members who agreed to participate in the 
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study were requested to complete an online questionnaire for each of their eligible 
patients (Additional File 1). The patients were identified by physician recall. The answers 
to the questionnaires were encrypted and saved on a protected server; these data did 
not contain any information that enabled identification of the identity of the patients. 
Clinical characteristics and identified immunological abnormalities were reported. Age-
matched reference values were used for interpretation of immunoglobulin levels and 
lymphocyte subpopulation counts; values below the age-matched reference values 
were scored as ‘low’ [29-31]. For the interpretation of the vaccine responses (i.e. before 
and after diagnostic vaccination with Tetanus and PneumoVax® or Pneumo(vax)23®) 
reference values from the laboratory performing the tests were used. For responses to 
Pneumovax® or Pneumo(vax)23® measured by serotype, a titer ≥1 IU/ml per serotype 
was considered to be a sufficient response. If only total IgG for S. pneumoniae was 
tested, a >4 fold increase of titer was considered as a positive response. Additional 
immunological tests were performed judged necessary by the treating physician and 
are therefore only available for some patients. Lymphocyte function tests included in 
vitro T-lymphocyte proliferation tests (to Concanavalin A (ConA), phytohaemagglutinin 
(PHA), pokeweed mitogen (PWD) and Staphylococcus aureus enterotoxin A (SAE)), 
natural killer (NK) cell and cytotoxic T cell toxicity (in vitro stimulated CD107a 
degranulation). Granulocyte function tests included oxidative burst, the quantitative 
nitroblue tetrazolium dye reduction (NBT) test and phagocytosis test (cells Escherichia 
coli opsonised). For these additional immunological test (e.g. lymphocyte and 
granulocyte function tests), the laboratory-specific reference values were used. 
Furthermore, we asked all the participating centers to provide us with the number of 
patients with chromosomal aberrations who had undergone an immunological 
evaluation but were subsequently found not to have an immunological abnormality. 
This was also based on physician recall. Descriptive statistics were performed. The 
International System for Human Cytogenetic Nomenclature 2013 (ISCN) was used for 
cytogenetic nomenclature [32]; an overview is given as a group, and in relation to the 
specific chromosomal aberrations concerned. The Medical Ethical Committee Brabant 
approved of the study procedures.
Results
Fifty-two patients from 16 different centers distributed globally were reported. Six patients 
had to be excluded because they did not meet the inclusion criteria: 3 patients did not 
have a confirmed chromosomal aberration, 1 patient with Rubinstein-Taybi Syndrome 
(no chromosomal aberration, only single gene mutation), 1 patient with suspected Kabuki 
Syndrome (no genetic diagnosis) and 1 patient with Rothmund-Thomson Syndrome (no 
chromosomal aberration, only single gene mutation). Three other patients did not have 
an immunodeficiency, these were 3 related patients with familial t(12;14). An overview 
of the excluded patients is presented in Additional File 2. 
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The 46 included patients consisted of 24 males and 22 females with a median age of 
10.4 years at the moment of reporting (range 1.0-69.2 years; 36 pediatric and 10 adult 
patients). Two families were reported: patients 17 and 20 are related, as well as patients 
18 and 19 (they are also related to the excluded patients 2, 3 and 4, see Additional File 
2). Fifteen of these 46 included patients have been published before and publication of 
two patients is currently in press (for details see Table 1).
Seven out of the total 16 centers provided the number of patients with chromosomal 
aberrations who had undergone an immunological evaluation but were subsequently 
found not to have an immunological abnormality. Together, they reported 27 patients 
with immunological abnormalities in this survey; they also reported 63 patients with 
chromosomal aberrations in whom immunological assessment revealed no abnormality. 
Thus, of these centers 30% of the patients with chromosomal aberrations who underwent 
immunological evaluation were diagnosed with some form of primary immunodeficiency. 
Symptoms indicative of PID can be divided into eight different clinical presentations [29]; 
‘recurrent ear-nose-throat (ENT) and airway infections’ were most commonly reported 
in this cohort (in 43/46 patients). In 31/46 patients, ‘recurrent ENT and airway infections’ 
was reported as the clinically most important presentation. Other PID-related 
manifestations reported as the most important clinical presentation include ‘auto-
immune or chronic inflammatory disease; lymphoproliferation’(n=5); ‘failure to thrive 
from early infancy’ (n=4); ‘unusual infections or unusually severe course of 
infections’(n=3); ‘recurrent pyogenic infections’ (n=2) and ‘recurrent infections with the 
same type of pathogen’(n=1). The most common syndromic-related manifestations 
were: developmental delay (n=37), ataxia, paresis or other motor disability (n=16), 
dysmorphic features (n=31), microcephaly (n=11), growth retardation (n=19), atopic 
eczema (n=8), hair and/or nail abnormalities (n=1) and hypopigmentation (n=1). 
A detailed overview of the clinical findings is shown in Table 1.
Antibody deficiency was the most common immunological defect identified. Of 33 patients 
reported to have low immunoglobulin isotype(s), 20 had low IgG (Figure 1). Nine patients 
had low IgG with completely absent IgA and 8 patients had low IgG in combination with 
low IgM. IgG subclass deficiency was identified in 18 patients, of which 15 had concomitant 
low total immunoglobulin isotype(s) and 3 did not. Vaccine responses were tested in 32/46 
patients and were found insufficient in 18 patients: 16/18 were insufficient for pneumococcal 
polysaccharide vaccine. Four patients (no. 2, 22, 23 and 24) showed normal antibody 
production after diagnostic vaccination despite low serum immunoglobulins. For patients 
23 and 24, however, the decreased response was based on total IgG for S. pneumoniae. 
Responses to live vaccines were not documented; no unfavorable outcomes of natural 
chickenpox infection were reported. 18/46 patients were treated with immunoglobulin 
replacement. The indication of immunoglobulin replacement therapy was based on clinical 
grounds, as judged by the treating physician. In 2 patients lymphopenia was reported; one 
of them was neutropenic as well. Lymphocyte subpopulations (CD3, CD4, CD8, CD19 and 
CD16/56) were determined in 36 patients; in 16 a decreased count of ≥1 (sub)populations 
was reported. In 11 patients more extensive B cell subpopulations were determined and 
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in 7 patients extensive T cell subpopulations (protocols differed per patient). In 1 patient 
total absence of B lymphocytes was reported (patient number 5; trisomy 13). Lymphocyte 
and granulocyte function tests were performed in 11 and 11 patients, respectively; in 2 
decreased lymphocyte as well as granulocyte function was reported (patients 2 and 3). A 
detailed overview of the immunological and other laboratory findings is presented in Table 
2 and Additional File 3.
Discussion
Our call identified 46 patients with chromosomal aberration associated with 
immunodeficiency, the largest cohort reported in the literature so far (42 isolated cases, 
and twice 2 patients from the same family). Based on data from 7/16 participating centers, 
up to one third of patients with chromosomal aberrations and recurrent infections may 
have some form of primary immunodeficiency. Because the patients in this study were 
identified by physician recall, reporter bias is possible. However, the relative number is 
much higher than the 6% found in a cohort of 259 ‘normal’ children screened for 
immunological abnormalities because of recurrent infections by Brodszki et al. [33]. 
The most common clinical presentation in our cohort was ‘recurrent ENT and airway 
infections’, which triggered their physician to perform immunological investigations. 
Figure 1. Levels of immunoglobulin isotypes. Every dot represents a patient. The bold black line is the lower limit 
of normal according to age-matched reference values (ref de Vries E. Clin Exp Immunol 2012;167(1):108-19.)
A. IgG in g/L. B. IgA in g/L; two values > 2.0 g/l are not displayed in the graph. C. IgM in g/L 
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Infantile pyloric stenosis 
Pulmonary congestion 
Intractable diarrhoea
2(a) M 3.4 46,XY.ish der(16)t(16;19)
(p13.3;p13.3) arr[hg19] 
16p13.3(106 271-1 024 153)
x1, 19p13.3(327 273-6 887 
622)x3 
Failure to thrive Developmental delay








3(a) M 9.4 46,XY.ish der(14)t(14;19)










Bilateral incarcerated inguinal hernia





4 M 5.6 46,XY,del(18)(p11.2) Airways Ataxia, paresis or other motor disability
Growth retardation
na

















8 M 1.0 No full karyotype available
Array CGH : gain of 144kB in 











9 F 5.2 46,XX,del(18)(q22) AI disease Developmental delay
Dysmorphic features





Type 1 diabetes mellitus
10 F 1.4 46,XX,arr[hg19] 16p11.2
(29,567,295-30,177,916)x1 dn
Failure to thrive Developmental delay
Growth retardation
Recurrent fever




12 F 6.5 45,X[42]/47,XXX[8] Airways Developmental delay
Growth retardation
Currarino syndrome
13 F 41.6 45,X Unusual 
infections
Growth retardation na
14 M 20.1 46,XY,der(X)t(X;18)(q28;q23) 
(MECP2 duplication)
Airways Developmental delay




Small intestinal villous atrophy
15(b) M 7.5 46,XY,r(18)(p11.2q23)
[97]/45,XY,-18[3]  
Airways Developmental delay


















Obesity, type II diabetes
Bronchiectasis
17(d) M 22.3 46,XY,der(18)t(10p;18q) with 
18q22.3–q23 deletion and 
partial trisomy of 10pter
Airways Developmental delay
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19(e) F 4.9 46,XX,t(12;14)(p11.2;q13) Airways None na
20(d) F 28.2 46,XX,der(18)t(10p;18q) with 
18q22.3–q23 deletion and 
partial trisomy of 10pter













22 M 34.3 46,XY,inv(10)(q21q23) AI disease None Asymptomatic
23(f) F 6.9 46,XX,del(19)(p13.13) Airways Developmental delay















25(g) M 16.8 46,XY,der(11)dup(11)(q22q23)
del(q24.3)
Airways Developmental delay
Ataxia, paresis or other motor disability
Dysmorphic features
Atopic eczema
Hair and/or nail abnormalities
na




Ataxia, paresis or other motor disability
Dysmorphic features
Defective absorption folinic acid





28 F 5.9 49,XXXXX Pyogenic 
infections
Developmental delay



















Dilated cardiomyopathy and small VSD
31(h) F 12.8 46,XX,del(18)(p11.1) Airways Developmental delay
Ataxia, paresis or other motor disability
Dysmorphic features
Growth retardation




Retrognathia with absent maxillary 
chondyles
32 M 6.8 46,XY,del(7)(q22.3 q31.3) Airways Developmental delay
Dysmorphic features
na
33 F 14.7 47,XX,+der(22)t(11;22)
(q23;q11) mat (partial trisomy 
11q)
Airways Developmental delay




34 F 7.9 46,XX.arr snp 
2p23.1(SNP_A-2078092-
>SNP_A-2248377)x1 mat
Same pathogen Developmental delay











Submucosal palatal schisis 
Transient neonatal macroglossi 
Hepatosplenomegaly
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36 F 6.8 45,X Airways None na







Ataxia, paresis or other motor disability






38(i) M 6.5 49,XXXXY Airways Developmental delay
Dysmorphic features
na
39(i) M 10.6 49,XXXXY Airways Developmental delay
Dysmorphic features
na
40(i) M 14.6 49,XXXXY Airways None na
41(i) M 13.3 49,XXXXY Airways Developmental delay
Dysmorphic features
na




43 M 12.2 47,XYY,dup(22)(q11.21) Pyogenic 
infections
Developmental delay






























Prematurity; gestational age 30 weeks
Bone anchored hearing aid
Periorbital hemangioma
46 F 12.9 46,XX,arr cgh 16p13.11p13.12
(14,687,636-16,452,200) x3.
Airways Developmental delay







Myopathy of unknown etiology




Nr= patient number; 1at the time of reporting; 2most prominent clinical immunological presentation; 3other 
clinical presentations as requested in the survey (Additional File 1).
Patients
(a) previously published in Seidel MG, Duerr C, Woutsas S, et al. J Med Genet 2014;51:254-263, (b) previously 
published in Celmeli F, et al. J Investig Allergol Clin Immunol. 2014;24(6):442-4, (c) previously published in 
Seppänen et al. J Clin Immunol 2014;34:114–118., (d) family members and previously published in Dostal et al. 
International Journal of Immu-genetics 2007;34: 143–147  : patient 17 as IV:4 and patient 20 as IV, (e) family 
members, together with excluded patient 2, 3 and 4, (f) publication in press, Calvo Campoverde K, et al. 
Allergologia et Immunopathologia 2016, (g) previously published in Fernandez-San Jose C, J Paediatr Child 
Health 2011;47(7):485-6, (h) previously published in Browning MJ, J Investig Allergol Clin Immu-l 2010;20(3):263-
266, (i) previously published in Keller MD, et al. Am J Med Genet C Semin Med Genet. 2013;163C(1):50-4.
Clinical presentations 
Airways = Recurrent ENT and airway infections; FTT = failure to thrive from early infancy; unusual infections = 
unusual infections or unusually severe course of infections; AI disease = autoimmune or chronic inflammatory 
disease, lymphoproliferation; pyogenic infections = recurrent pyogenic infections; same pathogen = recurrent 
infections with the same type of pathogen (de Vries E. Clin Exp Immunol 2012;167(1):108-19).
Other abbreviations
ALL: acute lymphatic leukemia, ASD: atrial septum defect, BCG: Bacillus Calmette-Guérin, F: female, HPV: human 
papilloma virus, IUGR: intra uterine growth retardation, JIA: juvenile idiopathic arthritis, M: male, na: not available, 
PDA: patent ductus arteriosus, PEG: percutaneous endoscopic gastrostomy, PS: pulmonary stenosis, VSD: 
ventricular septum defect, yrs: years.
* Samter’s triad: asthma, aspirin and NSAID sensitivity, and nasal/ethmoidal polyposis
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Not surprisingly, these were mostly ‘predominantly antibody deficiencies’[34] ranging 
from IgG-subclass deficiency and/or polysaccharide antibody deficiency to severe 
hypogammaglobulinemia or even agammaglobulinemia in one patient. While this study 
may have limitations inherent to a retrospective, observational survey (e.g. recall bias; 
reporting bias; convenience sampling), these findings suggest that 'syndromic 
immunodeficiency' may be under-diagnosed.
A previous study in patients with dysmorphic features found low CD19+ and CD16+ and/
or CD56+ cells as the most frequent immunological abnormalities, followed by low 
immunoglobulins [28]. However, in contrast to our survey this study also included a lot 
of patients with Down syndrome (11/29 patients) who are known to have lower CD19+ 
and CD3-CD16+ and/or CD56+ cells [6], precluding an appreciation for the possibility of 
underlying immunodeficiency in patients with non-Down, chromosomal syndromes. 
Until now, no other cohorts of patients with different chromosomal aberrations 
associated with immunological abnormalities have been described. The chromosomal 
aberrations described in our study may provide insight regarding novel genes involved 
in the immune system, either located directly within or adjacent to the anomalous loci. 
Several of the cytogenetic abnormalities in our patients have been linked to 
immunodeficiency or -dysregulation in the literature before.
The largest family in our cohort consists of 5 affected patients with 46,XX,t(12;14)
(p11.2;q13) (patients 18, 19 and excluded patients 2, 3 and 4). Only two had 
immunodeficiency (patients 18 and 19), both with low IgG-levels and one with additional 
IgA-deficiency and decreased numbers of CD19+ and CD3-CD16+and/orCD56+ cells. 
All patients in this family suffered from atopy, asthma and/or allergy (some with 
anaphylaxis); two developed acute lymphatic leukemia. A candidate gene located on 
chromosome 14q13 is nuclear factor of kappa light chain gene enhancer in B cells 
inhibitor alpha (NFKBIA) (OMIM 164008). NFKBIA inactivates NF-kappa-B by trapping it 
in the cytoplasm. Functional impairment of NFKBIA can result in increased activation of 
the NF-kappa-B pathway leading to immune dysregulation [35]. 
The other family in our cohort consists of two cousins with an unbalanced translocation 
t(18q;10p), namely t(18q-;10p+) (patients 17 and 20), effectively resulting in a 18q22.3–
q23 deletion and a partial trisomy of 10pter. Both showed IgA-deficiency and IgG-
subclass deficiency (both IgG4 and one also IgG2), and one showed decreased numbers 
of CD3-CD16+and/orCD56+ cells. One of the cousins showed diffuse thymic hyperplasia 
(patient 20) without evidence of developing thymoma. Although patients with complete 
10p trisomy are not reported to have immunodeficiency [36, 37], patients with terminal 
deletions of 10p have been reported with IgA- and IgG-deficiency before [21, 38]. The 
18q− syndrome is associated with IgA-deficiency and other autoimmune or 
immunodeficiency diseases, such as common variable immunodeficiency (CVID) [39], 
juvenile rheumatic arthritis [40], insulin-dependent diabetes mellitus [41], celiac disease 
[42] and thyroid hormone abnormalities [43]. This partly matches the clinical phenotypes 
of our related patients. The other patients in our cohort with chromosome 18q aberrations 
all but one also showed IgA-deficiency (patients 9, 14, and 20). The two cousins from 
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our study are part of a Finnish family with t(18q;10p), which was published in 2007 [20]. 
All members of this family showed IgA-deficiency; IgG-subclasses were not tested in 
the other family members. The authors hypothesized that the observed IgA-deficiency 
may result from haplo-insufficiency of one or multiple genes located in the 18q22.3–q23 
region in possible connection with a larger polygenic network.
Our cohort contains two patients with ring chromosome 18 (one mosaic (patient 15) and 
one with complete chromosome 18 deletion (patient 24)) and one patient with 18p deletion 
(patient 31). Deletions of chromosome 18p have also been associated with immune-related 
dysfunction like autoimmune thyroiditis, diabetes mellitus, IgA deficiency, atopic skin 
conditions, juvenile rheumatoid arthritis [12, 15, 22, 25], and in one patient with SLE [12]. 
This matches with our patients: two patients had an IgA-deficiency and the patient with 
18p deletion had multiple endocrine dysfunctions. However, our patient with a mosaic 
form of ring chromosome 18 (46,XY,r(18)(p11.2q23)[97]/45,XY,-18[3], patient 15) showed 
only low IgM with recurrent respiratory tract infections, as published before [27].
Four of our patients showed chromosome 11q deletions (patients 16, 25, 27 and 33); two 
of them were published before [14, 26]. Terminal deletion of chromosome 11 can cause 
Jacobsen syndrome [44] and has previously been associated with 
hypogammaglobulinemia, pancytopenia and low T-helper cell counts [45, 46]. Our 
patients with 11q deletion did not show neutropenia or lymphopenia, but three of them 
had both IgG- and IgA-deficiency. No low T-helper cell counts were reported.
Two centers reported a patient with deletion of chromosome 16p11.2 (patients 6 and 
10). Deletions in this region of chromosome 16 are associated with intellectual disability, 
congenital anomalies, obesity, macrocephaly, and autism [47]. This matches the clinical 
picture of one of our patients. Both patients showed only minor immunological 
abnormalities: IgA deficiency and global lymphocytosis. Recently, single nucleotide 
polymorphisms at the fused-in-sarcoma (FUS)/integrin CD11b (ITGAM) locus at 16p11.2 
were associated with CVID phenotypes [48]. In the literature, there is also a report of an 
autistic girl with a 16p11.2 deletion who also had severe combined immunodeficiency 
(SCID) caused by Coronin-1A deficiency (also located at 16p11.2) [49]. Coronin-1A is 
essential for development of a normal peripheral T cell compartment in mice as well as 
men [33, 50]. However, this girl had, in contrast to our patient, next to the 16p11.2 
deletion, also a 2 bp deletion of the Coronin-1A gene on the other (paternal) allele. 
Several patients with X-chromosome aberration were included. Turner syndrome (45,X) 
is known to be associated with immunodeficiency [5, 8], but with different clinical 
presentations. Our four Turner patients (patients 11, 13 and 36, and patient 12 with 
mosaicism Turner) also showed a variety of immunological abnormalities. The 
relationship, if any, between the immune defects in Turner syndrome and those in 
established X-linked PID remains unknown. Additionally, 5 boys with 49,XXXXY (patients 
38, 39, 40, 41 and 42) and 1 girl with 49,XXXXX (patient 28) were reported. The 49,XXXXX 
girl presented with pyogenic infections and low IgG and IgM levels, but with normal 
granulocyte levels and function. The 49,XXXXY boys all presented with ‘recurrent ENT 
and airway infections’, and they all showed impaired antibody responses to pneumococcal 
polysaccharide antigens, as was published before [11]. 
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Table 2. Results of immunological tests in the included patients.
Nr NP LP ↓G ↓A ↓M ↓IgG subclass Lymphocyte subsets Nr Resp TV Resp P L function G function 
1 - - + +* - na ↑ aCD3, ↑ aCD3CD4 1 ↓ ↓ na na
2(a) - - + - + + IgG1, IgG3 ↓ aCD3, ↓ a smB 2(a) nl Nl ↓ NK toxicity
In vitro lymphocyte proliferation: nl
Oxidative burst borderline ↓
3(a) - - - - - - Borderline ↓ a smB 3(a) nl Nl ↓ vitro lymphocyte proliferation decreased from 7 years on: SEA Moderate ↓ oxidative burst
4 - - - + - na na 4 na nl na na
5 - - + +* + + IgG1, IgG2, IgG3 Absence of CD19 cells 5 na na In vitro lymphocyte proliferation: nl na
6 - - - +* - - ↑ aCD3, ↑ aCD3CD4, ↑ aCD19 6 nl nl na nl
7 - - - +* - na ↓ aCD3, ↓ aCD3CD8 ↓ aCD19 7 ↓ na na na
8 - - + +* - na nl 8 na na na na
9 - - - - - - ↑ aCD16/56 9 ↓ na nl na
10 - - - - - na ↑ aCD3, ↑ aCD19, ↑ aCD16/56 10 nl na Thymic function: nl na
11 - - + - - na ↓ aCD3CD8, ↓ aCD19, ↑ aCD16/56 11 na nl na nl
12 - - + + - na ↑ aCD3, ↑ aCD3CD4, ↑ aCD19 12 nl na na na
13 + + + - - na ↓ aCD3CD4, ↓ aCD19, ↓ aCD16/56, 
↑ aCD3CD8
13 na na na na
14 - - - + + + IgG2, IgG4 nl 14 na ↓(j) na na
15(b) - - - - + - nl 15(b) na na nl nl
16(c) - - + + - + IgG1, IgG2, IgG4 ↓ aCD3, ↓ aCD3CD4, ↓ aCD19, 
↓ aCD16/56
16(c) na na na na
17(d) - - - +* - +** IgG2, IgG4 nl 17(d) na na na na
18(e) - - + - - + IgG1, IgG2, IgG4 ↓ aCD19, ↓ aCD16/56 18(e) na na na na
19(e) - - + +* - + IgG1 na 19(e) na na na na
20(d) - - - +* - + IgG4 ↓ aCD16/56 20(d) na na na na
21 - - - - - + IgG3, IgG4 ↓ aCD19 cells,  slightly ↓ aMZ-like B, 
↑ aCD3, ↑ aCD3CD8 
21 nl nl nl na
22 - + + + + - ↓ aCD3, ↓ aCD3CD4, ↓ aCD3CD8, ↓aCD19 cells (BM) 22 nl nl na na
23(f) - - + + - + IgG1, IgG2, IgG4 ↓ aCD3CD4, ↓ aCD16/56 23(f) nl nl (j) ↓ In vitro lymphocyte proliferation: PHA= 85%, PWD=72%, ConA=39% na
24(f) - - + +* - +*** IgG2, IgG3, IgG4 ↓ aCD3CD8 24(f) nl nl (j) ↓ In vitro lymphocyte proliferation: PHA= 92%, PWD=87%, ConA=28% na
25(g) - - + + + na Na 25(g) nl ↓ ↓ In vitro lymphocyte proliferation: PHA na
26 - - + - + + IgG1, IgG3 Na 26 na ↓ na na
27 - - - - - - ↓ aCD3, ↓ aCD3CD4, ↓ aCD3CD8, 
↓ aCD19, ↓ aCD16/56
27 ↓ ↓ ↓ In vitro lymphocyte proliferation: PHA na
28 - - - + + na ↑ aCD3, ↑ aCD3CD4, ↑ aCD3CD8, 
↑ aCD19
28 nl nl na nl
29 - - - - - - ↑ a CD3CD8, ↑ aCD19 29 nl ↓ na nl
30 - - - - + na ↓ aCD3, ↓ aCD3CD8 cells, ↑ aCD19 30 nl ↓ na nl
31(h) - - - + - + IgG2 ↑ aCD3, ↑ aCD3CD4, ↑ aCD3CD8, 
↑ aCD19
31(h) nl ↓ na nl
32 - - - + + na ↑ aCD19 32 nl nl na nl
33 - - - - - + IgG1 Na 33 na nl na na
34 - - - - - - Nl 34 na ↓ na nl
35 - - - + - + IgG2 Nl 35 na ↓ na na
36 - - + + - na Na 36 na na na na
37 - - + + + + IgG1, IgG2 ↓ aCD3, ↓ aCD3CD8, ↓ aCD19, 
↓ aCD16/56 cells, ↓ a memB
37 na na na na
38(i) - - + - - na Na 38(i) na ↓ na na
39(i) - - na na na na ↑ aCD3CD4 39(i) na ↓ na na
40(i) - - - - - na ↑ aCD3, ↑ aCD3CD4 40(i) na ↓ na na
41(i) - - - - - na Na 41(i) na ↓ na na
42(i) - - - - - - ↑ aCD3, ↑ aCD3CD4, ↑ aCD19, 
↑ aCD16/56
42(i) na ↓ na na
43 - - + + - + IgG2 ↑ aCD3, ↑ aCD3CD4, ↑ aCD3CD8,  
↑ aCD 19
43 nl ↓ na na
44 - - - - - + IgG1 Na 44 na na na na
45 - - - + - -   Na 45 na na na na
46 - - + + + na Nl 46 na na na na
Headings
Nr: patient number, NP: neutropenia, LP: lymphopenia,↓G: low IgG,↓A: low IgA,↓M: low IgM,↓IgG subclass: low IgG subclasses, Resp TV: response tetanus 
vaccine, Resp P: response PneumoVax® or Pneumo23®, L function: lymphocyte function tests, G function: granulocyte function tests.
Patients
(a) previously published in Seidel MG, Duerr C, Woutsas S, et al. J Med Genet 2014;51:254-263, (b) previously published in Celmeli F, J Investig Allergol Clin 
Immunol. 2014;24(6):442-4, (c) previously published in Seppänen et al. J Clin Immunol 2014;34:114–118., (d) family members and previously published in 
Dostal et al. International Journal of Immu-genetics 2007;34: 143–147  : patient 17 as IV:4 and patient 20 as IV, (e) family members, together with excluded 
patient 2, 3 and 4, (f) publication in press, Calvo Campoverde K, et al. Allergologia et Immunopathologia 2016, (g) previously published in Fernandez-San 
Jose C, J Paediatr Child Health 2011;47(7):485-6. (h) previously published in Browning MJ, J Investig Allergol Clin Immu-l 2010;20(3):263-266, (i) previously 
published in Keller MD, et al. Am J Med Genet C Semin Med Genet. 2013;163C(1):50-4, (j) decreased response to Pneumovax ® or Pneumo23® based on 
total IgG for S. pneumoniae.
* IgA completely absent, ** IgG2 completely absent, ***IgG3 completely absent.
Other abbreviations
a: absolute cell count, BM: bone marrow, CD: cluster of differentiation, ConA: Concanavalin A, memB: memory B cells, MZ: marginal zone, na: not 
available,  nl: normal,  PHA: phytohaemagglutinin, PWD: pokeweed mitogen, SEA: Staphylococcus aureus enterotoxin A, smB: switched memory B cells.
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Table 2. Results of immunological tests in the included patients.
Nr NP LP ↓G ↓A ↓M ↓IgG subclass Lymphocyte subsets Nr Resp TV Resp P L function G function 
1 - - + +* - na ↑ aCD3, ↑ aCD3CD4 1 ↓ ↓ na na
2(a) - - + - + + IgG1, IgG3 ↓ aCD3, ↓ a smB 2(a) nl Nl ↓ NK toxicity
In vitro lymphocyte proliferation: nl
Oxidative burst borderline ↓
3(a) - - - - - - Borderline ↓ a smB 3(a) nl Nl ↓ vitro lymphocyte proliferation decreased from 7 years on: SEA Moderate ↓ oxidative burst
4 - - - + - na na 4 na nl na na
5 - - + +* + + IgG1, IgG2, IgG3 Absence of CD19 cells 5 na na In vitro lymphocyte proliferation: nl na
6 - - - +* - - ↑ aCD3, ↑ aCD3CD4, ↑ aCD19 6 nl nl na nl
7 - - - +* - na ↓ aCD3, ↓ aCD3CD8 ↓ aCD19 7 ↓ na na na
8 - - + +* - na nl 8 na na na na
9 - - - - - - ↑ aCD16/56 9 ↓ na nl na
10 - - - - - na ↑ aCD3, ↑ aCD19, ↑ aCD16/56 10 nl na Thymic function: nl na
11 - - + - - na ↓ aCD3CD8, ↓ aCD19, ↑ aCD16/56 11 na nl na nl
12 - - + + - na ↑ aCD3, ↑ aCD3CD4, ↑ aCD19 12 nl na na na
13 + + + - - na ↓ aCD3CD4, ↓ aCD19, ↓ aCD16/56, 
↑ aCD3CD8
13 na na na na
14 - - - + + + IgG2, IgG4 nl 14 na ↓(j) na na
15(b) - - - - + - nl 15(b) na na nl nl
16(c) - - + + - + IgG1, IgG2, IgG4 ↓ aCD3, ↓ aCD3CD4, ↓ aCD19, 
↓ aCD16/56
16(c) na na na na
17(d) - - - +* - +** IgG2, IgG4 nl 17(d) na na na na
18(e) - - + - - + IgG1, IgG2, IgG4 ↓ aCD19, ↓ aCD16/56 18(e) na na na na
19(e) - - + +* - + IgG1 na 19(e) na na na na
20(d) - - - +* - + IgG4 ↓ aCD16/56 20(d) na na na na
21 - - - - - + IgG3, IgG4 ↓ aCD19 cells,  slightly ↓ aMZ-like B, 
↑ aCD3, ↑ aCD3CD8 
21 nl nl nl na
22 - + + + + - ↓ aCD3, ↓ aCD3CD4, ↓ aCD3CD8, ↓aCD19 cells (BM) 22 nl nl na na
23(f) - - + + - + IgG1, IgG2, IgG4 ↓ aCD3CD4, ↓ aCD16/56 23(f) nl nl (j) ↓ In vitro lymphocyte proliferation: PHA= 85%, PWD=72%, ConA=39% na
24(f) - - + +* - +*** IgG2, IgG3, IgG4 ↓ aCD3CD8 24(f) nl nl (j) ↓ In vitro lymphocyte proliferation: PHA= 92%, PWD=87%, ConA=28% na
25(g) - - + + + na Na 25(g) nl ↓ ↓ In vitro lymphocyte proliferation: PHA na
26 - - + - + + IgG1, IgG3 Na 26 na ↓ na na
27 - - - - - - ↓ aCD3, ↓ aCD3CD4, ↓ aCD3CD8, 
↓ aCD19, ↓ aCD16/56
27 ↓ ↓ ↓ In vitro lymphocyte proliferation: PHA na
28 - - - + + na ↑ aCD3, ↑ aCD3CD4, ↑ aCD3CD8, 
↑ aCD19
28 nl nl na nl
29 - - - - - - ↑ a CD3CD8, ↑ aCD19 29 nl ↓ na nl
30 - - - - + na ↓ aCD3, ↓ aCD3CD8 cells, ↑ aCD19 30 nl ↓ na nl
31(h) - - - + - + IgG2 ↑ aCD3, ↑ aCD3CD4, ↑ aCD3CD8, 
↑ aCD19
31(h) nl ↓ na nl
32 - - - + + na ↑ aCD19 32 nl nl na nl
33 - - - - - + IgG1 Na 33 na nl na na
34 - - - - - - Nl 34 na ↓ na nl
35 - - - + - + IgG2 Nl 35 na ↓ na na
36 - - + + - na Na 36 na na na na
37 - - + + + + IgG1, IgG2 ↓ aCD3, ↓ aCD3CD8, ↓ aCD19, 
↓ aCD16/56 cells, ↓ a memB
37 na na na na
38(i) - - + - - na Na 38(i) na ↓ na na
39(i) - - na na na na ↑ aCD3CD4 39(i) na ↓ na na
40(i) - - - - - na ↑ aCD3, ↑ aCD3CD4 40(i) na ↓ na na
41(i) - - - - - na Na 41(i) na ↓ na na
42(i) - - - - - - ↑ aCD3, ↑ aCD3CD4, ↑ aCD19, 
↑ aCD16/56
42(i) na ↓ na na
43 - - + + - + IgG2 ↑ aCD3, ↑ aCD3CD4, ↑ aCD3CD8,  
↑ aCD 19
43 nl ↓ na na
44 - - - - - + IgG1 Na 44 na na na na
45 - - - + - -   Na 45 na na na na
46 - - + + + na Nl 46 na na na na
Headings
Nr: patient number, NP: neutropenia, LP: lymphopenia,↓G: low IgG,↓A: low IgA,↓M: low IgM,↓IgG subclass: low IgG subclasses, Resp TV: response tetanus 
vaccine, Resp P: response PneumoVax® or Pneumo23®, L function: lymphocyte function tests, G function: granulocyte function tests.
Patients
(a) previously published in Seidel MG, Duerr C, Woutsas S, et al. J Med Genet 2014;51:254-263, (b) previously published in Celmeli F, J Investig Allergol Clin 
Immunol. 2014;24(6):442-4, (c) previously published in Seppänen et al. J Clin Immunol 2014;34:114–118., (d) family members and previously published in 
Dostal et al. International Journal of Immu-genetics 2007;34: 143–147  : patient 17 as IV:4 and patient 20 as IV, (e) family members, together with excluded 
patient 2, 3 and 4, (f) publication in press, Calvo Campoverde K, et al. Allergologia et Immunopathologia 2016, (g) previously published in Fernandez-San 
Jose C, J Paediatr Child Health 2011;47(7):485-6. (h) previously published in Browning MJ, J Investig Allergol Clin Immu-l 2010;20(3):263-266, (i) previously 
published in Keller MD, et al. Am J Med Genet C Semin Med Genet. 2013;163C(1):50-4, (j) decreased response to Pneumovax ® or Pneumo23® based on 
total IgG for S. pneumoniae.
* IgA completely absent, ** IgG2 completely absent, ***IgG3 completely absent.
Other abbreviations
a: absolute cell count, BM: bone marrow, CD: cluster of differentiation, ConA: Concanavalin A, memB: memory B cells, MZ: marginal zone, na: not 
available,  nl: normal,  PHA: phytohaemagglutinin, PWD: pokeweed mitogen, SEA: Staphylococcus aureus enterotoxin A, smB: switched memory B cells.
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Conclusion
This retrospective survey demonstrates that patients with chromosomal aberrations and 
recurrent infections may harbor underlying primary immunodeficiencies. By specifically 
excluding the syndromic immunodeficiencies associated with Down and DiGeorge 
syndromes, we showed that a diverse spectrum of chromosomal aberrations can be 
associated with immunological abnormalities. In our cohort antibody deficiency was the 
most prevalent; this is important because infectious complications can be prevented 
with early interventions like antibiotic prophylaxis or immunoglobulin replacement 
treatment in these patients. To assess whether this association is a truly causal relation, 
a large case-control study would be needed; this is not really feasible. And of course, 
our survey results do not negate other contributing factors (e.g. aspiration; abnormal 
anatomy) in the development of recurrent ENT and airway infections in these patients. 
Nonetheless, our findings suggest it is important to consider immunological investigations 
in patients with chromosomal aberration and recurrent infections. 
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Additional file 1: the Online Questionnaire
I. Physician submitting the survey (one form per submitted patient). NB the reporting physician, not the patient!
This information will be used as author information for the manuscript.




5. email address ...
II. Patient with chromosomal aberration and associated immunological abnormalities being reported
1. male/female
2. date of birth
3. date of report (today)
4. chromosomal aberration present not being Down syndrome (trisomy 21) or DiGeorge syndrome (22q11 deletion): yes/no
5.  please enter as full a description of the chromosomal aberration as possible (example: 46,XY,dup(6)(p12.2p21.31) or when 
SNP array was performed please state brand and type of chip used and SNP positions: example: Affymetrix 250k SNP 
46,XX,der (2) t (2;10) (q37.3;q26.3)mat .arr  snp 2q37.2q37.3(SNP_A-1957498->SNP_A-2027809)
x1,10q26.3(SNP_A-2264115->SNP_A-1934598)x3 ): ..................
III. Clinical characteristics of the reported patient
1. Which clinical presentations apply to the patient? (multiple answers possible)
a. Recurrent ENT and airway infections
b. Failure to thrive from early infancy
c. Recurrent pyogenic infections
d. Unusual infections or unusually severe course of infections
e. Recurrent infections with the same type of pathogen
f. Autoimmune or chronic inflammatory disease; lymphoproliferation
2. What is the clinically most important clinical presentation of the patient? (single answer):
a. Recurrent ENT and airway infections
b. Failure to thrive from early infancy
c. Recurrent pyogenic infections
d. Unusual infections or unusually severe course of infections
e. Recurrent infections with the same type of pathogen
f. Autoimmune or chronic inflammatory disease; lymphoproliferation
3. Does the patient suffer from (multiple answers possible):
a. developmental delay





g. hair and/or nail abnormalities
h. hypopigmentation
4. Any other relevant clinical information, specification of the above: 
IV. Immunological characteristics of the reported patient
1. Was a leukocyte differential performed (absolute numbers)? yes/no
2. if yes: granulocytes (10e9/l)
3. if yes: lymphocytes (10e9/l)
4. Were immunoglobulins (IgG, IgA, IgM) determined in serum? yes/no
5. if yes: level of IgG (g/l)
6. if yes: level of IgA (g/l)
7. if yes: level of IgM (g/l)
8. Were IgG-subclasses determined in serum? yes/no
9. if yes: level of IgG1 (g/l)
10. if yes: level of IgG2 (g/l)
11. if yes: level of IgG3 (g/l)
12. if yes: level of IgG4 (g/l)
13.  Were lymphocyte subpopulations determined? 
no / yes (percentage only) / yes (absolute number) (single answer)
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14. if yes (%): CD3+ T-lymphocytes
15. if yes (%): CD3+CD4+ helper-T-lymphocytes
16. if yes (%): CD3+CD8+ cytotoxic T-lymphocytes
17. if yes (%): CD19+ or CD20+ B-lymphocytes
18. if yes (%): CD3- CD16 and/or CD56+ NK-cells
19. if yes (10e9/l): CD3+ T-lymphocytes
20. if yes (10e9/l): CD3+CD4+ helper T-lymphocytes
21. if yes (10e9/l): CD3+CD8+ cytotoxic T-lymphocytes
22. if yes (10e9/l): CD19+ or CD20+ B-lymphocytes
23. if yes (10e9/l): CD3- CD16 and/or CD56+ NK-cells
24. Were any other lymphocyte subpopulations determined? yes/no. 
if yes: please email or fax an anonymized copy of the results
25. Were vaccine response(s) determined? no / yes (tetanus) / yes (PneumoVax®, Pneumo23®) / yes (other) (multiple answer)
if yes: please email or fax an anonymized copy of the results
26. Were any tests of granulocyte function performed? yes/no
if yes: please email or fax an anonymized copy of the results
28. Were any tests of lymphocyte function performed? yes/no
if yes: please email or fax an anonymized copy of the results
Thank you for returning this online survey!
Additional File 2. Clinical and immunological characteristics of the excluded patients.
Part A. Clinical characteristics of the excluded patients.




Other clinical presentations3 Other symptoms
Excl 1 M 39.4 Rubinstein Taybi Syndrome 





Excl 2* F 41.7 46,XX,t(12;14)(p11.2;q13) Airways Atopic eczema Atopy, eczema, asthma, allergy and 
angioedema; no immunodeficiency
Excl 3* F 16.8 46,XX,t(12;14)(p11.2;q13) Airways Atopic eczema Atopy, asthma, allergy and 
anaphylaxis; no immunodeficiency
Excl 4* F 13.7 46,XX,t(12;14)(p11.2;q13) AI disease Atopic eczema ALL, atopy, asthma and allergy; no 
immunodeficiency





Excl 6 M 4.6 Rothmund Thomson Syndrome 








Nr= patient number; 1at the time of reporting; 2most prominent immunological clinical presentation; 3other 
clinical presentations as requested in the survey (Additional File 1).
Clinical presentations
Airways = Recurrent ENT and airway infections; unusual infections = unusual infections or unusually severe 
course of infections; AI disease = autoimmune or chronic inflammatory disease; lymphoproliferation (de Vries 
2012).
Patients
* family members together with included patients 18 and 19
Other abbreviations
ALL: acute lymphatic leukemia, Excl: excluded patient,F: female, M: male, yrs: years.
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Part B. Immunological characteristics of the excluded patients.








Excl 1 - - + + + na ↓ aCD16/56 na na na na
Excl 2* - - - - - - na na na na na
Excl 3* - - - - - - na na na na na
Excl 4* - - - - - - na na na na na
Excl 5 - - + + - + IgG1, IgG2, IgG4 ↑ aCD3 cells, ↓ a sm and MZ B, ↑ CD21low B nl nl** na na
Excl 6 - - + + - na   ↓ aCD3, ↓aCD3CD4, ↓ aCD3CD8, ↓ aCD19,  
↓ aCD16/56 cells








Nr: patient number, NP: neutropenia, LP: lymphopenia,↓G: low IgG,↓A: low IgA,↓M: low IgM.↓IgG subclass: low 
IgG subclasses, Resp TV: response tetanus vaccine, Resp P: response PneumoVax® or Pneumo23®, L function: 
lymphocyte function tests, G function: granulocyte function tests.
Patients
* family members together with included patients 18 and 19, ** decreased response to Pneumovax® or 
Pneumo23® based on total IgG for S. pneumoniae.
Other abbreviations
a: absolute count, CD: cluster of differentiation, MZ: marginal zone, na: not available, nl: normal, PHA: 
phytohaemagglutinin, PWM: pokeweed mitogen, OKT3: a monoclonal IgG2 antibody which binds the ε 
component of the CD3 signal-transduction complex.
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Additional File 3.
Additional test results of the included patients.





1 CD3 2.19, CD3 1.70, CD8 0.52, 
CD19 0.50, CD16/56 0.15
na na na
2(a) CD3 1.21, CD4 1.70, CD8 0.20, 





Alpha-Thalassemia Trait Multiple diffuse hyperintense 
white matter lesions, pronounced 
atrophy, hydrocephalus, 
microcysts basal ganglia
3(a) CD3 3.78, CD4 1.85, CD8 1.43, 





na Hypoplastic inferior vermis, 
sligthly extended temporal lobe
4 na na na na
5 na na na na
6 CD3 3.05, CD4 1.91, CD8 0.94, 
CD19 1.97, CD16/56 0.40
na na na
7 CD3 1.03, CD4 0.72, CD8 0.32, 
CD19 0.29, CD16/56 0.10
Auto-immune anemia na na
8 CD3 4.09, CD4 2.76, CD8 1.26, 
CD19 0.58, CD16/56 0.46
na na na
9 CD3 1.70, CD4 0.93, CD8 0.54, 
CD19 0.46, CD16/56 0.74
Hypergammapathy, pernicious anemia na na
10 CD3 5.60, CD4 3.20, CD8 2.00, 
CD19 3.40, CD16/56 0.63
Lymphocytosis na na
11 CD3 0.74, CD4 0.56, CD8 0.16, 
CD19 0.10, CD16/56 0.44
na na na
12 CD3 3.69, CD4 2.78, CD8 0.91, 
CD19 1.48, CD16/56 0.34
na na na
13 CD3 2.26, CD4 0.43, CD8 1.80, 
CD19 0.05, CD16/56 0.02
Monocytopenia na na
14 CD3 0.99, CD4 0.46, CD8 0.41, 
CD19 0.24, CD16/56 0.11
na na na
15(b) na Isohemagglutinin titers 1:1 na Corpus callosum hypoplasia, 
delayed myelinisation
16(c) CD3 0.37, CD4 0.09, CD8 0.27, 
CD19 0.02, CD16/56 0.05
Chronic Paris-Trousseau type 
thrombocytopenia
na na
17(d) CD3 0.80, CD4 0.51, CD8 0.02, 
CD19 0.29, CD16/56 0.16
na na na
18(e) CD3 1.41, CD4 0.89, CD8 0.42, 
CD19 0.14, CD16/56 0.09
na na Occult subarachnoidal cyst left 
frontal lobe
19(e) na na na na
20(d) CD3 0.96, CD4 0.67, CD8 0.28, 
CD19 0.24, CD16/56 0.07
na na Demyelinating white matter 
lesions
21 CD3 1.94, CD4 1.10, CD8 0.97, 






22 CD3 0.60, CD4 0.33, CD8 0.16, 
CD19 0.07, CD16/56 0.12
Thrombocytopenia na na
23(f) CD3 2.16, CD4 1.20, CD8 0.80, 
CD19 0.53, CD16/56 0.12
na na Hypoplasia corpus callosum, 
ventriculomegaly
24(f) CD3 1.16, CD4 0.80, CD8 0.26, 
CD19 0.26, CD16/56 0.26
na na na
25(g) CD3 0.72, CD4 0.46, CD8 0.21, 
CD19 0.06, CD 16/56 0.07
Thrombocytopenia na na
26 na na na na
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27 CD3 0.53, CD4 0.25, CD8 0.27, 
CD19 0.11, CD16/56 0.09
na na na
28 CD3 3.08, CD4 1.98, CD8 1.15, 
CD19 0.91, CD16/56 0.31
na na na
29 CD3 1.96, CD4 1.08, CD8 0.82, 
CD19 0.59, CD16/56 0.32
na na na
30 CD3 0.86, CD4 0.61, CD8 0.22, 
CD19 0.84, CD16/56 0.24
na na na
31(h) CD3 2.57, CD4 1.35, CD8 1.11, 
CD19 0.66, CD16/56 0.15
na na Low myelinisation
32 CD3 2.79, CD4 1.66, CD8 1.00, 
CD19 0.77, CD16/56 0.21
na na na
33 na na na na
34 na na na na
35 na na na na
36 na na na na
37 na na na na
38(i) na na na na
39(i) CD3 1.97, CD4 1.50, CD8 0.37, 
CD19 0.35, CD16/56 0.22
na na na
40(i) CD 3 2.68, CD4 1.93, CD8 0.66, 
CD19 0.60, CD16/56 0.78
na na na
41(i) na na na na
42(i) CD3 22.70, CD4 15.60, CD8 0.65, 
CD19 3.97, CD16/56 1.70
na na na
43 CD3 2.61, CD4 1.57, CD8 0.87, 
CD19 1.26, CD16/56 0.35
na na na
44 na na na na
45 CD3 1.70, CD4 0.80, CD8 0.80, 
CD19 0.20, CD16/56 0.55
na na na
46 CD3 1.35, CD4 0.81, CD8 0.54, 
CD19 0.45, CD16/56 0.18
na na na
Patients
(a) previously published in Seidel MG, Duerr C, Woutsas S, et al. J Med Genet 2014;51:254-263, (b) previously published in Celmeli F, J Investig Allergol Clin 
Immunol. 2014;24(6):442-4, (c) previously publised in Seppänen et al. J Clin Immunol 2014;34:114–118., (d) family members and previously published in 
Dostal et al. International Journal of Immu-genetics 2007;34: 143–147  : patient 17 as IV:4 and patient 20 as IV, (e) family members, together with excluded 
patient 2, 3 and 4, (f) publication in press, Calvo Campoverde K, et al. Allergologia et Immunopathologia 2016, (g) previously published in Fernandez-San 
Jose C, J Paediatr Child Health 2011;47(7):485-6. (h) previously published in Browning MJ, J Investig Allergol Clin Immu-l 2010;20(3):263-266, (i) previously 
published in Keller MD, et al. Am J Med Genet C Semin Med Genet. 2013;163C(1):50-4.
Other abbrevations
AH: alternative complement,  CD: cluster of differentiation, CH: classical complement, MBL: mannose binding ligand, na: not available,  nl: normal.
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Discussion
Diagnosing primary immunodeficiency (PID) in children is challenging. On the one hand, 
this is due to the maturing immune system which makes it difficult to distinguish between 
a physiologically immature and a pathologically dysfunctional immune system. On the 
other hand, it is also due to the unawareness of doctors. The aim of this thesis was (1) 
to get more insight into the pitfalls of the developing immune system for doctors 
confronted by children with potential primary immunodeficiency and (2) to study in detail 
the clinical picture of hypogammaglobulinemia in children using data from (inter)national 
registries and surveys. Our age-matched reference values for lymphocyte subpopulations 
presented in this thesis help to distinguish between normal and abnormal results. 
Furthermore, we show that analysis of larger patient cohorts, using registries and/or 
surveys, can detect unknown patterns, like the predominance of boys with 
hypogammaglobulinemia. These findings can give new impulse to future research.
Pediatric immune reference values for diagnosis and classification
Predominantly antibody disorders (PAD), the most common forms of PID, result from 
either quantitative or qualitative/functional cellular deficits. For diagnosis principally 
antibody concentrations are used and compared to age specific references values. In 
addition functional responses to vaccinations and natural infections help making a 
diagnosis. As PAD are a heterogeneous group of disorders, further classifications have 
been developed relating to molecular, cellular development or functional deficits. Most 
of these classifications were developed for CVID patients, it is important to realise 
however that the diagnostic criteria for CVID used by the various authors have varied 
with time (and opinion).
At first, flow cytometric classification schemes of common variable immunodeficiency 
disorders (CVID) were developed in small patient groups [1, 2]. In 2008 a large European 
trial was published, proposing a B cell phenotypic classification of a large cohort of 
CVID patients: the EUROclass trial [3]. This study, including mainly adult patients, showed 
that a severe reduction of switched memory B cells was associated with a higher risk 
for splenomegaly and granulomatous disease. An expansion of CD21low B cells marked 
patients with splenomegaly, and lymphadenopathy was significantly linked with 
transitional B cell expansion. There are only a few studies looking at specific classification 
schemes in pediatric CVID patients [4, 5]. Because of their maturing immune system, 
classification schemes developed in adult CVID patients, cannot simply be extrapolated 
to use in children. One study showed that there is a relation between decreased class-
switched memory B cells in combination with increased transitional B cells and the 
occurrence of disease related complications. In this pediatric CVID group, no correlation 
between clinical characteristics and T cell phenotype could be made [4]. Another study 
looking at peripheral B cell analysis in pediatric CVID patients showed that patients with 
a block in the early B cell maturation phase require earlier immunoglobulin replacement 
therapy and that these patients were at significantly greater risk of enteropathy, 
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granuloma formation, cytopenia, and lymphoproliferation. B cell maturation inhibited 
at the natural effector stage was associated with higher risk of autoimmune 
manifestations other than autoimmune cytopenia (i.e. arthritis, auto-immune thyroiditis 
and auto-immune hepatitis) [5].
Subsequently, a classification of CVID based on clinical phenotypes was proposed [6]. 
Five distinct clinical phenotypes were defined: no complications, autoimmunity, 
polyclonal lymphocytic infiltration, enteropathy and lymphoid malignancy. A total of 83% 
of included patients had only one of these phenotypes. Higher serum IgM and lower 
circulating CD8 proportions were found to be predictive markers for polyclonal 
lymphocytic infiltration and autoimmunity respectively, but further there was a widespread 
variation in immunoglobulin levels and B cell numbers among the different clinical 
phenotypes. A pediatric CVID cohort showed that children fitting into one of the above 
mentioned clinical phenotypes were more affected in their numbers of class switched 
memory B cells than children without any disease related complications [4].
Others looked at the functional defects and described five different B cell patterns in 
CVID patients [7]. These five patterns give a good overview of possible defects in the late 
B cell development that can cause hypogammaglobulinemia: 1) B cell production and 
germinal center defect, 2) early peripheral B cell maturation or survival defect, 3) B cell 
activation and proliferation defect, 4) germinal center defect and 5) post germinal center 
defect. Splenomegaly significantly clustered in patients with B cell pattern 1 (B cell 
production and germinal center defect).
To determine whether the above described classification schemes based on or correlated 
with peripheral lymphocyte counts and all developed with mainly adult data, are 
applicable in children, reliable age-matched reference values are needed. This thesis 
provides these pediatric references values for B- and T-lymphocyte subpopulations in 
chapter 1 and chapter 2, including also newly described lymphocyte subpopulations. 
These reference values are displayed as means with a range per specific age group, giving 
a 95% chance that 90% of healthy children will show numbers within this range. We show 
that the greatest changes in the peripheral B cell and T cell compartment occur in the 
first years of life, reflecting immune maturation. For B cells the increase in the first months 
of life is almost entirely caused by expansion of the naive B-lymphocyte pool, and to a 
small extent by expansion of transitional cells. The increase in T cells in the first 9-15 
months of life is mainly caused by expansion of recent thymic emigrants and naive T 
cells. Regulatory T cells increase only in the first 5 months of life and then gradually 
decrease, whereas CXCR5+ memory cells are virtually absent at birth and rapidly increase 
in the first months of life. These changes in the peripheral lymphocyte population are 
reflected best when using absolute numbers of cells, relative numbers can be misleading. 
Therefore, absolute B and T cell numbers should be used  for diagnosis and research in 
PID [8].
Furthermore we tested the existing CVID classification schemes for applicability in 
children. In our study, 40 out of 97 healthy children would be classified in one of the 
EUROclass CVID subgroups due to the fact that they show lower relative numbers of 
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switched memory B-lymphocytes. The low relative numbers of switched memory 
B-lymphocytes in these healthy children are not a sign of immunodeficiency, but a 
reflection of physiological immune maturation. Although this mainly concerns young 
children below two years of age (38 out of 40), this illustrates that one should be careful 
when using adult flow cytometry classification schemes in children. In the functional 
classification scheme [7], patients are not only divided based on quantitative B cell 
numbers, but also on B cell replication history and SHM levels. Pattern 3 (B cell activation 
and proliferation defect) showed decreased proliferation of marginal zone like B cells 
with reduced SHM levels in combination with a reduction of marginal zone like and 
memory B cells. This thesis shows in chapter 3 that SHM levels are also age dependent 
and seem to increase in the first two years of life. This can not only be explained by 
increase in mature B cells in these children. We hypothesize that increase of SHM in 
childhood reflects an increase of proportion of memory B cells originating from 
secondary GC-dependent B cell responses as well as increase of the SHM frequency 
within the memory B cell compartment, reflecting immune maturation. Finally, we show 
that age is the primary determinant of TACI expression on B cells, suggesting that 
decreased TACI expression on B cells in young children is not automatically indicative 
of a potential TACI mutation.
Insights from analysis of registry and survey cohorts
Male predominance PAD suggests hidden X-linked inheritance
The pathogenesis of PAD is still largely unclear, only in agammaglobulinemia and class 
switch recombination problems several gene defects have been identified. With the 
hallmark of hypogammaglobulinemia, the common immune defect is a loss of B cell 
function, but the causes of these abnormalities remain largely unknown. Several 
autosomal localized genetic defects in CVID patients have been discovered lately (i.e. 
ICOS [9], TACI [10], BAFF-R [11], lipopolysaccharide responsive beige-like anchor protein 
(LRBA) [12], phospholipase Cγ2 (PLCG2) [13], protein C kinase δ (PRKCD) [14], CD19 [15], 
CD20 [16], CD21 [17], CD81 [18] and NF-κB1 Subunit p50 [19]). 
But in more than 95% of CVID patients the genetic background is unknown [20] and 
even less is known as yet about the genetic defects in primary hypogammaglobulinemias 
other than CVID. A genome-wide association study (GWAS) using single nucleotide 
polymorphism (SNP) arrays in a large cohort of CVID patients showed associations with 
the MHC region, the metalloproteinases ADAM28, ADAM7, ADAMDEC1 and STC1 [21]. 
Another GWAS study of IgAD patients from Sweden and Iceland identified an association 
with a variant in IFIH1 and CLEC16A, both known to be associated with autoimmune 
disease, as well as associations with class II alleles in the HLA region [22]. Furthermore, 
copy number variants association analysis uncovered several novel genes that were 
significantly associated with CVID [21].
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Our studies suggest that X-linked inheritance may play a role in the development of 
primary hypogammaglobulinemia. In both clinical studies described in Part 2 of this thesis 
boys predominate in the cohorts. In the hypogammaglobulinemia category of the ESID 
online database 63% were boys (chapter 4), and in the Dutch cohort of children with 
IgG-subclass deficiency and/or SPAD 67% were boys (chapter 5). Also, in the ESID registry 
boys were younger at diagnosis (mean age males 5.3, females 5.8 years) and suffered 
from more complications (12% in boys, 5% in girls). In the Dutch cohort, only boys 
showed progressive immunodeficiency during follow-up. This predominance of males 
can be found in other papers [3, 23-26] but was generally not given much attention. We 
hypothesize that this male predominance can be due to either insufficient diagnostic 
procedures or atypical presentation (e.g. a known X-linked PID diagnosis has been missed 
in both cases), or to unknown X-linked disease(s) that cause primary 
hypogammaglobulinemia.
IgG subclass deficiency and/or SPAD are identified in the majority by pediatric 
immunologist – do we miss patients in the general pediatric population?
As PIDs are rare, the awareness of PID among health care professionals is low; most 
professionals are not familiar with the details of these complex diseases. A recent study 
in Brazil among 4026 physicians (40% pediatricians) revealed that only 40% performed 
immunological screening in patients with frequent use of antibiotics. 77% of the doctors 
were not familiar with the PID warning signs [27]. The majority of children with recurrent 
infections however will present to a general pediatrician. Little is known about the 
prevalence, clinical presentation and prognosis of ‘milder’ forms of PAD, such as IgG-
subclass deficiency and/or SPAD in children in the general pediatric population. The 
study described in chapter 5 of this thesis was the first study published in a Western-
European cohort of children with IgG-subclass deficiency and/or SPAD, and the first that 
included children followed outside tertiary centers [28-31]. We show that the most 
prevalent IgG-subclass deficiency in our cohort was IgG2 deficiency. This is in contrast 
with other published cohorts, where IgG3 deficiency was most common [28, 30]. These 
cohorts contained a higher number of children on prophylactic antibiotics, and were 
performed in tertiary populations. This may explain this difference in phenotype. 
Moreover, the majority of children (69%) in our cohort were reported by four secondary 
hospitals with a pediatric immunologist in the staff, which raises the question whether 
many of these patients are missed in the general pediatric population in the Netherlands. 
Although often considered to be mild, IgG2 deficiency and SPAD are risk factors for 
invasive pneumococcal disease [32], so awareness of these diseases is important.
PAD in chromosomal syndromic disorders – Importance of partial chromosomal 
monosomies and trisomies as hints for relevant genetic loci
Patients with chromosomal syndromic disorders often have recurrent infections, but 
physicians can easily ascribe these infections to other factors such as food and saliva 
aspiration, structural abnormalities of the upper respiratory tract, neuromuscular 
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problems, malnutrition or institutionalization [33]. Not always immunological workup is 
performed. However, several chromosomal disorders are known to be associated with 
PID. Down syndrome (trisomy 21) [34] and DiGeorge syndrome (22q11 deletion) [35] are 
well-known examples, but not the only ones. Our survey among ESID members (chapter 
6) showed the association of a wide range of other chromosomal aberrations with 
immunological abnormalities. Up to one third of patients with chromosomal aberrations 
(defined as a missing, extra, or irregular portion [i.e. involving more than one gene] of 
chromosomal DNA) and recurrent infections may have some form of primary 
immunodeficiency. Antibody deficiency was the most prevalent in our cohort, which 
means that it might be possible to prevent infectious complications with antibiotic 
prophylaxis or immunoglobulin substitution in these patients. This is an important 
awareness message for pediatricians treating these patients. We could not identify a 
specific suspicious chromosome or region, however the described partial chromosomal 
monosomies and trisomies can serve as hints for relevant genetic loci in future studies.
Future perspective
Unravelling the genetic background of primary hypogammaglobulinemia will require 
further research in large patient cohorts. When ‘using’ patients with chromosomal 
aberrations for further research, it would be interesting to perform case-control studies, 
to assess whether various chromosomal aberrations are causally related to 
immunodeficiency and give us specific gene regions to explore and maybe target in the 
future. Furthermore, a search for known (i.e. BtK deficiency, CD40L deficiency and 
X-linked hypogammaglobulinemia and isolated growth hormone deficiency [XLH-GHD]) 
and unknown X-linked genetic defects in boys with complicated and early onset primary 
hypogammaglobulinemia could be very interesting as well. Exome sequencing of the 
X-chromosome in this population could be a suggestion. 
But should we invest in knowing all these genetic details if therapy of 
hypogammaglobulinemia is simply prophylactic antibiotics and immunoglobulin 
substitution? This treatment is indeed effective in prevention of lower respiratory tract 
infections, but the effect of immunoglobulin substitution on non-infectious comorbidities 
(e.g. autoimmunity, lymphocytic hyperplasia and enteropathy) is doubtful [36-38]. More 
insight in the genetics and pathogenesis could also provide new treatment options for 
these non-infectious comorbidities. A good example are the recently discovered 
heterozygous loss-of-function mutations in CTLA-4 protein in patients with 
hypogammaglobulinemia, recurrent infections and multiple autoimmune features [39]. 
CTLA-4 is an essential negative regulator of immune responses by inhibiting CD28 T cell 
- B cell co-stimulation and loss-of-function mutations of CTLA-4 can therefore play an 
important role in developing multiple autoimmune features. Treatment with soluble 
CTLA-4 fusion proteins (i.e. Abatacept and Belatacept) could potentially be beneficial in 
the context of CTLA-4 deficiency. Another consequence could be the awareness of yet 
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unknown complications in the future, like the risk of vasculopathy in deficiency of 
Adenosine Deaminase 2 (ADA2) in patients with antibody deficiency and immune 
dysregulation [40]. Identification of single gene disease could even raise the possibility 
of gene therapy, like it is used nowadays in certain severe combined immunodeficiencies 
[41]. Of course this would only be suitable for severely affected patients, or for patients 
with a bad prognosis. This last patient category could benefit from early genetic diagnosis.
Next to the genetic background of PAD, it would also be good to know which 
hypogammaglobulinemic children are at risk for developing more severe disease and 
thus need special attention. It is known that in children presenting with 
hypogammaglobulinemia, low IgM values between 2 and 5 years of age, an impaired 
antibody response as well as low B cell counts seem to be a risk factor for developing 
persistent hypogammaglobulinemia [42]. Recently it was also shown that a decreased 
IgA response to pneumococcal polysaccharides indicates persistent disease in children 
with hypogammaglobulinemia [43], and that absent or low numbers of switched memory 
B cells was found to be associated with a higher frequency of pneumonia and 
bronchiectasis in children with early onset hypogammaglobulinemia (defined as onset 
before the age of 6 years) [44]. To assess whether these are real risk factor for persisting 
and/or progressive hypogammaglobulinemia in children, a large prospective cohort 
study has to be performed. Online registries, like the ESID online database, should 
preferably be used to set up such a large international prospective trial. Automatic 
inferfaces transferring the patient data from the hospital file to specific registries, 
standardization of ethical procedures in Europe for using patient data for international 
registries and complex automated data quality checks in the registries are needed to 
make such trials feasible and worthwhile.
Final conclusions of the thesis
1. The greatest changes in the peripheral B cell and T cell compartment occur in the 
first years of life, reflecting immune maturation.
2. PID classification schemes developed with adult data cannot be used in children.
3. The increase of SHM in the first years of life can not only be explained by increase in 
numbers of mature B cells.
4. The male predominance in PAD patients suggests hidden X-linked inheritance.
5. Milder PAD, i.e. IgG-subclass deficiency and/or SPAD, are often missed in general 
pediatric care.
6. PID (mostly PAD) can also be a cause of recurrent infections in patients with 
chromosomal aberrations, next to other known risk factors.
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Children often suffer from respiratory infections, which are usually innocent and self-
limiting. However, in some cases these infections continuously recur; this can be a sign 
of underlying primary immunodeficiency (PID). Identifying children with PID, especially 
the milder forms, among the many children seen in everyday practice, can be challenging. 
This is further complicated because of the maturing immune system in children; it is 
often not easy to distinguish a physiologically immature from a pathologically 
dysfunctional immune system. Furthermore, little is known about the prevalence and 
prognosis of hypogammaglobulinemia in children, the most common form of primary 
immunodeficiency. The aim of this thesis was (1) to get more insight into the pitfalls of 
the developing immune system for doctors confronted by children with potential primary 
immunodeficiency and (2) to study in detail the clinical picture of hypogammaglobulinemia 
in children using data from (inter)national registries and surveys.
In Part 1, we describe extensive reference values for newly described lymphocyte 
subpopulations in children. In children it is necessary to use age-matched reference 
values, because of their developing immune system. The then available age-matched 
reference values were determined in relatively small samples, which question their 
accuracy especially in the youngest children. Moreover, age-matched reference values 
for newly discovered lymphocyte subpopulations that are thought to play an important 
role in the pathogenesis of primary immunodeficiency were not yet determined. 
Chapter 1 shows the age-matched reference values for B cell subpopulations we 
determined in healthy children using leftover blood. Because healthy young children do 
not often need blood examination, the number of subjects in the different age groups 
were 10-21. Therefore, we used the statistical method of tolerance intervals which 
determines a reliable interval despite the small numbers tested per age group. The 
presented reference values define a range with a 95% chance that 90% of healthy children 
will have absolute numbers within the reported range. This study again showed that the 
greatest changes in the composition of the B cell compartment occur in the first 2 years 
of life. The increase in B cells in the first months of life is almost entirely caused by 
expansion of the naive B-lymphocyte pool, and to a small extent by expansion of 
transitional cells.
Immunophenotyping of B cell subpopulations is increasingly used to classify patients 
with common variable immunodeficiency disorders (CVID) into subgroups related to a 
different clinical prognosis. CVID is a heterogeneous group of primary immunodeficiency 
diseases characterized by late-onset hypogammaglobulinemia. We compared the 
obtained age-matched reference values with the EUROclass CVID classification scheme. 
Forty out of our 97 normal healthy children could be ‘classified’ in the CVID subgroup 
with the highest risk of complications according to the EUROclass system. Even though 
most of these children were younger than 2 years of age, when a diagnosis of CVID 
cannot yet be made, we advise to be cautious when using these classification schemes 
in children. We also looked at the frequency and intensity of TACI and BAFF-R expression 
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on B cells. Both are transmembrane receptors that belong to the TNF family and are able 
to transduce signals that result in isotype switching of B cells. Mutations in TACI and 
BAFF-R have been described in CVID patients. We demonstrated that age is the primary 
determinant of TACI expression on B cells (i.e. % of TACI+ B cells). This means that a low 
number of TACI-positive B cells in young children is not automatically indicative of a 
potential TACI mutation. We did not find any effect of age on the BAFF-R expression 
(frequency and intensity) of B cells.
The same methods and comparable statistics were used to determine the reference 
values for T cell subpopulations in the healthy children, which we describe in chapter 2. 
Next to the different naive, effector and memory CD4+ and CD8+ T cells, we also looked 
at recent thymic emigrants, regulatory T cells and CXCR5+ helper T cells using the whole 
lysed blood method, which is most often used in diagnostic procedures. We show that 
total absolute T cell numbers increase 1.4-fold during the first months of life, and that 
after 9–15 months they gradually decrease threefold to adult values. The increase in the 
first months of life is mainly caused by the expansion of recent thymic emigrants and 
naive cells. Helper and cytotoxic T cell subpopulations show the same pattern. Regulatory 
T cells increase in the first 5 months of life and then gradually decrease to adult values, 
although the absolute numbers remain small. CXCR5+ memory T cells are virtually absent 
at birth and increase in numbers during the first year of life, paralleling the start of infantile 
IgA and IgG production. Our age-related reference values for these subpopulations can 
be used to help discern normal from abnormal T cell development in children.
Antigen exposure is a trigger for proliferation and differentiation of lymphocytes in the 
peripheral blood. During this process of differentiation antigen exposure also leads to 
the process of somatic hypermutation (SHM). SHM is a programmed process in which 
mutations in the DNA coding for the variable regions of immunoglobulin genes are 
induced to generate higher-affinity B cell receptors. It has not been studied in detail how 
SHM develops with increasing age, nor how it is related to the development of populations 
of different memory B cells. In chapter 3, we determined the SHM levels in different age 
groups using the Igκ-REHMA assay, an analysis that estimates the amount of SHM in 
expressed Vk3/20 gene segments in a specific sequence motif (hot-spot), displayed as 
percentage of mutated segments within the total peripheral blood cell population. We 
show that the estimated level of SHM increases rapidly during the first 2 years of life. This 
increase was associated with changes in size of the two B cell subpopulations that 
contain SHM (switched memory B cells [smB] and non-switched memory B cells [nsmB]), 
but this could not explain the total observed increased SHM frequency. We hypothesize 
that the increase of SHM in childhood reflects an increase of the proportion of memory 
B cells originating from secondary GC-dependent B cell responses as well as an increase 
of the SHM frequency within the memory B cell compartment, reflecting immune 
maturation.
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In Part 2 we study in detail the clinical picture of antibody deficiency in children focusing 
on hypogammaglobulinemia using data from (inter)national registries and surveys.
Chapter 4 shows the results from the PedPAD study: a study using the ESID online 
database. Characteristics from 2076 children with hypogammaglobulinemia collected 
in 46 centres situated in 18 different countries are described. Unfortunately, the data set 
showed several limitations, making interpretation of the data challenging. There were 
obvious data entry errors and many missing values. The data showed there were country-
related differences in the use of diagnostic criteria for the classification of different types 
of primary hypogammaglobulinemia. Analysis of the data was performed on the cleaned 
data set of ‘total hypogammaglobulinemia patients’. The most striking observation was 
the predominance of male patients in this group of children with primary 
hypogammaglobulinemia (n = 1292, 63%). This male predominance was observed in 
each of the 18 countries involved and had not been described in the literature before. 
Moreover, the boys were younger at diagnosis (mean age males 5.3 years; mean age 
females 5.8 years) and complications, like auto-immunity, polyclonal lymphocytic 
infiltration, enteropathy and lymphoid malignancy, were more frequently reported in 
boys (12%) compared to girls (5%). This male predominance suggests that patients with 
an undetected or unknown X-linked genetic disease are included in this group of children 
registered as primary hypogammaglobulinemia.
In chapter 5, we describe a cohort of 49 children with IgG-subclass deficiency and/or 
specific polysaccharide antibody disorders (SPAD) collected from secondary and tertiary 
centers all over the Netherlands using the national surveillance institute for pediatric 
diseases (“Nederlands Signalerings Centrum voor Kindergeneeskunde” [NSCK]) to collect 
the data. Both diseases are generally considered as milder forms of hypogamma-
globulinemia. IgG-subclass deficiency is defined as a deficiency in one or more IgG-
subclasses (>2 SD below age-matched reference values) with normal or near normal 
IgG concentration. SPAD is diagnosed when there is profound alteration of the antibody 
response to polysaccharide antigens. This was the first study published in a Western-
European cohort, and the first that included children followed outside tertiary centers. 
The most prevalent IgG-subclass deficiency in our cohort was IgG2 deficiency. This is 
in contrast with other published cohorts, where IgG3 deficiency was most common. 
These cohorts contained a higher number of children on prophylactic antibiotics, and 
were performed in tertiary populations. This may explain this difference in phenotype. 
However, ten percent of the children in our study with ‘milder’ immunodeficiencies 
already showed bronchiectasis. Again, significantly more boys (67%) than girls were 
reported. After the age of 9, only boys were reported, and only boys (11/33 boys at 
baseline) showed progressive immunodeficiency during follow-up. Overall, twenty-five 
percent of the children with IgG-subclass deficiency and/or SPAD recovered during 
follow-up. The majority of children (69%) were reported by four secondary hospitals with 
a pediatric immunologist in the staff, which raises the question whether many of these 
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patients are missed. If we want to identify more patients, probably the awareness of these 
diseases among general pediatricians should increase.
A special group of children with recurrent infections are children with chromosomal 
disorders. In chapter 6, we present a cohort of children with chromosomal aberration 
and primary immunodeficiency recruited with a survey among ESID members. We invited 
all members of the ESID to report patients with chromosomal aberration in combination 
with one or more identified immunological abnormalities relating to primary 
immunodeficiency. Our call identified 46 patients with a wide variety of chromosomal 
aberration associated with immunological abnormalities potentially relating to primary 
immunodeficiency. This is the largest cohort reported in the literature so far (42 isolated 
cases, and twice 2 patients from separate families). Their most common clinical 
presentation was ‘recurrent ENT and airway infections’, which triggered their physician 
to perform immunological investigations. Not surprisingly, the detected primary 
immunodeficiencies were mostly ‘predominantly antibody deficiencies’, ranging from 
IgG-subclass deficiency and/or SPAD to severe hypogammaglobulinemia or even 
agammaglobulinemia in one patient. Recognition of hypogammaglobulinemia in these 
patients, and not automatically ascribing the recurrent infections to factors such as 
anatomic and/or neuromuscular problems, is important because these infections can 
be prevented with interventions like antibiotic prophylaxis or immunoglobulin substitution.
The studies in this thesis demonstrate the challenge of diagnosing predominantly 
antibody disorders in children. This is partly due to their maturing immune system, but 
also due to the unawareness of doctors. Our developed age-matched reference values 
provide some grip to distinguish normal from disease. As shown, analysis of large patient 
cohorts using registries and/or surveys can detect unknown patterns, like the 
predominance of boys with hypogammaglobulinemia, which gives entries for future 
research.
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Jonge kinderen hebben vaak last van infecties. Deze zijn meestal onschuldig en gaan 
vanzelf weer over. In sommige gevallen komen de infecties steeds terug omdat de afweer 
niet goed is. De meest voorkomende afweerstoornis bij kinderen is een tekort aan 
antistoffen (‘immuunglobulinen’) in het bloed. Dit wordt ‘hypogammaglobulinemie’ 
genoemd. Er is nog maar weinig bekend over hypogammaglobulinemie bij kinderen. 
Hoeveel kinderen hebben hier eigenlijk last van? Wat zijn hun klachten? En hoe is het 
beloop van de ziekte? Daarnaast is het vaak lastig om een afweerstoornis bij kinderen 
vast te stellen. Dit heeft te maken met het feit dat het immuunsysteem nog in ontwikkeling 
is. Bij de geboorte zijn kinderen nog maar weinig beschermd tegen infecties, ze worden 
deels beschermd door de antistoffen die ze via de placenta van hun moeder hebben 
gekregen. In de loop van het eerste levensjaar komt de eigen antistofproductie op gang. 
Echter, net zoals het ene kind vroeg kan lopen en praten en dit bij een ander kind langer 
duurt maar uiteindelijk ook lukt, is er een grote variatie in de snelheid van uitrijping van 
het immuunsysteem. Het is vaak lastig bij (jonge) kinderen ‘trage rijping’ van ‘gestoorde 
afweer’ te onderscheiden. Het doel van dit proefschrift was om meer inzicht te krijgen 
in het zich ontwikkelende immuunsysteem bij kinderen en om de kenmerken van 
kinderen met een hypogammaglobulinemie beter in kaart te brengen. Hiervoor is gebruik 
gemaakt van (internationale) patiënten registratie systemen en enquêtes onder collega’s 
om patiënten met deze ziektebeelden te verzamelen.
In hoofdstuk 1 en 2 laten we de normaalwaarden zien van verschillende soorten 
afweercellen bij gezonde kinderen. Het immuunsysteem bestaat uit veel soorten 
afweercellen die allemaal hun eigen functie hebben. Wij hebben naar de lymfocyten 
gekeken. Dit zijn witte bloedcellen die een specifieke afweerreactie op bacteriën en 
virussen kunnen maken. Daarnaast zorgen ze er ook voor dat er geheugen wordt 
gevormd, zodat je een volgende keer niet, of minder, ziek wordt van eenzelfde verwekker. 
Lymfocyten bestaan voor een belangrijk deel uit B cellen en T cellen. De B cellen kunnen 
zich ontwikkelen tot antistof producerende plasmacellen. De antistoffen die deze 
plasmacellen maken zijn specifiek gericht tegen een bepaalde ziekteverwekker. Ze 
markeren de ziekteverwekker zodat andere afweercellen in het lichaam deze beter 
kunnen herkennen en opruimen. Bepaalde soorten T cellen (de cytotoxische T cellen) 
kunnen bijvoorbeeld zo de ziekteverwekkers uit de weg ruimen. Andere T cellen (de 
helper T cellen) helpen de B cellen om nog sterkere en specifiekere antistoffen te maken 
zodra ze een ziekteverwekker voor de eerste keer zijn tegengekomen. We zien in onze 
studies dat er vooral in de eerste twee levensjaren grote veranderingen in de aantallen 
van de verschillende B en T celsoorten plaatsvinden. Vanaf de leeftijd van twee jaar zijn 
er minder schommelingen in de aantallen te zien, maar duurt het nog een aantal jaar 
voordat de volwassen waarden zijn bereikt. Omdat de aantallen van de verschillende 
lymfocyten bij kinderen zo duidelijk verschillen met die van volwassenen, dient men 
voorzichtig te zijn met het toepassen van classificatie criteria die op basis van lymfocyten 
subpopulatie aantallen zijn opgesteld voor volwassen patiënten met afweerstoornissen. 
De door ons gevonden normaalwaarden kunnen in de dagelijkse praktijk gebruikt worden 
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om onderscheid te maken tussen een zich normaal ontwikkelend en een afwijkend 
immuunsysteem bij kinderen.
In hoofdstuk 3 gaan we meer op de details van de antistofproductie van B cellen in. Zoals 
gezegd helpen de T helper cellen de B cellen om nog sterkere en specifiekere antistoffen 
te maken. Dit gebeurt in de zogenaamde ‘germinal centers’ in de lymfeklieren. Het DNA 
(erfelijke materiaal) van de B cellen dat codeert voor de antistoffen wordt een klein beetje 
veranderd met als doel om een sterkere binding aan ziekteverwekkers te krijgen. Dit 
proces wordt somatische hypermutatie (SHM) genoemd. We hebben in dezelfde gezonde 
kinderen gekeken naar de hoeveelheid van deze DNA veranderingen in verschillende 
leeftijdsgroepen. Ook hier zagen we dat er in de eerste twee levensjaren de grootste 
veranderingen optraden. Vanaf twee jaar blijft de hoeveelheid van deze DNA 
veranderingen nagenoeg stabiel. De toename van deze DNA veranderingen in de eerste 
twee levensjaren komt enerzijds door de toename van het aantal B cellen waarin deze 
SHM kan plaatsvinden, maar kan niet alleen hierdoor verklaard worden. Wij denken dat 
ook een toename van frequentie van de SHM per cel hiervoor verantwoordelijk is.
Het volgende deel van het proefschrift bekijkt de kenmerken van kinderen met een 
hypogammaglobulinemie. Als eerste beschrijven we in hoofdstuk 4 een groep van 2076 
kinderen met hypogammaglobulinemie in de PedPAD studie. De gegevens van deze 
kinderen hebben we verzameld door gebruik te maken van een reeds bestaande Europese 
patiënten registratie die opgezet is door de European Society for Immunodeficiencies 
(ESID online database). De kinderen waren afkomstig van 46 ziekenhuizen uit 18 
verschillende landen. Doordat er in de verschillende landen andere diagnostische criteria 
werden gebruikt, was het lastig om verschillende groepen met elkaar te vergelijken. We 
hebben daarom alle kinderen met een hypogammaglobulinemie bij elkaar genomen. 
Het meest opvallende was de grote hoeveelheid aan jongens in dit cohort (n = 1292, 
63%). Dit zagen we terug in alle landen en was niet eerder uit andere studies 
gerapporteerd. Ook zagen we dat de jongens gemiddeld jonger waren bij diagnose 
(gemiddelde leeftijd jongens 5,3 jaar; gemiddelde leeftijd meisjes 5,8 jaar) en dat ze 
daarnaast ook vaker last hadden van complicaties (12% van de jongens tegen 5% van de 
meisjes).
In hoofdstuk 5 bekijken we een groep van Nederlandse kinderen met een milde vorm 
van hypogammaglobulinemie. Deze groep kinderen hebben we verzameld via het 
Nederlands Signalerings Centrum voor Kindergeneeskunde (NSCK) waar in periode van 
1 maart 2009 tot 1 november 2011 kinderen met deze milde vorm van hypogamma-
globulinemie werden verzameld. Dit gaat om kinderen met een tekort in 1 of meerdere 
antistof subtypes (IgG-subklasse deficiëntie). De totale hoeveelheid antistoffen in het 
bloed is dan wel (nog) normaal. Ook kinderen die geen specifieke antistoffen tegen 
suikerkapsels van bacteriën konden maken werden bekeken (specifieke polysacharide 
antistof deficiëntie [SPAD]). Ondanks het feit dat deze afweerstoornissen beschouwd 
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worden als ‘mildere’ ziektes, hadden 10% van de kinderen al chronische schade aan de 
longen opgelopen. Daarnaast zagen we ook hier dat de meerderheid van de kinderen 
jongens waren (67%). Sterker nog, vanaf de leeftijd van 9 jaar bleven er alleen nog maar 
jongens over in de groep. Ook waren het alleen jongens die tijdens de follow-up een 
verslechtering van de ziekte lieten zien. Vijfentwintig procent van de kinderen liet 
uiteindelijk een normalisatie van de antistoffen zien tijdens follow-up. Opvallend was dat 
kinderen met een IgG-subklasse deficiëntie en/of SPAD vooral gerapporteerd werden 
door kinderarts-immunologen en minder vaak door een algemeen kinderarts. Wij denken 
dat als er meer aandacht komt voor het opsporen van onderliggende afweerstoornissen 
door algemene kinderartsen, er in de toekomst wellicht meer kinderen met deze ziekte 
aan het licht kunnen komen.
Ten slotte beschrijven we in hoofdstuk 6 een speciale groep kinderen met recidiverende 
infecties, namelijk kinderen met een afwijking in de chromosomen (de dragers van het 
erfelijk materiaal). We weten dat deze kinderen vaker last hebben van infecties, maar dit 
wordt vaak geweten aan andere oorzaken zoals het feit dat ze minder sterk zijn, of zich 
vaak verslikken. Natuurlijk spelen deze factoren mee, maar het blijkt belangrijk om ook 
bij deze kinderen de afweer goed te bekijken. Een oproep via de ESID leverde 46 patiënten 
op die zowel een afwijking in de chromosomen hadden als een afweerstoornis. 
De meeste patiënten hadden last van recidiverende KNO en luchtweginfecties. De meest 
voorkomende afweerstoornis in deze groep bleek hypogammaglobulinemie te zijn.
Samenvattend laat dit proefschrift de uitdagingen zien van het vaststellen van afweer-
stoornissen bij kinderen. Dit heeft enerzijds te maken met het zich nog ontwikkelende 
immuunsysteem maar ook de onbekendheid bij artsen speelt hierin een rol. De door ons 
opgestelde normaalwaarden van lymfocytensubpopulaties kunnen helpen bij het 
vaststellen bij welk kind met frequente infecties mogelijk een afweerstoornis aanwezig 
is. Daarnaast hebben wij laten zien dat meer jongens last hebben van 
hypogammaglobulinemie dan meisjes. Toekomstig onderzoek is nodig om uit te vinden 
wat hier de oorzaak van is. Daarnaast is het belangrijk om de bekendheid met 
hypogammaglobulinemie bij artsen te vergroten zodat meer kinderen met een 
afweerstoornis herkend worden en een passende behandeling kunnen krijgen.
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Dit proefschrift is niet alleen tot stand gekomen dankzij mijn inspanningen, maar ook 
door de inzet en steun van vele andere enthousiaste en bereidwillige mensen. Zonder 
jullie was dit mij nooit gelukt, dankjewel!
Allereerst wil ik alle kinderen (en ouders) die hebben deelgenomen aan de verschillende 
onderzoeken bedanken. Zonder jullie bereidheid tot deelname was dit onderzoek 
überhaupt niet mogelijk geweest. 
Daarnaast wil ik graag mijn promotoren, co-promotor en andere leden van de 
promotiecommissie bedanken.
Prof. dr. E. de Vries, beste Esther, zonder jou was dit proefschrift er zeker nooit gekomen. 
Los van het feit dat ik in een rijdende trein kon springen, heb je mij ook tussentijds 
gestimuleerd om door te gaan en samen met mij projecten gezocht die ik naast mijn 
reguliere werk kon blijven uitvoeren. Dat het een meerjarig traject ging worden, was voor 
jou geen belemmering. En door jouw immer snelle respons op al mijn e-mails, kon ik 
vaak in korte tijd heel veel werk verzetten. Enorm bedankt voor je begeleiding de 
afgelopen jaren. 
Prof. dr. N. Wulffraat, beste Nico, wat fijn dat jij mijn promotor wilt zijn. Jouw kritische 
vragen en kijk op het grotere geheel zijn van grote waarde geweest voor mijn uiteindelijke 
proefschrift. Hartelijk dank voor de altijd prettige samenwerking, fijn dat jouw deur altijd 
open staat voor mij.
Dr. M. de Flier, beste Michiel, jouw bijdrage aan het laatste deel van mijn proefschrift was 
super. Jij hebt de gave om complexe zaken op een heel heldere manier te verwoorden 
en uit te leggen. Dit heeft mij vooral bij het schrijven van de discussie enorm geholpen. 
Dankjewel hiervoor. Ik hoop dat we in de toekomst nog vaker kunnen samenwerken.
Prof. dr. D.H. Bakker, prof. dr. P.M. van Hagen, prof. dr. F.H.J. van den Hoogen, dr. J.G. 
Noordzij en prof. dr. G.T. Rijkers wil ik graag bedanken voor het bestuderen van dit 
manuscript. Prof. dr. F.H.J. van den Hoogen, beste Frank, aan jouw een speciaal woord 
van dank voor je vertrouwen in mij als (hopelijk) toekomstig kinderreumatoloog in het 
Nijmeegse. Ik kijk er naar uit om weer ‘terug’ te komen en vind het fijn dat jij deel uit wilt 
maken van de promotiecommissie.
Ook wil ik alle co-auteurs van alle artikelen heel hartelijk bedanken voor hun hulp en 
commentaren. 
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Extra dank aan Eugenie Gemen, zonder jou Eugenie was het normaalwaarden onderzoek 
niet (zo snel) gegaan. Naast het feit dat jij alle analyses in het lab hebt uitgevoerd (of hebt 
laten uitvoeren), was jij tijdens mijn afwezigheid de coördinator van dit onderzoek in het 
Jeroen Bosch Ziekenhuis. Ik kon blindelings op jou vertrouwen, dankjewel.
Beste Roeland van Hout, hartelijk dank voor al je hulp bij de statische analyses. Zonder 
jou was dit deel een ware uitdaging geweest, nu ging het fluitend, dankjewel!
Gertjan Driessen en Mirjam van der Burg, ook aan jullie een speciaal woord van dank 
voor de samenwerking in de referentiewaarden studie en het onderzoek naar somatische 
hypermutatie. Ik ben dankbaar dat ik gebruik heb kunnen maken van jullie kennis en 
faciliteiten op het lab. 
Dear Benjamin Gathmann, a special thanks to you for your cooperation in the PedPAD 
study and your help with analysing the data from the ESID Online Database. You are the 
fastest email responder I have ever met. 
Beste Yumely, dankjewel voor het verzamelen van de patiëntengegevens in de diverse 
ziekenhuizen voor de IgG-subclasse deficiëntie en/of SPAD studie. 
Natuurlijk wil ik ook alle collega’s van de afgelopen jaren bedanken voor de prettige 
samenwerking. Alle arts-assistenten in het Jeroen Bosch Ziekenhuis en het Radboudumc 
tijdens mijn opleidingstijd, het waren gezellige tijden! 
Beste Ruud en Maaike, hoewel jullie promotie al weer even geleden is, waren we in het 
begin toch een soort ‘onderzoeksgroep’. Dankjewel voor het beantwoorden van al mijn 
(praktische) vragen.
Beste onderzoekscollega’s bij Tranzo, dankjewel voor het veilige en inspirerende 
onderzoeksklimaat waar ik nu af en toe van mag mee genieten als externe promovendus.
Extra dank aan de kinderartsen in het Jeroen Bosch Ziekenhuis voor het vertrouwen in 
mij, al vanaf het vroege begin van mijn loopbaan, en de mogelijkheid om nu ook als 
kinderarts mijn steentje te kunnen bijdragen. Speciale dank aan dr. Hans Hoekstra, zonder 
jou had ik nooit zo’n vliegende start in de kindergeneeskunde kunnen maken, ik blijf je 
daar altijd dankbaar voor. 
Dr. Jos Draaisma, dankjewel voor je prettige coachende opleidersrol. Ik heb veel van je 
geleerd. 
Alle reumatologen in de St. Maartenskliniek, dankjewel voor mijn zeer leerzame stage 
bij de ‘volwassen’ reumatologie, ik kijk er naar uit om in de toekomst weer met jullie 
samen te werken. 
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De kinderreumatologen en -immunologen in het Wilhelmina Kinderziekenhuis, beste 
Annet, Bas, Berend, Caroline, Jaap-Jan, Joost & Joost, en Joris, wat een voorrecht dat 
ik bij jullie een deel van mijn opleiding tot kinderreumatoloog heb mogen volgen. Een 
betere en fijnere leerschool had ik me niet kunnen wensen, ik voel me heel welkom bij 
jullie. 
En last, but certainly not least, beste Esther Hoppenreijs, onze samenwerking gaat nu 
pas echt beginnen en daar ben ik echt heel blij mee. Dankjewel voor de mogelijkheden 
die jij voor mij gecreëerd hebt, ik hoop maar dat ik alle verwachtingen waar kan maken. 
Zeker niet minder belangrijk een dankwoord aan al mijn lieve vrienden en (schoon)familie. 
Alleen al het feit dat jullie er zijn is genoeg!
Mijn lieve paranymfen, Annelieke en Susan, wat vind ik het fijn dat jullie mij willen 
ondersteunen bij mijn promotie. Op jullie vriendschap kan ik altijd rekenen, dat vind ik 
heel bijzonder, dankjewel.
Mijn lieve BoegBeeldig vriendinnetjes, Annedien, Bettine, Hanneke, Marije, Nieke, Steffie, 
Tine en Tirza, dankjewel voor al jullie gezelligheid de afgelopen jaren. Ik kijk altijd enorm 
uit naar onze momenten samen, never a dull moment. Jullie zijn allemaal precies goed 
zoals jullie zijn.
Lieve Nicky, ik ben blij dat wij elkaar tijdens de studie zijn tegengekomen. Jouw oprechte 
interesse, enthousiasme en positivisme maken mij blij.
Lieve Esmee en Iris, wat fijn dat ik het met jullie over alledaagse dingen kan hebben, 
heerlijk.
Lieve Henny en Nel, bedankt dat wij altijd op jullie kunnen rekenen.
Leef oma, wat fijn dat geej heej nog beej kint zien. 
Leef pap, mam en Tom, door óg bin ich gewaore wae ich bin. Dankjewel veur n fijne 
kingertied en veur nog idderskier alle fijne momenten samen. 
Mijn lieve Sophie en Julius, dat ik jullie mama mag zijn, is werkelijk waar het allermooiste 
in mijn leven. Ik zal er altijd voor jullie zijn.
Allerliefste Raymond, als jouw ogen glinsteren, dan doen die van mij dat ook. Met jou 
ben ik gelukkig!
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ADA2  adenosine deaminase 2
AID  activation-induced cytidine deaminase
APC  antigen presenting cell or allophycocyanin
APRIL  a proliferation-inducing ligand
BAFF-R  B cell activation factor receptor
BCR  B cell receptor
BD  Becton Dickinson
BLNK  B cell linker
bp  base pair
BTK  Bruton’s kinase
CAML  calcium-modulating cyclophilin ligand
CD  cluster of differentiation
CDR  complementary determining region
CSR  class-switch recombination
CTLA-4  cytotoxic T-lymphocyte-associated 4
CVID  common variable immunodeficiency disorders
CXCR5  CXC chemokine receptor 5
EDTA  ethylenediaminetetraacetic-acid
ENT  ear-nose-throat
ESID  European Society for Immunodeficiencies
Fab  variable region of immunoglobulin
Fc  constant domain of immunoglobulin
FITC  fluoresceïne-isothiocyanate
GC  germinal center
GWAS  genome wide association study
ICOS  inducible T cell costimulator
Ig  immunoglobulin
IgH  immunoglobulin heavy chain
IGHM  μ-heavy chain
IgK-REHMA  IgK-restriction enzyme hot-spot mutation assay 
IFN  interferon
IL  interleukin
IPH  idiopathic primary hypogammaglobulinemia
ISCN  international system for human cytogenetic nomenclature
ITAM  immunoreceptor tyrosine-based activation motif
IUIS  international union of immunological societies
KRECs  kappa-deleting recombination excision circles
LRBA  lipopolysaccharide responsive beige-like anchor protein
MAb  monoclonal antibody
MHC  major histocompatibility complex
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NFKBIA   nuclear factor of kappa light chain gene enhancer in B cells inhibitor alpha
NK  natural killer
NSCK  Nederlands Signalerings Centrum voor Kindergeneeskunde
nsmB  non-switched memory B cells
PAD  predominantly antibody deficiencies
PD-1  programmed cell death 1
PerCP-Cy-5.5 peridinin chlorophyll protein–cyanin 
PE  phycoerythrin
PedPAD pediatric predominantly antibody deficiencies
PI3K  phosphoinositide 3-kinase
PID  primary immunodeficiencies 
PLCG2  phospholipase Cγ2
PRKCD  protein C kinase δ
RT-PCR  reverse transcription–polymerase chain reaction
SCID  severe combined immunodeficiency
SHM  somatic hypermutation
smB  switched memory B cell
SNP  single nucleotide polymorphism
SPAD  specific polysaccharide antibody deficiency
TACI   transmembrane activator and calcium-modulator and cyclophilin ligand 
interactor
TCR  T cell receptor
Tfh  follicular T helper cell
Th  T helper cell
THI  transient hypogammaglobulinemia of infancy
TI  T cell independent
TNF  tumor necrosis factor
TRECs  T cell receptor excision circles
Treg  regulatory T cells
VDJ  variable, diversity, joining
WASP  Wiskott–Aldrich syndrome
XLA  X-linked agammaglobulinaemia
XLH-GHD  X-linked hypogammaglobulinemia and isolated growth hormone 
deficiency
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